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Abstract 
Microbicidal Approaches to Interdict Virus Infections on Human Epithelial Cell 
Cultures, Organ Tissue Cultures and Human Epithelial Xenografts 
Veronica Holmes 
Mary K. Howett, Ph.D. 
 
 
 
 Sexually transmitted infections (STIs) are causing a hidden epidemic. Everyday 
infected individuals and their families quietly suffer physically, psychologically and 
financially.  Worldwide, STIs are a major economic burden with direct medical costs 
for treating these diseases in United States alone is $15.3 billion per year. As with 
many diseases and infections, prevention is the key and with our current technology 
the best hope for prevention is microbicides.  The work set forth in this thesis 
examined three vastly different microbicides each with very different modes for 
preventing the initial stages of HIV-1 infection. The prototypic SDS Hydrogel is a 
broad-spectrum microbicide.  We show that our prototypic SDS Hydrogel has potent 
antiviral activity against enveloped (HIV-1 and HSV-2) and non-enveloped (HPV-11) 
sexually transmitted viruses.  The second microbicide is comprised of a liposomal 
delivered short interfering RNA (siRNA) pool targeting human chemokine receptor 5 
(CCR5). The down-regulation of CCR5 along with other molecules (gp340, 
syndecans, a4ß7 integrin), which allow HIV-1 to remain infectious, may potentially 
inhibit binding of R5 forms of HIV-1 from binding to the co-receptor, therefore, 
preventing the subsequent infection. Lastly, the recombinant L. plantarum secreting 
cyanovirin is a pro-biotic microbicide that decreased HIV-1 infectivity in vitro and we 
were able to recolonize human vaginal epithelia ex vivo and in vivo.  
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 1. Introduction 
1.1 The sexually transmitted disease epidemic, the crux of the problem. 
 The vastness of the sexually transmitted infection (STI) epidemic is astounding 
(for review see (Low, Broutet et al. 2006; Aral, Fenton et al. 2007; Da Ros and 
Schmitt Cda 2008)).  The STI epidemic has been compared to an iceberg, what you 
see is just a minute fraction of a much larger problem, most of which is unseen. 
(Dymally 2008) As of December 2007, 34 million people worldwide are infected 
with human immunodeficiency virus type 1 (HIV-1) (UNAIDS 2007), 
approximately 20 million people are infected with human papillomavirus (HPV) 
(CDC 2007) and at least 45 million people, in the United States alone, are infected 
with herpes simplex virus type 2 (HSV-2).(CDC 2006)  These infections may be 
life-long and there are no cures just pharmacological maintenance regimes or 
surgical treatments.  If these infections are diagnosed in the early stages often the 
best a person can hope for is to manage the resulting recurrent or chronic disease. 
These diseases can cause major physical and psychological limitations in daily 
living for the people who are infected.  Although these chronic viral diseases are 
among the most common and costly health problems, they are preventable. In 
tandem with prevention strategies there are direct cost benefits to society due to 
preventing infections versus the cost of treating these infections.   According to the 
Center for Disease Control (CDC), for every $1 spent on the Safer Choice Program 
(a school-based HIV, other STI, and pregnancy prevention program), about $2.65 is 
saved on medical and social costs. Every $1 spent on preconception care programs 
for women with diabetes, can reduce healthcare costs by up to $5.19 by preventing 
costly complications in both mothers and babies. (CDC, 2008) A recent 
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government report estimated the numbers of newly acquired STIs in teenagers in 
California for 2005 was 1.12 million with a resulting combined cost of treatment of 
$1.11 billion. (Dymally 2008) This cost estimate included lifetime medical costs 
based on incidence rates, undiagnosed and untreated disease and treatment costs.  
This estimate does not include indirect costs, such as lost wages due to time off of 
work or productivity. (Dymally, 2008) In light of such reports combined with the 
major economic burden in the United States having nationwide direct medical costs 
for treating STIs as high as $15.3 billion per year, almost 60 congressman 
introduced a resolution to Congress asking the Federal Government, States and 
localities to provide additional funding for screening and increased programming to 
educate Americans of all ages on the risks and the prevention of STIs. (Williams 
2008) 
 Several studies have shown that infection with one STI increases a person’s 
susceptibility to another STI with women being the most susceptible population to 
STIs. (Madkan, Giancola et al. 2006) This is a special concern in regards to HIV-1 
transmission. (Wald and Corey 2003; Freeman, Weiss et al. 2006) Many times it is 
not recognized that sexually transmitted diseases affect our society and the world 
population as a whole.  These diseases cause some of the biggest problems in our 
society such as, infertility, cervical cancer and AIDS.  The pandemic of HIV-1 
infection emerged in the 1980’s and has raised many new challenges to infectious 
disease paradigms that existed at that time. (Yang 2004) Continued lack of an 
effective anti-HIV-1 vaccine and the unabated spread of HIV-1 emphasize the 
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urgent need for the development of new preventative measures to stop transmission, 
such as topical microbicides (for review see (Balzarini and Van Damme 2007; van 
de Wijgert and Shattock 2007)). Currently there is uncertainty in the scientific 
community as to whether an efficacious vaccine can be developed with our current 
technology.  One group, the AIDS Healthcare Foundation, has requested that 
National Institute of Allergy and Infectious Diseases (NIAID) suspend HIV-1 
vaccine research. (IAVI 2008) They believe the wisest and most effective use of the 
limited public resources should be focused on preventing new infections. (IAVI 
2008)  The most prudent way to prevent new infections is the use of microbicides.  
A microbicide is defined as any compound that can be placed inside the vagina or 
rectum to prevent the transmission of STIs.  As a complex retrovirus, HIV-1, the 
positive stranded RNA virus infects specific immune cell populations, which results 
in the infection eventually destroying the host’s immune system leaving the 
infected individual in a severely immunocompromised state and vulnerable to many 
infectious pathogens and opportunistic infections. (Knipe and Howley 2001; Yang 
2004)  In developed countries the introduction of combination antiretroviral therapy 
has had a significant impact on the course of HIV-1 infection, with AIDS-related 
mortalities having decreased by more than 80% since the their introduction in the 
mid-1990s. (Egger, May et al. 2002; Porter, Babiker et al. 2003; Schneider, Gange 
et al. 2005) There are more than twenty different antiretroviral drugs in four 
different classes approved by the FDA for the treatment of HIV-1 infection (Knipe 
and Howley, 2007) The antiretroviral treatments each target different stages of the 
viral lifecycle.  There are drugs that block fusion of virion to the host cells 
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(Lalezari, Henry et al. 2003; Fatkenheuer, Pozniak et al. 2005), drugs that block 
reverse transcription (Parker, White et al. 1991; Merrill, Moonis et al. 1996; Havlir, 
Tierney et al. 2000) (nucleoside, nucleotide and non-nucleoside, inhibitors) and 
drugs that block the processing of the gag-pol polyprotein by protease into their 
mature subunits.  
The two primary methods of STI transmission are exposure of mucosal 
surfaces to infected semen or vaginal fluids. In contrast, genital ulcer and genital 
lesion diseases such as genital herpes and human papillomavirus, respectively, are 
primarily transmitted through contact with infected skin or mucosal surfaces.  Latex 
condoms are designed to impede the contact of semen and/or vaginal secretions to 
mucosal surfaces thereby providing a greater level of protection against HIV-1.  
Condoms provide less protection against HSV-2 and HPV because these infections 
may be transmitted by exposure to infected areas that are not covered or protected 
by the condom. (CDC 2008) Vaccines against HIV-1 are in development but 
success is not expected until the distant future and while pharmaceutical treatments 
exist they are not always effective and many times increase the prevalence of 
multidrug resistant strains.(Wolkowicz and Nolan 2005) In addition, many of these 
therapeutics or preventatives are economically unfeasible and inaccessible in many 
parts of the world where the infection is the most prevalent.   
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1.2 HIV-1 pathogenesis and life cycle. 
AIDS was first discovered in the early eighties after a spectrum of clinical 
disorders that included Kaposi’s Sarcoma, Pneumocytis jiroveci pneumonia and  
 
Candida esophagitis, afflicting male homosexuals and intravenous drug users. 
(Knipe and Howley 2007)  The causative virus, HIV-1 belongs to the family 
Retroviridae genus lentiviridae.  The viral genome is a homodimer of linear, 
positive-sense, single stranded RNA with each monomer being approximately 9.7 
kb in size.(Knipe and Howley 2001) The homodimer is maintained by interactions 
between the two 5’ ends of the RNAs in a self-contain a string of poly (A) 
sequences, approximately 200 long at the 3’ end. (Knipe and Howley 2001) The 
intrinsic mutation rate for HIV-1 is extremely high because of the non-proofreading 
ability of the viral reverse transcriptase that reverse transcribes the viral RNA 
genome into double stranded viral cDNA, which is later integrated into the host’s 
genome.  HIV-1 infects CD4 positive (CD4+) lymphocytes, with the M-Tropic 
form (R5) of HIV-1 using CCR5 as the co-receptor and the T-Tropic (X4) form 
using CXCR4 as the co-receptor. (Lederman 2006) When the virion binds to the 
target, cell it must bind the CD4 receptor as well as a co-receptor, CCR5 or CXCR4 
before fusion can occur. This is mediated by binding of the viral envelope protein 
gp120 to two proteins on the surfaces of the target cells, namely CD4 and a co-
receptor.(Agrawal, VanHorn-Ali et al. 2004) In the initial stages viral infection, 
trimeric gp120 binds the cell surface receptor, CD4, and undergoes a 
conformational change exposing a second binding site for the co-receptor to bind to  
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Figure 1: Diagram of mature the HIV-1 Structure 
HIV-1 is an enveloped RNA retrovirus.  The lipid bilayer is derived from the host 
and helps HIV-1 to evade the immune system.  There are two viral glycoproteins, 
gp120, referred to as the surface unit that binds CD4 and co-receptor, and gp41, 
which is the transmembrane unit that is inserted into the host target cell drawing the 
virion and cell closer together allowing fusion to occur.  The matrix protein (p17) 
interacts with the host cell membrane and plays an important role in infectivity.  
Capsid proteins (p24) form the core domains.  Protease protein cleaves the 
polyprotein gp160 into gp120 and gp41.  Integrase is a component of the pre-
integration complex and is responsible for integrating the reverse transcribed double 
stranded viral cDNA into the host’s cell genome.  Reverse transcriptase is 
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responsible for reverse transcribing the viral RNA genome into viral cDNA.  The 
nucleocapsid proteins encapsidates full length unspliced genomic RNA into virions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: HIV-1 Lifecycle 
HIV-1 glycoprotein 120 (gp120) binds CD4 and undergoes a conformational 
change exposing a binding site for a co-receptor, CCR5or CXCR4.  There is 
another confirmational change in gp120 allowing gp41 to be inserted into the host 
membrane.  After which, gp41 undergoes a confirmational change folding back on 
itself allowing fusion to occur.  Following viral fusion, uncoating and reverse 
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transcription occurs with the resulting viral cDNA associating with viral proteins 
and translocating into the nucleus where integration occurs.   
 
 
 
 
gp120.  After gp120 has bound the co-receptor, CCR5 or CXCR4, gp120 undergoes 
a conformational change exposing the viral trimeric glycoprotein 41 (gp41) allowing 
gp41 to be inserted into the host cell membrane. (Lederman 2006) Once gp41 is 
inserted into the host cell membrane, it undergoes an additional conformational 
change forming a six helix bundle.  This six helix bundle undergoes a 
conformational change, folding back on itself bringing the infectious virion and the 
CD4 positive lymphocyte closer together thereby allowing subsequent fusion to 
occur.   Following fusion and internalization, uncoating of the capsid occurs and 
viral reverse transcriptase reverse transcribes the viral RNA genome into double 
standed cDNA in the cytoplasm of the host cell.  The double stranded cDNA 
associates with several viral proteins, integrase, vpr, tat and matrix proteins, forming 
the pre-integration complex (PIC).   The PIC is translocated into the nucleus with the 
help of integrase and vpr, which associates with the nucleoporin components and 
contains a nuclear localization signal. (Heinzinger, Bukinsky et al. 1994; 
Muthumani, Choo et al. 2005) Once inside the nucleus integration occurs in a two 
step process, processing and strand transfer. (Fujiwara and Mizuuchi 1988; Brown, 
Bowerman et al. 1989) In the processing step, the viral protein integrase 
endonucleolytically removes two or three nucleotides from the 3’ termini of the 
blunt ended double stranded viral cDNA, creating staggered ends.  The second step, 
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strand transfer, occurs when the viral integrase catalyzes a staggered cleavage cuts in 
the cellular target DNA creating 5’ overhangs and the 3’ recessed ends of the viral 
cDNA are joined to the 5’ overhanging termini of the cleaved cellular DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: HIV-1 provirus 
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(Fujiwara and Mizuuchi 1988; Brown, Bowerman et al. 1989; Roth, Schwartzberg et 
al. 1989) The host’s cellular machinery ligates the integrated viral cDNA.  The 
integrated viral cDNA is now referred to as the provirus. At this point in the viral 
life cycle the provirus can be actively transcribed into viral RNA genome, viral 
mRNA, which may or may not be spliced depending on the protein to be translated 
or alternatively the provirus can remain latent and transcriptionally inactive until the 
host target cell is activated.  Once the provirus is stably integrated into a resting 
memory CD4+ lymphocyte’s DNA that cell continually harbors replication 
competent provirus, creating a “latent reservoir” of infection regardless of treatment. 
(Chun, Carruth et al. 1997; Finzi, Hermankova et al. 1997) Medical treatment and 
the immune system are ineffective against these proviruses or the cells they infect 
because they are transcriptionally inactive and not producing any viral proteins. Due 
to the half-life of infected cells, current estimates to achieve viral elimination by 
slowly activating infected memory CD4+ lymphocytes is more than 70 years. (Zhou, 
Zhang et al. 2005) Thus, there is no way to eliminate the stably integrated provirus.   
The exact mechanisms, of viral spread in the female genital tract are still 
unknown, including which cells and tissues are first infected.  However, there are 
three proposed mechanisms of viral spread in women that have been described for 
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HIV-1 during vaginal intercourse.  The first is the classical route of entry, which is 
characterized by the binding of cell-free virions in semen to a permissive host cell 
(vagina or cervix) via receptor interactions (binding of CD4 and co-receptor), 
followed by entry into the cytoplasm by fusion and subsequent steps in the 
replicative process. (Kilby and Eron 2003; Pierson and Doms 2003; Piguet and 
Quentin 2004) Second, resident immune cells, such as dendritic cells can capture 
virus via viral binding to the C-type lectins or other cell surface receptors, without 
necessarily becoming infected and re-present infectious virions to a permissive 
target lymphocyte (a process known as infection in trans). (Jameson, Baridaud et 
al. 2002; Piguet and Quentin 2004)  Third, an HIV-1 infected cell (in semen or 
from a primary infected site) can infect a second cell without the requirement for 
release of cell-free virions into the surrounding extracellular environment, which 
represents viral  transmission/propagation through direct cell-to-cell contact (Piguet 
and Quentin 2004) To understand the pathogenesis of HIV-1 and halt its spread 
heterosexually and perinatally, it is important to examine the virus in the genital 
tract of women. (Philpott, Burger et al. 2005) A recent study has demonstrated that 
the genital tract and blood harbor genetically distinct populations of replicating 
HIV-1 and provide evidence that recombination between strains from the two 
different compartments may contribute to the rapid evolution of viral sequence 
variation in infected individuals. (Philpott, Burger, et al. 2005) Another study 
reported that in both treated and untreated women, the plasma viral load may not be 
a reliable marker of transmission since one forth of the non-viremic patients in the 
study were still shedding virus in the genital tract, which indicates that caution is 
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required in judging the infectivity of women based on the plasma loads only in both 
sexual and mother to child transmission. (Fiore, 2004) Information about HIV-1 
replication in the genital tract of infected women suggests that most of the cell-free 
viral quasispecies is shed in vaginal and cervical secretions are the products of local 
virus infection. (Sullivan, Mandava et al. 2005)  Therefore, a successful topical 
microbicide applied vaginally should and would prevent the sexual transmission of 
HIV-1 from an infected person to a naïve or uninfected person.  This latter property 
is in addition to the previously stated requirement of being able to inactivate 
incoming virus and virus infected cells.    
1.3 The Human papillomavirus lifecyle, pathogenesis and association with 
cervical cancer. 
Human papillomavirus (HPV) infection is the most common sexually transmitted 
disease in the United States (CDC 2007; Dunne, Unger et al. 2007; Forhan 2008), 
HPV DNA has been found in 90% of cervical cancers (zur Hausen 2002) and HPV-
16 represents about 50% of the viral types identified in these cancers (Bosch,  
Manos et al. 1995). Every year 450,000 women are diagnosed with cervical cancer 
and 250,000 women worldwide and 5,000 women in the United States die 
needlessly due to cervical cancer. In 2006, the vaccine Gardasil® developed by 
Merck Laboratories was approved by the FDA and made commercially available.  
This vaccine is comprised of coat proteins from HPV 6, 11, 16 and 18. Another 
vaccine, Cervarix™ developed by Glaxo SmithKline (GSK) is currently approved 
only in Europe but GSK is currently seeking approval by the FDA for use in the 
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United States.  Both of these vaccines are designed for pre-sexually active females, 
ages 9-26, to prevent the initial HPV infection and the subsequent possibility of 
developing cervical cancer.  These vaccines do not cure existing infections nor do 
not protect against other high-risk types.  They only convey prophylactic protection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: HPV16 genome structure 
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Note the overlapping open reading frames.   The early 1 (E1) gene product controls 
viral replication and maintains the episome.  The early 2 (E2) gene product regulates 
transcription and is a co-factor for viral replication.  The early 4 (E4) gene product 
disrupts cytokeratins.  The early 5 (E5) gene product interacts with growth factor 
receptors.  The early 6 (E6)  and early 7 (E7) produce an oncogenic gene products that 
associated with p53 and Retinoblastoma tumor suppressor genes, respectively.  The 
late 1 (L1) gene product is the major capsid protein and late 2 (L2)  is the minor capsid 
protein.   
 
 
against the most prevalent types of HPV associated with cervical cancer.  This 
leaves a significant number of the women, in the U.S. population and worldwide,  
unprotected and all women, vaccinated or not, vulnerable to infection by other 
types of human papillomaviruses. Thus, there is an urgent need for a broad 
spectrum microbicide that has been shown to have anti-HPV activity.  HPVs are 
non-enveloped DNA viruses that contain supercoiled, ∼8000 base pair circular, 
double stranded DNA genomes with a tightly packed and highly geometric 
proteinaceous capsid, consisting of major  (L1) and minor (L2) capsid proteins. 
(Favre 1975; Gissmann, Pfister et al. 1977) Only one strand of the double stranded 
DNA genome is transcribed into mRNA, (for review see (Psyrri and DiMaio 
2008)).  Figure 4 illustrates how the HPV-16 genome is divided into three portions:  
a portion that encodes proteins primarily involved in viral DNA replication and cell 
transformation; ~3,000 base pair region that encodes the structural proteins (capsid) 
of the virus particle; and ~1,000 base pair noncoding region that contains the origin 
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of viral DNA replication and transcriptional regulatory elements. (Psyrri and 
DiMaio 2008; Munger, Baldwin et al. 2004)    
HPV infects human epithelia with strict host and tissue target specificity and 
induces benign human neoplasms called “warts”, “papillomas” or “intraepithelial 
neoplasias”.  Out of more than 100 HPV types, only a subset infects genital 
epithelia in men and women and a subset of these includes “high risk” viruses that 
may lead to cervical cancer. As shown in Figure 5, the natural history of HPV 
infection, it can take up to nine to fifteen years before cervical carcinoma develops 
and is diagnosed. (Goldie, Grima et al. 2003) The early gene 7 (E7) produces an 
oncogenic product that binds tumor suppressor protein, Retinoblastoma.  A small 
subset of women demonstrate rapid onset of the disease.  In the absence of external 
or frank genital lesions and because of a women’s anatomical structure many 
women are unknowingly infected. This is especially true of cervical infection.  In 
male dominated, resource poor countries many women never receive the proper 
medical screening for early diagnoses and treatment, so unfortunately many do not 
find out until it is too late, when they are diagnosed with cervical carcinoma.  One 
prominent example of this is cervical carcinoma associated with infection by HPV 
types 16, 18, 31, 35 and others (Ledwaba, Dlamini et al. 2004).  In the U.S., fifty 
percent of cervical cancers are associated with HPV 16. Interestingly, not all 
women infected with high risk HPV develop cervical cancer and as shown in 
Figure 5 many cervical intraepithelial neoplasias (CIN I and II) can be cleared.  It is 
accepted by the scientific community that another co-factor is required after HPV 
infection for progression to cervical intraepithelial neoplasia III (CIN III), 
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carcinoma in situ and frank cancer.  For example, smoking increases the risk for 
cervical cancer by 4.5-7.0 fold relative to non-smokers.  However, the mechanism 
remains unknown. For review, see (Harris, Kulasingam et al. 2004). Infection with 
a high-risk type human papillomavirus (HPV) constitutes the major and apparently 
required risk factor for developing cervical cancer in more than 90% of cases (zur 
Hausen 1994).  For many years scientists were not able to grow HPV in the 
laboratory because of its fastidious nature.  HPV requires the differentiation of the 
epidermis for its complete lifecycle.  As illustrated in Figure 6, during the initial 
stages of the infection, HPV gains access through a cut or laceration in the 
squamous epithelia and infects the basal layer, the main mitotic layer, establishing 
its genome in low copy numbers as an episome in the nucleus of the cells.  Very 
recently, one publication reported the presence of suprabasal stem cells in the 
epidermis.  If correct, it remains possible that such cells could also be targets.  
Replication of the HPV genome is dependent on the host-cell DNA replication 
machinery and HPV-DNA replicates to high copy number only in terminally 
differentiated cells near the epithelial surface.  The late viral genes, which encode 
the capsid proteins (L1 and L2), are expressed only in the highly differentiated 
cells, where infectious progeny virus may self assemble and are released in infected 
squames that are normally shed. (Psyrri and DiMao 2008)  In many lesions, 
however, especially cervical lesions, L1 and L2 amounts are low and not much 
“infectious virus” appears to be present. It is not clear how this can be true for a 
virus group that successfully infects large numbers of women. This limitation in 
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virus particle production may not be representative of selected periods of the 
infection where virus assembly and shedding may be more active.   In addition to 
the presence of HPV DNA in cervical neoplasias, active transcription of HPV DNA 
within dysplastic cervical lesions further establishes a strong molecular association 
of HPV with cervical neoplasia (Stoler 2000).  The expression of early genes E6 
and E7 predominates in high-grade CIN and invasive cancers, and E6 and E7 are 
also actively transcribed in cervical carcinoma cell lines containing HPV-16 or 
HPV-18 (Stoler 2000).  Experimental studies on the viral oncoproteins E6 and E7 
and their interactions with host cellular proteins provide a mechanistic basis for the  
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Figure 5: HPV Natural History of Infection 
TO BE ADDED 
 
 
 
link between HPV infection and cervical cancer.  Several in vitro transformation 
assays have demonstrated that high-risk types of HPV E6 and E7 oncoproteins can 
immortalize primary human foreskin or cervical keratinocytes (McDougall 1994).  
However, the E6 and E7 genes can transform primary cells to cancers only in the 
presence of a second oncogene (Storey, Massimi et al. 1995), and continued 
expression of E6 and E7 is required to maintain the transformed  phenotype. 
(DiPaolo, Popescu et al. 1993)  The E6 proteins of the high-risk types inactivate the 
tumor suppressor protein p53 by inducing its degradation through the ubiquitin-
mediated proteolysis pathway  (Scheffner 1998).  The E7 proteins of high-risk HPV 
bind to the tumor suppressor retinoblastoma protein (pRb).  The binding of HPV E7 
to pRb destabilizes pRb and results in the release of E2F (Berezutskaya and Bagchi 
1997), which is capable of activating transcription of a variety of host genes, many 
  
30 
of which are involved in DNA synthesis and cell cycle progression (zur Hausen 
2000).  The activity of these oncoproteins results in genomic instability, and this 
may further contribute to the deregulation of HPV gene expression during 
carcinogenic progression and to mutation of host DNA.  Cells with a growth 
advantage may be selected and give rise to clonal expansion and tumorigenic 
progression, which will ultimately result in full malignant transformation.  
Carcinomatous cells most often exhibit integration of the virus genome, which 
further increases the transcription of E6 and E7.  Originally, scientists believed that 
HSV-2 was the causative agent of cervical cancer but it was later found to be HPV,  
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Figure 6: HPV Lifecycle 
HPV infects the basal layer of the epithelia through a cut or wound and establishes its 
genome as an episome. Using the cell’s machinery the cells and virus replicate 
together producing viral genomes and early gene products (E1, E2, E4, E5, E6 and 
E7).   In the upper intermediate layers where the cells are beginning to change their 
morphology to a more flatten shape, the late gene products (L1 and L2) which are 
required for capsid assembly are produced.  In the flattened most upper superficial 
layers viral assembly is completed and infected squames containing infectious HPV 
are released.   
 
 
 
 
however, HSV-2 may still be a co-factor for development of cervical carcinoma in 
certain cases. (Orth, Jablonska et al. 1978; Boshart, Gissmann et al. 1984) 
1.4 Herpes simplex virus type 2, compounding the problem 
Herpes simplex virus type 2 (HSV-2) are large double stranded enveloped DNA 
viruses in the Herpesviridae family. (Knipe and Howley 2007) The genome 
consists of two unique regions, UL (long) and US (short), flanked by repeated 
sequences. (Wadsworth, Jacob et al. 1975; Latchman 1991) HSV-2 infection is 
acquired through close contact with an infected person who is shedding virus from 
their epithelia or genital secretions. (Gupta, Warren et al. 2007) In the initial stages of 
the primary infection the HSV-2 particle attaches to cell surface receptors in mucosal 
tissues followed rapidly by viral fusion with the host cell plasma membrane.  HSV-2 
attaches and fusions to cells in three stages:  (1) attachment of virion to muscoal cell 
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surface (WuDunn and Spear 1989; Herold, WuDunn et al. 1991); (2) interactions of 
glycoproteins with cellular receptors (Spear and Longnecker 2003); and (3) fusion of 
viral envelope with host cell plasma membrane resulting the viral capsid and 
tegument entry into the cell. (Campadelli-Fiume, Cocchi et al. 2000)  HSV-2 has the 
ability to bind multiple receptor targets giving the virus the ability to infect almost all 
cell types in vitro, however in vivo HSV-2 infects epithelia in part because of 
availability of target sites in genital skin and mucosal surfaces.  During attachment 
viral glycoprotein D (gD) interacts with one of several cell surface receptors, herparin 
sulphates or other glycoaminoglycans (for example, chondroitin sulfate) and a co-
receptor.  The co-receptors HSV-2 can utilize and bind are proteins belonging to the  
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Figure 7: HSV-2 Lifecycle 
HSV-2 particle attaches to mucosal cell surfaces and through interaction of viral 
glycoproteins with several different types of cells surface receptors, the virion fuses 
with the cell with viral capsid and tegument entry.  Viral host shutoff protein (VHS) 
shuts off host functions and VP16 is translocated into the nucleus.  Through 
interaction with the cell microtubule network, the capsid is transported to the nucleus 
where it releases the double stranded viral DNA into the nucleus.  Viral DNA 
undergoes circularization and transcription begins.  Transcription of the immediate 
early genes occurs first with the transcripts being transported into the cytoplasm for 
translation.  Some of the immediate early proteins are transported back into the 
nucleus to shut off immediate early transcription and turn on genes for early gene 
transcription.  The early gene products are translated in the cytoplasm and control 
cellular functions and some are translocated back into the nucleus to start viral DNA 
replication and late gene expression.  The late gene products are structural capsid and 
tegument proteins required for assembly.   
 
 
nectin family of proteins (Cocchi, Menotti et al. 2000), herpesvirus entry mediator 
proteins that belong to the tumor necrosis factor receptor family (Montgomery, 
Warner et al. 1996) or 3-O-sulfated heparan sulfate. (Shukla, Liu et al. 1999) 
Following viral envelope and host cell plasma membrane fusion some tegument 
proteins remain in the cytoplasm and start to effect cellular metabolism in several 
ways.  Some proteins (viral host shut off factor) shut off host functions, while others 
(VP16) are translocated into the nucleus.  The capsid interacts with the host cell 
microtuble network and is transported to the nucleus where it associates with a  
nuclear pore releasing the viral double stranded DNA genome into the nucleus. 
(Kristensson, Lycke et al. 1986; Sodeik, Ebersold et al. 1997)  After the viral 
double stranded DNA genome enters the nucleus it rapidly circularizes and 
transcription of immediate early genes commences. (McNamee, Taylor et al. 2000)  
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The host’s RNA polymerase II and viral protein, VP16, facilitate this highly 
regulated process.  The resulting immediate early mRNAs produced undergo 
splicing events and are transported to ribosomes in the cytoplasm for translation.  
Some of the resulting viral proteins are translocated back into the nucleus to shut 
off immediate early gene production and turn on early gene production. A portion 
of the subsequent proteins produced by early gene transcription and translation, 
remain in the cytoplasm to control cellular function and a portion translocates into 
the nucleus to start viral DNA replication via a rolling circular mechanism. (Strang 
and Stow 2005) This produces concatameric viral DNA, which serves as a template 
for late gene expression and viral genome replication.  The proteins produced from 
late gene expression are mainly structural capsid proteins required for assembly, 
tegument and envelope proteins.  Once the envelope proteins have been 
glycosylated in the Golgi they are transported to the host cell membrane for 
assembly.  However, the capsid and tegument proteins are translocated into the 
nucleus where packing enzymes package the viral genome into the nucleocapsid.  
The completed resulting nucleocapsid combined with the tegument proteins line up 
at the nuclear membrane and bud into the endoplasmic reticulum (ER).  After 
passing through the ER the partially assembled virus is processed in the Golgi, 
transported to the host cellular membrane where the fully packaged virus is released 
by exocytosis.  However, when latency is established the virus enters sensory 
neurons and is transported via retrograde transport from the initial site of infection 
in the mucosal tissue to the sensory ganalion. (Gupta, Warren et al. 2007) The 
HSV-2 genome is maintained in a unintegrated circular latent state, with low level 
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expression of latently active transcript (LAT) gene products but without active 
replication of cytotoxicity.  Studies suggest that cytotoxic T cells play a major role 
in maintaining viral latency by active surveillence. (van Lint, Ayers et al. 2004; 
Lang and Nikolich-Zugich 2005) When the immune system is stressed for some 
reason (i.e., fever, immunodeficiency, illness, stress, UV light) HSV-2 is 
reactivated in the neurons and is transported back to epithelia cells by anterograde 
transport and subsequent recurrent infection ensues. (Bloom 2004; Decman, 
Freeman et al. 2005) 
 HPV, HSV-2 and increasing HSV-1 infections (Xu, Sternberg et al. 2006) are 
all major causative agents of genital lesions or ulcers, respectively, causing lifelong 
infections with intermittent viral reactivation and vaginal shedding.(Gupta, Warren 
et al. 2007) When an infected individual has viral activation and an outbreak with 
genital lesions, CD4 positive T-lymphocytes infiltrate the tissue providing more 
target cells for HIV-1 infection (Rebbapragada, Wachihi et al. 2007; Kaul, 
Pettengell et al. 2008), thereby possibly increasing susceptibility to HIV-1 
infection. 
1.5 A modern approach to microbicides at a time when urgently needed. 
The original concept of a microbicide arose from the over the counter 
(OTC) availability of spermicides.  These spermicides, which are topical 
alternatives to birth control systems, are available in foams, creams, films and 
condom coatings, gained great popularity in the 1960s and 1970s with the onset of 
the sexual revolution.(Howett Kuhl 2005)  Most of these spermicides contain N-9, 
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an non-ionic detergent that in vivo exhibits rapid killing of sperm at concentrations 
above 0.1%. By the mid 1970s scientists realized that N-9 worked by dissolving the 
sperm cell membrane and could possibly be used to dissolve the membranes of 
enveloped viruses.  Several early reports (Rapp and Wrzos 1985; Hermonat, Daniel 
et al. 1992) showed efficacy in vitro against HSV-2 but not against non-enveloped 
viruses, such as bovine papillomavirus. A recent report presented at the National 
STD Conference in March 2008 by the CDC reported that one in four female 
adolescents (26%) in the United States has at least one of the most common 
sexually transmitted diseases (HPV, HSV-2, Chlamydia or trichomoniasis). 
The impact of HIV-1 and consequent acquired immunodeficiency syndrome 
(AIDS) on women is severe, particularly in areas of the world where heterosexual 
transmission is the dominant mode of HIV-1 transmission.(UNAIDS 2004)  
According to the World Health Organization there were 2.5 million newly reported 
cases in 2007(UNAIDS 2007) and over 50% of the new infections are 
women.(UNAIDS 2003) Since 2003, women have increasingly become the face of 
the HIV-1 pandemic (UNAIDS 2003) and represent a source of infection for their 
uninfected partners and their children. The main HIV-1 prevention tools, condom 
use, reducing the number of sexual partners and treating other reproductive tract 
infections are not always feasible for many women living in resource poor settings 
and in male dominated societies.  Women often have limited ability to enforce 
cooperation by their male partners to use condoms due to social, cultural and 
economic gender inequalities.(Van De Wijgert and Coggins 2002) Throughout the 
world, many women are submissive to their husbands or partners wishes due to 
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cultural, social or financial arrangements.  In many instances, women are unable to 
refuse the sexual advances of their partners, thereby eliminating the opportunity to 
use contraceptive foams or creams.  This issue is compounded by the ignorance of 
their partner’s sexual activity or use of intravenous drugs, increasing the women’s 
risk of acquiring STIs in both consensual and non-consenual relationships. 
Availability of an effective inexpensive and safe, female-controlled microbicide 
would provide women the tools to protect themselves against STI and impact the 
health of their uninfected partners and children. 
Condoms, diaphragms and cervical caps all are coated with microbicides 
specifically designed for use with these devices.  Since 2000 we have known that 
Nonoxynol 9 (N-9), the most broadly distributed spermicide in over-the-counter 
(OTC) products including lubricants in male latex condoms (FDA 2007), increases 
the risk of HIV-1 transmission to women frequently exposed to N-9.(Van Damme, 
Ramjee et al. 2002; van de Wijgert and Coggins 2002; Davis and Doms 2004)  N-9 
has not been banned by the US Food and Drug Administration (FDA), but in 
December 2007 the FDA emitted a final ruling requiring all OTC products 
containing N-9 to be prominently labeled indicating its risks of HIV-1 transmission 
to women.(FDA 2007)  This ruling however, however, does not apply to condoms, 
which are subject to FDA’s medical device regulation instead of under the 
jurisdiction of OTC products.(FDA 2007)  
As previously described, HIV-1 is a sexually transmitted virus; it is found in 
two different infectious forms, cell-free and cell-associated. Since both forms are 
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found in semen and vaginal secretions an ideal microbicide must be efficacious 
against both forms. The complexity and multi-faceted aspects of HIV-1 infection 
have caused researchers to recognize the value of combining microbicides to 
interfere with infection using multiple modes of action or blocking multiple entry 
points.  The most basic definition of a microbicide is a chemical or physical agent 
that can kill a microbe.(Howett Kuhl)  But in the context of the STI epidemic, the 
term microbicide is defined by the World Health Organization (WHO) as “any 
compound that can be applied inside the vagina or rectum to protect against 
sexually transmitted diseases”.  Potential microbicides can be placed into one of 
three broad categories: (1) compounds that inactivate or disrupt viruses; (2) 
compounds that inhibit specific stages of virus infection and replication such as, 
fusion, uncoating, reverse transcription, etc.; and (3) compounds that specifically or 
non-specifically block infection by physically binding to the cell or virus surfaces 
(Davis and Doms 2004). The three different microbicides studied in this thesis each 
fall into one of these three broad categories and may be used accordingly based the 
person’s circumstance.  The SDS Hydrogels have broad spectrum activity and 
inactivate HIV-1, HSV-2 and HPV-11.  The microbicide containing short 
interfering RNA (siRNA) targeting human chemokine receptor 5 (CCR5) may 
potentially inhibit binding of M-tropic HIV-1 forms from binding to the co-
receptor, thereby, preventing subsequent infection.  Lastly, is a pro-biotic approach 
by using recombinant lactobacilli secreting cyanovirin as a microbicide by 
specifically blocking infection by binding the HIV-1 glycoprotein 120 (gp120).  
Some microbicides have broad-spectrum activity against bacteria and viruses while 
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other microbicides are only specific for HIV-1, for example, attacking specific 
stages of the HIV-1 lifecycle.  An ideal microbicide must have the following traits:  
broad spectrum activity against bacterial and viral sexually transmitted infections, 
efficacy against cell-free and cell-associated HIV-1, no or little effect on the 
structural integrity of vaginal and cervical mucosal epithelium, stability at tropical 
temperatures and resistant to acidic pH.  To make it attractive and available for use, 
it must be odorless, colorless, tasteless, of low cost and readily accessible.(Balzarini 
and Van Damme 2007)     
1.6 The prototypic SDS Hydrogel a versatile potential answer for the problem 
While searching for compounds that would inactivate HPV, Dr. Howett and 
colleagues identified a prototype alkyl sulfate, sodium dodecyl sulfate (SDS) CAS 
#151-21-3, as a potential microbicide. Non-ionic surfactants, such as N-9, were 
found not to inactivate HPV because of the tightly packed protein coat of the virus.  
Sodium dodecyl sulfate (SDS) and other alkyl sulfates are anionic surfactants that 
also possess chaotropic properties. At concentrations below critical micellar 
concentration, (CMC), SDS enters into membranes and alters membrane fluidity.  
At and above the CMC concentrations, SDS will form micelles, solubilize cell 
envelopes and form mixed micelles with the solubilized lipids.  When added to 
cells in culture, SDS will dissociate membranes into their lipid and protein 
components.  In addition to previously being shown to disrupt enveloped 
viruses.(Becker, Helenius et al. 1975; Howett, Neely et al. 1999)  Long term (24 
hour) patching of SDS on skin can induce biochemical changes, namely 
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mobilization of dendritic cells and recruitment of lymphocytes, however, exposures 
up to three hours were not irritating.(Effendy and Maibach 1995; Aramaki, Loffler 
et al. 2001)   Importantly, the combined surfactant and chaotropic properties of 
alkyl sulfates give SDS and other family members very effective anti-microbial and 
anti-viral activity. As far back as 1952, SDS was combined with sodium perborate 
for use as a douche to treat vaginal infections. (Karnaky 1952; O'Brien and Thoms 
1955) Although SDS clearly can disrupt cells in culture, in intact mucosal tissues 
the surface keratinization, mucus and cellular exudates form a protective layer that 
is not easily disrupted by SDS.  Sodium dodecyl sulfate and other alkyl sulfates are 
in the Generally Recognized As Safe (GRAS) list of the FDA (FDA 2006), are 
routinely used as a common ingredient in consumer products applied topically to 
the skin and mucosa (e.g. body lotions, baby wipes, toothpaste and shampoo) and 
as food additives (e.g. marshmallows and gelatin). SDS is metabolized and has 
been classified by the United Nations Environmental Program as readily 
biodegradable.(Howett Kuhl)  
Our laboratory has shown that at concentrations ranging from 0.01% to 1% 
SDS kills HIV-1, HPV, herpes simplex virus (HSV) types 1 and 2 (Howett, Neely 
et al. 1999; Krebs, Miller et al. 1999; Krebs, Miller et al. 2000; Krebs, Miller et al. 
2002; Howett and Kuhl 2005; Urdaneta, Wigdahl et al. 2005; Hartmann, Wigdahl 
et al. 2006), Chlamydia trachomatis (Achilles, Shete et al. 2002) Neisseria 
gonorrhea as well as Gram positive and Gram negative bacteria (Hartmann and 
Howett, unpublished results). Viral plaque assays proved that 0.1% and higher 
concentrations of SDS in aqueous solution inactivated HSV-2 and MAGI assays 
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proved that at these concentrations SDS also inactivated HIV-1.  At the same 
concentrations, SDS prevented bovine papillomaviruses from inducing foci in 
epithelial cell monolayers, prevented Shope cottontail rabbit papillomavirus from 
forming papillomas in vivo, prevented HPV-11 from inducing experimental human 
papillomas. (Howett 1999)  Control epithelia exposed to 1% SDS in vitro were not 
killed and the tissue yielded histologically normal epithelia 3 months after 
implantation in immunocomprised mice.  0.1% SDS in aqueous solution reduces 
HPV-11 virus titer by three fold, can directly affect dissolution of virions and 
release of virus DNA (Fang & Howett, Kish & Howett, unpublished observations). 
Because of its chaotropic properties SDS is also routinely used in laboratories for 
protein separation in polyacrylaminde gel electrophoresis.  Our laboratory and 
others have shown that other alkyl sulfates including potassium laureth sulfate, 
lauric acid, lauryl alcohol, monolaurin and the related monocaprin also have 
antiviral activity.  Yet, SDS remains the most efficacious.   
 Another potential use for SDS as a microbicide is the treatment of HIV-1 
infected human breast milk.  At low treatment concentrations (0.1-1%), SDS has 
been shown to inactivate high concentrations of purified HIV-1 added to expressed 
human breast milk. (Urdaneta). In addition, SDS was successfully removed, >90%,  
with a commercial resin (SDS Detergent Out) without substantially altering the 
nutritional or immunologic properties of the treated milk.  The presence of the 
microbicide was sufficient to reduce infectivity of both cell-free and cell-associated 
virus and to allow rapid degradation of virus RNA in the treated milk.  Thus, we are 
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proposing that prototypic SDS Hydrogel can be used as a vaginal microbicide but 
the compound SDS can also be utilized as a microbicidal treatment for breast 
milk.(Urdaneta) 
1.7 Using RNAi to outsmart HIV-1 
In 1996 a Hemophilia Growth and Multicenter AIDS Cohort study (Dean, 
Carrington et al. 1996) found that mutations in the Chemokine Receptor 5 (CCR5) 
co-receptor, confers some resistance in humans to infection by HIV-1 M-tropic 
forms.  This mutation was found to be present at a frequency of ~0.10 in the 
Caucasian population in the United States. 
The rate of HIV-1 disease progression varies considerably among infected 
individuals.  A small but rare subset of chronically infected, therapy naïve 
individuals appear to maintain high and stable CD4+ and CD8+ T cell counts with 
low to undetectable plasma viral loads for an prolonged number of years.(Dean, 
Carrington et al. 1996; Mikhail, Wang et al. 2005) The importance of CCR5 in 
HIV-1 infection and pathogenesis was revealed by the discovery of the CCR5Δ32 
allele, a 32 base pair deletion in the portion of the human CCR5 open reading frame 
that encodes the second extracellular protein loop between transmembrane domains 
four and five of the seven transmembrane architecture.(Dean, Carrington et al. 
1996; Agarwal, Zainab Van Horn et al. 2004; Oppermann 2004) CCR5Δ32 encodes 
a truncated protein that is retained in the endoplasmic reticulum, which is not 
detectable on the cell surface.(Benkirane, Jin et al. 1997; Agrawal, VanHorn-Ali et 
al. 2004) People who are homozygous for the CCR5Δ32 mutation are resistant to 
HIV-1 infection from M-Tropic strains, which is the form most commonly sexually 
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transmitted, and heterozygous individuals expressing CCR5Δ32 progress more 
slowly to AIDS.(Dean, Carrington et al. 1996) Also, people that are homozygous 
for the CCR5Δ32 mutation appear to be phenotypically normal and to date the only 
immunodeficiency found was an increased susceptibility to a fatal West Nile Virus 
infection.  For these reasons CCR5 has become a very attractive target of 
investigation to many researchers.   
 CCR5 is a G-coupled protein receptor, which has seven transmembrane 
domains with an extracellular N-terminal portion and a cytoplasmic C-terminal 
portion.  It is found on CD4 positive T cells with memory/effector phenotype, 
monocytes, macrophages and Langerhan cells.(for review see Oppermann, 2004) 
 
 
 
 
 
 
 
 
 
 
 
 
Double Stranded RNA 
Cleaved by Dicer, an RNase III enzyme 
 siRNA ~23 nt in length 
siRNAs associate with RISC 
siRNA unwinding activates RISC 
DICER 
RISC 
protein 
components 
  
44 
 
 
 
 
 
 
 
 
 
Figure 8: RNAi Pathway 
This pathway is activated by the introduction of double stranded RNA into the 
cytoplasm of a cell.  An RNase III type enzyme, Dicer, cleaves the double stranded 
RNA into short 20-23 nucleotide segments, which associate with the RISC complex.  
The RISC is comprised of Argonant proteins that are activated by the unwinding 
siRNA.  The RISC helps to guide the siRNA to its complementary mRNA, which in 
turn is degraded.    
 
 
CCR5 binds MIP-1α, MIP-1β and RANTES ligands.  Initially, chemokines 
were identified as chemoattractant cytokines involved in leukocyte trafficking to 
sites of inflammation however, their biological functions do not end with 
chemotaxis.  Chemokines have been shown to be involved in many different 
biological functions, such as angiogenesis, haematopoiesis, embryonic development 
and metastasis.(Oppermannm 2004; Yoshie, 2001; Gerard 2001)  CCR5 is an 
important co-receptor for HIV-1 and is preferentially used by HIV-1 during the 
primary infection macrophages and lymphocytes.(Shea & Deng Nature 1997) 
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One promising approach scientists have taken in creating microbicides is 
creating synthetic chemokines molecules that compete with HIV-1 for the CCR5 co-
receptor.  CCR5 is a human chemokine that normally binds MIP-1ą, MIP-1β and 
RANTES chemokines.  The most successful of the synthetic chemokines to inhibit 
binding of HIV-1 is PSC-RANTES, which is a RANTES analog chemically 
identical to native RANTES except for the substitution of a nonanoyl group, 
thioproline and cyclohexylglycine for the first three N-terminal amino acids of the 
native protein.(Lederman, Veazey et al. 2004)  This synthetic PSC-RANTES was 
vaginally applied to rhesus macaques and upon challenging with SHIV, a simian 
immunodeficiency virus and human immunodeficiency virus chimera, it was shown 
that 12 out of the 15 monkeys treated were protected by 100 ųM 
treatment.(Lederman, Veazey et al. 2004)   
 Much of the human genome consists of remnants of previous transposon/virus 
invasions and elements that are still active to date, therefore one would expect that 
organisms need to fight off such invasions to prevent the genome from being 
completely taken over by molecular invaders.(Plasterk 2002) A novel approach in 
developing a microbicide is to use RNA interference (RNAi) (for review see 
Shrivastava, 2008; de Fougerolles, 2007) targeted towards the CCR5 chemokine 
receptor.  This RNA-based silencing mechanism has emerged as an ancient 
mechanism that is conserved among species from different kingdoms (fungi, animals 
and plants) and very likely acts as the “immune system” of the genome.(Plasterk 
2002) RNA interference was originally identified in Caenorhabditis elegans, while 
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studying a gene encoding a nonessential myofilament protein, unc-22.(Fire)  Fire 
and colleagues demonstrated that the injection of a mixture of sense and antisense 
RNA molecules homologous to a 742 nucleotide segment of the unc-22 produced 
more potent gene inhibition as compared to using sense or antisense molecules 
injected alone.  As illustrated in Figure 9, RNAi is a sequence specific 
posttranslational gene silencing, which is triggered by double stranded RNA.  After 
double stranded RNA introduction or formation, the long double stranded RNAs are 
cleaved by Dicer, a member of the RNase III family, into 21 – 23 nt small interfering 
RNA (siRNA) with two nucleotide 3’ overhangs and 5’ phosphate 
termini.(McManus, Haines et al. 2002; Milhavet, Gary et al. 2003) Then the 
processed siRNAs are incorporated into a multi-component nuclease complex, 
known as RNA induced silencing complex (RISC), which is responsible for the 
association and degradation of the target mRNA.(Martinez, Patkaniowska et al. 
2002; Yu, DeRuiter et al. 2002)  It has been shown that siRNA has been successful 
in down-regulating CCR5.  In U87-CCR5 cells, which are engineered to express 
CCR5, CCR5 was down-regulated by 48% decreasing viral entry by 55% resulting 
in inhibition of HIV-1 replication.(Martinez, Gutierrez et al. 2002) siRNA targeted 
against CCR5 and HIV-1 p24 antigen together in infected macrophages also down-
regulated CCR5 and inhibited viral entry for fifteen days.(Song, Lee et al. 2003)  
Another study showed down-regulation of CCR5 in MAGI-CCR5 cells that 
decreased CCR5 expression by ten fold, which in turn decreased viral replication by 
three to seven fold.(Qin, An et al. 2003) 
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1.8 Can recombinant probiotics be used to secrete a microbicide? 
Probiotic is from the Greek meaning “for life” and is used to describe a 
specific type of live, beneficial bacteria that may be used to replace or replenish 
resident, commensal bacterial populations.  The United Nations’ Food and 
Agriculture Organization (FAO) and the World Health Organization (WHO) 
formally define probiotics as live microorganisms, which, when administered in 
adequate amounts, confer a health benefit on the host. (Report of a Joint FAO/WHO 
Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics 
in Food Including Powder Milk with Live Lactic Acid Bacteria, Amerian Córdoba 
Park Hotel, Córdoba, Argentina. 1-4 October 2001). Therefore, probiotics are a class 
of beneficial bacteria that help to restore and maintain a healthy balance of “good” 
versus “bad” bacteria.  
The bacterial species that colonize the human body are both numerous and 
diverse.  These bacteria or normal flora inhabit the skin, the entire digestive system 
and urogenital tract in women. Many of these normal flora contribute to the healthy 
development of the immune system, prevent infection from pathogenic and 
opportunistic microbes as well as maintain the intestinal barrier function.  Illness, 
poor nutrition, use of antibiotics and other factors can affect this delicate balance and 
cause emergence of harmful bacterial. In 1907 the Russian scientist, Elie 
Metchnikoff, hypothesized that replacing or diminishing the number of putrefactive 
bacteria in the gut with lactic acid bacteria could normalize bowel health and 
prolong life.(Anukam, 2007) For decades gynecologists have recommended women 
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include yogurt in their normal diet because of  the beneficial nutritional and 
probiotic properties.  Yogurt helps to maintain the normal flora in the vaginal 
environment.  Daily ingestion of yogurt containing live lactobacilli has been shown 
to decrease vulvovaginal Candida infections by three fold.(Hilton, 1992) 
The predominate normal flora found in the vagina is lactobacilli.  These 
bacteria are gram-positive rods, primarily facultative anaerobes that generally have a 
fastidious growth environment.  They prefer an acidic environment and help create 
one by producing lactic and other acids.(Reid 2001)  Byproducts produced from 
lactobacilli metabolism have antagonistic effects against urinary and vaginal 
pathogens. One approach for delivering microbicides is to use probiotics, 
specifically recombinant normal flora in the vaginal environment.  
Recent studies have shown that exogenously applied lactobacilli or 
indigenous lactobacilli can reduce the risk of urinary tract infections, where 
lactobacilli depletion is associated with bacterial vaginosis and yeast 
vaginosis.(Reid, 2001; Reid, 1995; Raz, 1993; Gupta, 1998)  Ingested lactobacilli, 
specifically L. rhamnosus GR-1 and L. reuteri RC-14, have been shown to influence 
the vaginal environment by being delivered to the vagina following oral ingestion 
via the natural passage through the intestine and along the perineal and vulval 
skin.(Reid and Bruce, 2001; Anukam, 2007) An imbalance in or a depletion of 
normal flora in the vaginal environment has been associated with an increased risk 
of acquiring opportunistic infections, including HIV-1. (Chang, 2003; Taha, 1998)  
Recently, recombinant lactobacilli as a delivery method for microbicidal molecules 
and compounds has attracted a lot of attention and may provide a unique opportunity 
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to prevent the transmission of HIV-1.  The first recombinant lactobacilli tested was a 
recombinant L. jensenii Xna, which secreted CVN and a two domain soluble CD4 
(2D CD4) molecule.(Chang, 2003) In vitro testing of this lactobacilli showed a small 
decrease in HIV-1 binding.(Chang, 2003) Our collaborator has designed a 
recombinant lactobacilli that secretes CVN and optimized the CVN secretion in the 
lactobacilli L. plantarum.(Pusch, 2006).  The studies presented in this thesis are the 
first steps in testing our recombinant L. plantarum for reconstituting human vaginal 
tissue ex vivo and in vivo as well as for anti-HIV-1 activity.   
In 1997 a novel protein, Cyanovirin-N (CVN), was discovered to have potent 
anti-HIV-1, anti-HIV-2 and anti-SIV activity.(Boyd, 1997)  CVN is an 11-kD 
protein, which is produced by the cyanobacterium, Nostoc ellipsosporum.  This 
protein has been shown to be resistant to physico-chemical degradation, multiple 
freeze-thaw cycles, heat and can withstand treatment with denaturants, detergents 
and some organic solvents. (Bewly, 1998; Boyd, 1997) Ex vivo experiments utilizing 
human cervical tissue and in vivo experiments utilizing adult female cynomolgus 
macaques (Macaca fasciularis) showed treatment with low doses of CVN in a gel 
formulation prevented infection from HIV-1 and SIV, respectively, when treatments 
occurred up to an hour before inoculation. (Tsai, 2004) Another recent study has 
shown that combining CVN with the peptide 12p1, which was isolated from a phage 
display library, has a synergistic effect increasing the anti-HIV-1 activity of both 
compounds allowing lower dosages to be used without decreasing 
efficacy.(McFadden, 2007) The antiviral activity of CVN is due to the irreversible 
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multivalent interactions between CVN and high mannose residues on the HIV-1 
envelope glycoprotein, gp120.(TSal, 2004; Botos, 2002; Shenoy, 2002) It is these 
molecular interactions that prevent fusion of the virus particle with the target cells 
and make CVN an ideal candidate for investigation as a potential microbicide.   
1.9 ex vivo and in vivo experimental systems utilized to test microbicides.  
When testing microbicides it is imperative to test the compounds in the exact 
tissues that will be exposed to the compound in the vaginal environment.  A very 
important aspect of the work set forth in this thesis involves utilizing human vaginal, 
cervical and foreskin tissue in both ex vivo and in vivo model systems.  Before 
beginning experiments utilizing human tissues the compounds were tested in vitro 
for toxicity and efficacy using several different cell lines.  The different cell lines 
and the experimental procedures used will be discussed in detail in each individual 
chapter for each microbicide.  However, a brief overall description of the ex vivo and 
in vivo model systems are discussed below.   
 The organ tissue culture (OTC) system, originally developed by Gupta and 
colleagues, was the ex vivo model system selected to test the compounds before 
going into the immunocompromised mouse human epithelial model system.  The  
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Figure 9: Organ Tissue Culture System 
Originally developed by Gupta and colleagues, to study microbicides to prevent the 
transmission of HIV-1.  Human tissue is placed epithelia surface upwards in a 
transwell dish, surrounded by agarose and then placed in a 12 well dish that has 1 ml 
of media in each well.  The OTC was used to test FITC-tagged siRNA absorption into 
human vaginal tissue.  After treatment with non-specific FITC-tagged siRNA the 
tissue was snap frozen, cryosectioned and examined by immunofluorescent 
microscopy (IF).  Also, the bottom chamber was examined by IF to check for leakage.  
This system was also used to determine CCR5-siRNA down-regulation in human 
vaginal tissue.  After treatment the tissue was homogenized and Western Blot analysis 
was performed, as described in Chapter 3.   
 
OTC model system permits the compound or substance to naturally traverse the 
tissue from epithelial to stromal surface, just as it would in the normal vaginal 
environment. As shown in Figure 9, the OTC system uses human tissue placed 
epithelia surface upwards in a 0.3 µm membrane transwell dish, surrounded by 5% 
sterile agarose.  The sterile agarose forms an intact seal around the top of the 
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epithelial tissue, simulating a fully intact epithelia layer as found in normal vaginal 
walls.  Once the agarose solidifies around the epithelia the transwell dish is placed in 
a twelve well plate, which has one milliliter of cell culture media in each well.  This 
allows the tissue to be fed from underneath with the appropriate nutrients from the 
cell culture media.  The application of the specified compound is then added to the 
top of the tissue in the top chamber of the OTC and following incubation in a 
humidified chamber the tissue is processed for either immunofluorescent 
microscopy, standard hematoxylin and eosin staining or Western blot analysis.  This 
in vitro/ex vivo system was selected because it most closely emulates the natural 
process that the microbicide and the virus must traverse to infect the tissue in the 
vaginal environment. 
The human vaginal epithelia system was selected as the in vivo model 
system to test the efficacy of the compounds.  This system was developed by 
Howett and Krieder to grow a fastidious organism, human papillomavirus, that 
could not be grown in cell culture.(Kreider, Howett et al. 1985) This model system 
overcomes many of the problems that limit biological experimentation with HIV-1; 
it is a human system with human tissue.(Kish, Budgeon et al. 2001) This system  
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Figure 10: Human Epithelial Xenograft System 
Cervicaovaginal tissue is prepared by slicing away the epithelia from the stroma, 
taking minimal amounts of stroma and implanting the epithelia with an estrogen pellet 
in the subcutaneous space in the back of NOD/SCID mice. The epithelia is allowed to 
heal for three weeks forming a tube similar to the vaginal tube in women, after which 
the lumen of the graft is treated with specified compound and challenged with virus.  
It is important to note in the diagram how the vaginal tissue takes on a tube 
conformation, modeling the vaginal tube in women and reproducing how the 
heterosexual transmission of STI occurs.   
uses non-obese diabetic severely compromised immunodeficient  (NOD/SCID) 
mice, which do not have any humoral or cell mediated immunity, lack natural killer 
cells and circulating complement system.(Janeway, Travers et al. 2001; Kish, 
Budgeon et al. 2001)  By using the NOD/SCID mice graft rejection is eliminated 
  
54 
and decreases other variables, such as, mouse immune cells infiltrating the 
xenograft and affecting the analyses.  Previous studies have shown that this in vivo 
model system can sustain active HIV-1 transmission  
and replication in human vaginal tissue, vagina or cervix, its normal environment 
during transmission.(Kish, Budgeon et al. 2001) In the NOD/SCID animals 
complete restoration of the epithelial layer across the entire xenograft occurred 
within three weeks and the human CD45+ cell populations and distribution were 
present at baseline levels (equivalent to freshly excised tissue) up to two months 
after engraftment.(Kish, Budgeon et al. 2001) Figure 10, outlines the basic 
procedure for the xenograft system.  Briefly, human vaginal or cervical tissue is 
first prepared by separating the epithelia from the stroma (leaving a minimal 
amount of stroma) then the tissue is rolled with the epithelium on the inside and 
subcutaneously implanted, along with an estrogen pellet, on the back (in between 
the skin and muscle) of the mouse.  After healing for approximately three weeks, 
the tissue has re-epithelialized with resulting tissue morphology and architecture 
comparable to normal vaginal epithelial tissue.  The healed xenograft forms a tube, 
similar to the vaginal tube in women, and since the treatment and/or virus is 
introduced directly into the lumen of the xenograft it mimics the natural 
heterosexual transmission of HIV-1.  
Specific Aims: 
Chapter 2:  SDS Hydrogel 
To determine if formulated SDS Hydrogels have broad spectrum anti-viral activity 
(HIV-1, HSV-2 & HPV).   We hypothesize that our formulated SDS Hydrogels will 
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have potent anti-HIV-1, anti-HSV-2 and anti-HPV activity at very low 
concentrations. 
Chapter 3: Liposomal delivered CCR5 siRNA in human vaginal epithelial 
xenografts. 
To determine whether liposomal delivered siRNA can mediate knockdown in vivo 
of CCR5 on immune cells found in vaginal epithelium and if so ascertain the effects 
on transmission.   We hypothesize that down-regulating human CCR5 will decrease 
HIV-1 binding and fusion in vitro, ex vivo and in vivo, thereby, providing proof-of-
principle that liposomal delivered siRNA targeting human genes can successfully 
be used as a microbicide. 
Chapter 4:  Cyanovirin secreting L.plantarum 
To determine whether lactobacilli secreting Cyanovirion can effect HIV-1 
transmission in vitro and in vivo.  We hypothesize that utilizing recombinant forms 
of normal vaginal flora that secretes cyanovirin, a anti-HIV-1 compound, 
decreasing HIV-1 transmission in vivo providing proof-of-principle for using 
recombinant L.plantarum as a means of re-colonizing the vaginal environment as a 
microbicide.   
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2. A Hydrogel Formulation Containing Alkyl Sulfate Inactivates a 
Broad Spectrum of Sexually Transmitted Viruses 
Veronica Holmes, Joseph A. Fraietta, Sandra Urdenata Hartmann, Yana Thaker, 
Erika Briggs, Vani Dandolu, Silke von Dyck and Mary K. Howett 
 
The following chapter is written as an independent manuscript to allow for an easy 
transition from thesis format to submission format. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. 1 Introduction 
The breath and depth of the sexually transmitted infection (STI) epidemic is 
staggering (for review see (Low, Broutet et al. 2006; Aral, Fenton et al. 2007; Da 
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Ros and Schmitt Cda 2008)).  As of December 2007, 34 million people worldwide 
are infected with human immunodeficiency virus type 1 (HIV-1) (UNAIDS 2007), 
approximately 20 million people are infected with human papillomavirus (HPV) 
(CDC 2007) and at least 45 million people, in the United States alone, are infected 
with herpes simplex virus type 2 (HSV-2).(CDC 2006).  In especial concern to 
HIV-1 susceptibility and transmission, several studies have shown that infection 
with one STI increases a person’s susceptibility to another STI with women being 
the most susceptible population to STI.(Wald and Corey 2003; Freeman, Weiss et 
al. 2006; Madkan, Giancola et al. 2006) The pandemic of HIV-1 infection emerged 
in the 1980’s and has raised many new challenges to infectious disease paradigms 
that existed at that time.(Yang 2004) Continued lack of an effective anti-HIV-1 
vaccine and the unabated spread of HIV-1 emphasizes the urgent need for the 
development of new preventative measures to stop transmission, such as topical 
microbicides (for review see (Balzarini and Van Damme 2007; van de Wijgert and 
Shattock 2007)).   
When HIV-1 is sexually transmitted it is found in two different forms, cell-
free and cell-associated.  Since both forms are found in semen and vaginal 
secretions an ideal microbicide must be efficacious against both forms. Topical 
microbicides are defined as any compound that can be applied inside the vagina or 
rectum to protect against sexually transmitted diseases.  Potential microbicides can 
be placed into one of three broad categories: (1) compounds that inactivate or 
disrupt viruses; (2) compounds that specifically or non-specifically block infection 
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by physically binding to the cell or virus surfaces; and (3) compounds that inhibit 
specific stages of virus infection and replication such as, fusion, uncoating, reverse 
transcription, etc.(Davis and Doms 2004).  An ideal microbicide must have the 
following traits:  broad spectrum activity against bacterial and viral sexually 
transmitted infections, efficacy against cell-free and cell-associated HIV-1, no 
effect on the structural integrity of vaginal and cervical mucosal epithelium, 
stability at tropical temperatures and resistant to acidic pH.  To make it attractive 
for use, it must be odorless, colorless, tasteless, low cost and readily 
accessible.(Balzarini and Van Damme 2007)    
 HPV infection is the most common sexually transmitted disease in the United 
States (CDC 2007; Dunne, Unger et al. 2007; Forhan 2008) and HPV DNA has 
been found in 90% of cervical cancers.(zur Hausen 2002)  Every year 250,000 
women worldwide and 5,000 women in the United States die needlessly due to 
cervical cancer.  HPV, HSV-2 and increasing HSV-1 infections (Xu, Sternberg et 
al. 2006) are all major causative agents of genital lesions or ulcers, respectively, 
causing lifelong infections with intermittent viral reactivation and vaginal 
shedding.(Gupta, Warren et al. 2007) When an infected individual has viral 
activation and an outbreak with genital lesions, CD4 positive T-lymphocytes 
infiltrate the tissue providing more target cells for HIV-1 infection (Rebbapragada, 
Wachihi et al. 2007; Kaul, Pettengell et al. 2008), thereby increasing susceptibility 
to HIV-1 infection. 
 The impact of HIV-1 and consequent acquired immunodeficiency syndrome 
(AIDS) on women is severe, particularly in areas of the world where heterosexual 
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transmission is the dominant mode of HIV-1 transmission.(UNAIDS 2004)  
According to the World Health Organization there were 2.5 million newly reported 
cases in 2007(UNAIDS 2007) and over 50% of the new infections are 
women.(UNAIDS 2003) Since 2003, women have increasingly become the face of 
the HIV-1 pandemic (UNAIDS 2003) and represent a source of infection for men 
and their children. The main HIV-1 prevention tools, condom use, reducing the 
number of sexual partners and treating other reproductive tract infections are not 
always feasible for many women living in resource poor settings and in male 
dominated societies.  Women often have limited ability to enforce cooperation by 
their male partners to use condoms due to social, cultural and economic gender 
inequalities.(Van De Wijgert and Coggins 2002) In addition, since 2000 we have 
known that Nonoxynol 9 (N-9), the most broadly distributed spermicide in over-
the-counter (OTC) products including lubricants in male latex condoms (FDA 
2007), increases the risk of HIV-1 transmission to women frequently exposed to N-
9.(Van Damme, Ramjee et al. 2002; van de Wijgert and Coggins 2002; Davis and 
Doms 2004)  N-9 has not been banned by the US Food and Drug Administration 
(FDA), but in December 2007 the FDA emitted a final ruling requiring all OTC 
products containing N-9 to be prominently labeled indicating its risks of HIV-1 
transmission to women.(FDA 2007)  This ruling however, however, does not apply 
to condoms, which are subject to FDA’s medical device regulation instead of under 
the jurisdiction of OTC products.(FDA 2007)  Availability of an effective 
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inexpensive and safe female-controlled microbicide would provide women the tools 
to protect themselves against STI and impact the health of the men and children.    
 Sodium dodecyl sulfate (SDS) and other alkyl sulfates are anionic surfactants 
that possess chaotropic properties.  SDS will dissociate membranes of cells in 
culture into their lipid and protein components and has previously been shown to 
disrupt enveloped viruses.(Becker, Helenius et al. 1975; Howett, Neely et al. 1999) 
Long term (24 hour) patching of SDS on skin can induce biochemical changes, 
namely mobilization of dendritic cells and recruitment of lymphocytes, however, 
exposures up to three hours were not irritating.(Effendy and Maibach 1995; 
Aramaki, Loffler et al. 2001)   Importantly, the surfactant and chaotropic properties 
of alkyl sulfates give SDS very effective anti-microbial and anti-viral activity.  As 
far back as 1952, SDS was combined with sodium perborate for use as a douche to 
treat vaginal infections. (Karnaky 1952; O'Brien and Thoms 1955) In intact 
mucosal tissues, surface keratinization, cellular exudate and mucus form a 
protective layer that is not easily disrupted by 1% or lower SDS.  Sodium dodecyl 
sulfate and other alkyl sulfates are in the Generally Recognized As Safe (GRAS) 
list of the FDA (FDA 2006), are routinely used as a common ingredient in 
consumer products applied topically to the skin and mucosa (e.g. body lotions, baby 
wipes, toothpaste and shampoo) and as food additives (e.g. marshmallows and 
gelatin).  Our laboratory has shown that at concentrations ranging from 0.01% to 
1% SDS kills HIV-1, HPV, herpes simplex virus (HSV) types 1 and 2 (Howett, 
Neely et al. 1999; Krebs, Miller et al. 1999; Krebs, Miller et al. 2000; Krebs, Miller 
et al. 2002; Howett and Kuhl 2005; Urdaneta, Wigdahl et al. 2005; Hartmann, 
61 
 
 
Wigdahl et al. 2006), Chlamydia trachomatis (Achilles, Shete et al. 2002) Neisseria 
gonorrhea as well as Gram positive and Gram negative bacteria (Hartmann and 
Howett, unpublished results). Based on these results we concluded that the three 
different concentrations of SDS in the formulated gel would be 0.1%, 0.5% and 
1%, which would provide a range of anti-viral activity with the lowest possibility of 
adverse effects.   Because of its chaotropic properties SDS is also routinely used in 
laboratories for protein separation in polyacrylaminde gel electrophoresis.  
 Our laboratory has previously shown that low concentrations of sodium 
dodecyl sulfate (SDS) in cell culture media is relatively non-toxic compared to 
Nonoxynol-9 (N-9) and C31G (Krebs, Miller et al. 2000) and has broad-spectrum 
activity against enveloped and non-enveloped viruses. (Howett, Neely et al. 1999) 
Our collaboration with Hydromer, Inc. (Branchburg, NJ), has produced a 
formulated SDS Hydrogel for use as a potential vaginal microbicide.  Hydromer, 
Inc., has combined SDS with their patented Aquadapt® hydrophilic polymer 
medical technology, which incorporates chitosan derivatives complexed with 
polyvinylpyrrolidone.(Hydromer 2008)  Aquadapt® gels also exhibit lubricious 
properties when in the vaginal environment.  These highly biocompatible polymer 
systems naturally bind one another to form gels, providing excellent physical 
strength and stability.   Currently, the Aquadapt® gels are being utilized to coat 
commercially available medical devices, such as catheters, without exhibiting and 
any signs of tissue toxicity.  It is also used as a vehicle of pharmaceutical 
formulations to mucosal surfaces, such as paranasal sinuses In this study we 
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demonstrate that our prototypic formulated SDS Aquadapt® gel (SDS Hydrogel) 
has potent anti-HIV-1, anti-HSV-2 and anti-HPV-11 activity in vitro and ex vivo 
without being toxic to human vaginal, cervical or newborn foreskin tissue.   
2.2 Materials and Methods 
2.2.1 Hydrogels.  
SDS has been combined with Hydromer’s patented Aquadapt® hydrophilic 
polymer medical technology, which incorporates chitosan derivatives complexed 
with polyvinylpyrrolidone.(Hydromer 2008) These highly biocompatible polymer 
systems naturally bind one another to form gels, providing excellent physical 
strength and stability 
2.2.2 Ex vivo toxicity assay  
Human vaginal tissue was obtained from patients undergoing elective 
reconstructive surgeries for vaginal prolapse.  All experiments utilizing vaginal 
tissue were performed within three hours of excision from the patient and in 
accordance with Drexel University and Temple University Hospital Internal 
Review Board rules and regulations. Human vaginal tissue was cut into 2 mm x 2 
mm x 0.5 cm pieces and placed with the epithelia oriented up on filter paper 
(Whatman, Philadelphia, PA) saturated with DMEM (Mediatech Inc., Herdon, VA) 
supplemented with 10% fetal bovine serum.  Tissue was then treated with either 
placebo, 0.1%, 0.5% or 1% SDS Hydrogel and incubated for 3, 5, 16 or 24 hours.   
Following the incubation periods the tissue was harvested, immediately fixed in 
10% neutral-buffered formalin and processed by standard histological techniques 
for staining with hematoxylin and eosin. 
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2.2.3. HSV-2 Inactivation Assay       
Experiments were performed as previously described.(Howett, Neely et al. 1999) 
For inactivation of HSV-2, 100 µl of virus stock (initially diluted 1000-fold in 
medium, an amount equal to approximately 8.7x104 plaque forming units (pfu/ml)) 
was combined with 100 µl of each of the SDS Hydrogel formulations to achieve 
final concentrations of 0.05%-0.5% and incubated for 10 min at 37°C. Following 
the incubation, each virus/Hydrogel mixture was further diluted in cell culture 
medium (1:50), and 200 µl of each sample was adsorbed onto CV-1 monolayers for 
1 h at 37°C. The monolayers were then re-fed with medium and incubated at 37°C 
in 5% CO2. At 48 h post-infection, the  
cells were fixed and stained with crystal violet and plaques were counted with a 
dissecting microscope. Each datum in Table 1 represents an average for duplicate 
plates.  A two-tailed unpaired Student t-test was performed using GraphPad 
Software to determine statistical significance.  
2.2.4 HIV-1 Cell Free Inactivation Assay.   
Experiments were performed as previously described.(Urdaneta, Wigdahl et al. 
2005) Briefly, one day prior to the assay, P4-R5 HeLa cells (Charneau, Mirambeau 
et al. 1994) were seeded into 12-well culture dishes at a concentration of 8x104 
cells per well and incubated overnight at 37°C with 5% CO2.  The cells used in this 
assay, P4-R5, are HeLa cells that have been engineered to express HIV-1 receptors 
(CD4, CCR5 and CXCR4) and have an integrated HIV-1 promoter fused to a B-
Galactosidase (β-gal) reporter gene.(Charneau, Mirambeau et al. 1994) This allows 
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β-gal expression to be measured when the HIV-1 promoter has been activated.  On 
the day of the assay 5 µl of a high titer stock (107.17 tissue culture infective dose 
50/ml) (TCID50) of HIV-1 (strain IIIB; Advanced Biotechnologies, Inc., Columbia, 
MD) was treated with an equal volume (5 µl) of placebo, 0.1%, 0.5% or 1% SDS 
Hydrogel and incubated for ten minutes at 37°C.  To stop the reaction and to dilute 
the SDS, 990 µl of RPMI media (supplemented with 10% FBS) was added to the 
virus/SDS Hydrogel mixture and 300 µl of this dilution was applied to the P4-R5 
cells in triplicate.  Following a two-hour incubation at 37°C with 5% CO2, 2 ml of 
fresh DMEM media (supplemented with 10% FBS and with half the concentration 
of puromycin 250 ug/ml) was added to each well.   After incubation for 46 hours at 
37°C with 5% CO2, cells were washed twice with phosphate buffered saline, lysed 
and incubated for one hour at room temperature with reaction buffer supplied in 
Galacto-Star™ β-Galactosidse Reporter Gene Assay System (Applied Biosystems, 
Foster City, CA), per the manufacturer’s instructions.  Following the incubation β-
gal expression was quantified utilizing Fluoroskan Ascent FL Luminometer 
(Thermo Scientific, Waltham, MA). β-gal expression was measured in relative 
luminescence units per second (RLU/s).  A one-way ANOVA followed by 
Dunnett’s (compare all versus control) post-test was performed using GraphPad 
Software to determine statistical significance.   
2.2.5 HIV-1 Cell Associated Inactivation Assay.  
Experiments were performed as previously described.(Urdaneta, Wigdahl et al. 
2005) Briefly, three days prior to the assay, Sup-T1 (ATCC, Manassas, VA) cells 
were seeded at a density of 3x106 in 30 ml per T75 flask, infected with a high titer 
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stock (107.17 tissue culture infective dose 50/ml) (TCID50) of HIV-1 (strain IIIB; 
Advanced Biotechnologies, Inc., Columbia, MD) diluted 1:10 (30 µl) in serum free 
antibiotic free media and incubated for 72 hours at 37°C with 5% CO2.  At 48 hours 
post-infection, P4-R5 HeLa cells were seeded into 12-well culture dishes at a 
concentration of 8x104 cells per well. At 72 hours post-infection, the infected Sup-
T1 cells, 1x106 cells in 95 µl for each group, were treated with 5 µl of placebo, 
0.1%, 0.5% or 1% SDS Hydrogel and incubated for ten minutes at 37°C.  To stop 
the reaction and to dilute the SDS, 900 µl of RPMI media (supplemented with 10% 
FBS) was added to the infected Sup-T1/SDS Hydrogel mixture and 300 µl of this 
dilution was subsequently applied to the P4R5 cells in triplicate.  Following a two-
hour incubation at 37°C with 5% CO2, the mixture was aspirated from each well, 
the P4-R5 cells were washed twice with PBS and 2 ml of fresh DMEM media 
(supplemented with 10% FBS and with half the concentration of puromycin 250 
ug/ml) was added to each well.   Following an incubation period of 46 hours at 
37°C with 5% CO2 β-gal expression was quantified and analyzed as described in 
the previous section for the HIV-1 cell free inactivation assay. β-gal expression was 
again measured in relative luminescence units per second (RLU/s). 
2.2.6 HPV-11 Inactivation Assay and RT-PCR.   
Experiments were performed as previously described.(Fang, Budgeon et al. 2006) 
One day prior to the assay A431 cells (established from human epidermoid 
carcinoma(Giard, Aaronson et al. 1973)) were seeded in six-well plates at a density 
of 5x105 cells per well and incubated overnight at 37°C with 5% CO2.  On the day 
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of the assay 30 µl of HPV-11 (2x106 per ml) was mixed with equal volumes of 
either placebo, 0.1%, 0.5% or 1% SDS Hydrogel and incubated for ten minutes at 
37°C.  Immediately following the incubation, 450 µl of media was added to the 
HPV-11/SDS Hydrogel mixture followed by serial dilutions with a total of 1 ml 
being added to each well.  Cells were incubated overnight at 37°C with 5% CO2 
then re-fed with an additional 2 ml media and allowed to incubate for an additional 
2 days. Total cellular RNA was extracted 72 hours postinfection using a 
QIAshredder and RNeasy mini kit (Qiagen, Valencia, CA). Reverse transcription 
polymerase chain reaction (RT-PCR) analysis of the HPV-11 E1^E4 transcript was 
used to determine the end-point dilution of virus that still initiated infectivity in 
50% of the samples as previously described. (Smith, Foster et al. 1995; Ludmerer, 
McClements et al. 2000; Fang, Budgeon et al. 2006) The final expected size for the 
E1^E4 amplified product was 294 bp, and the amplified product for β-actin was 
429 bp.  
2.3 Results: 
2.3.1 Concentrations of SDS Hydrogel formulations are non-toxic to intact 
vaginal and cervical tissue at the histologic level.  
To determine toxicity to the tissues that would be exposed to an SDS-based 
microbicide, human vaginal, cervical and newborn foreskin tissues were exposed ex 
vivo to either placebo, 0.1%, 0.5% or 1% SDS Hydrogel formulations and 
incubated for 3, 5, 16 or 24 hours. In total we tested three concentrations (0.1%, 
0.5% and 1%) for four different treatment times (3, 5, 16 and 24 hours) with Figure 
11 and Figure 12 containing representative pictures showing foreskin, cervical and 
vaginal tissues after treatment for three hours (Figure 12) and cervical tissue after 
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16 hour treatment and vaginal tissue after 24 hour treatment (Figure 13).  Results 
were similar after exposure to either 0.1% or 0.5% SDS Hydrogel formulations 
(data not shown). In all tissues there was no histologically visible squamous 
epithelium disruption after treatment with all of the different concentrations and 
time points.  
2.3.2 SDS Hydrogel formulations inactivate HSV-2.   
Our laboratory has previously shown effective HSV-2 inactivation by 0.1% SDS 
diluted in cell culture media.(Howett, Neely et al. 1999) We performed HSV-2 
plaque assays with SDS Hydrogels to determine the potency of the formulated SDS 
Hydrogels against this enveloped virus.  In two separate experiments with duplicate 
samples all of the SDS Hydrogel treatment concentrations showed strong anti-HSV-
2 activity.  As shown in Table 1, treatment concentrations as low as 0.05% to 0.5% 
were effective in eliminating the ability of the virus to induce plaques in a 
monolayer of monkey kidney cells by completely inactivating HSV-2 in vitro. Since 
there was an increased number of plaques counted in the placebo group a two tailed 
unpaired Student t-test was performed comparing the HSV-2 control to the placebo 
group.  No statistically significant difference was found between the HSV-2 control 
and placebo group in inducing plaque formation (p=0.2625).  This data is consistent 
with previously published reports, which demonstrate that aqueous SDS solution 
completely inactivated HSV-2 by dissolving the lipid envelope and denaturing viral 
proteins.(Howett, Neely et al. 1999)   
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2.3.3 Inactivation of cell-free and cell associated HIV-1 (IIIB) by SDS Hydrogel 
formulations.  
HIV-1 is found in two different infectious forms, cell-free and cell-associated, in 
semen and vaginal secretions.  We tested our SDS Hydrogels against both forms.  
 
 
Figure 11: H&E of Hydrogel treated tissue 3 hr 
Staining shows treatment with 1% SDS Hydrogel did not disrupt squamous 
epithelium in human foreskin (A, D, G), cervical (B, E, H) and vaginal tissue (C, F, I) 
when compared to untreated controls.  The untreated controls (A, B, C) show tissue 
integrity; placebo treated controls (D, E, F)) show the Hydrogel vehicle also did not 
disrupt the epithelium; and 1% SDS Hydrogel treated tissues (G, H, I) show no 
visible disruption of epithelium from a histological perspective.  All tissues were 
treated for 3 hours.  Arrows indicate basal layer.  Above the basal layer is the 
squamous epithelium and below is the stroma, the connective tissue.  All 
magnifications shown are 10X. 
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Our laboratory has previously shown that SDS diluted in cell culture media in 
semenand vaginal secretions.  We tested our SDS Hydrogels against both forms. 
Unformulated SDS inactivated cell free HIV-1 within 1 minute.(Howett, Neely et 
al. 1999; Urdaneta, Wigdahl et al. 2005) To confirm that the SDS Hydrogel 
formulations have the same efficacy against HIV-1 as SDS in cell culture media, 
five separate experiments with triplicate samples was performed to determine 
inactivation of each of the HIV-1 forms, cell-free and cell-associated. In each 
experiment highly statistically significant anti-HIV-1 activity (p<0.0001) was 
observed in all concentrations of SDS Hydrogel against both infectious forms 
relative to untreated HIV-1 control, as shown in Figure 13, HIV-1 infectivity 
experiments were performed using P4R5 MAGI HeLa cells to test if the formulated 
SDS Hydrogels had anti-HIV-1 activity against both cell-free and cell-associated 
virus as demonstrated in Figure 13 the 0.5% and 1% SDS Hydrogels completely 
inactivated cell-associated HIV-1. Furthermore, Figure 13 shows that all 
concentrations of the formulated SDS gels were highly active against cell free HIV 
with a highly statistically significant p value of 0.0001.  In the cell free HIV-1 
infectivity assays it was observed in all experiments that the placebo slightly 
increased HIV-1 infectivity.  However, this pro-infectivity effect was completely 
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ablated in the presence of even the lowest concentrations of SDS in the Hydrogel 
formulations.  SDS has such potent anti-viral activity that at 1% and 0.5% SDS 
Hydrogel completely inactivated HIV-1 and at the lowest concentration (0.1%) of 
the SDS formulation viral infectivity decreased >95%.   
 
  
 
 
 
 
 
 
Figure 12: H&E of Hydrogel treated tissue 16/24 hr 
Staining shows treatment with 1% SDS Hydrogel did not disrupt squamous epithelium 
in human cervical (A, C, E) and vaginal tissue (B, D, F) when compared to untreated 
controls.  The untreated controls (A, B) show tissue integrity; placebo treated controls 
(C, D) show the Hydrogel vehicle also did not disrupt the epithelium; and 1% SDS 
Hydrogel treated tissues (E, F) show no visible disruption of epithelium from a 
histological perspective.  All cervical tissues were treated for 16 hours and all vaginal 
tissues were treated for 24 hours.  Arrows indicate basal layer.  Above the basal layer 
is the squamous epithelium and below is the stroma, the connective tissue.  All 
magnifications shown are 10X. 
 
 
 
 
 
 
 
71 
 
 
 
 
 
2.3.4 SDS Hydrogel formulations decrease HPV-11 infectivity.   
To determine if the SDS Hydrogel formulations had activity against non-enveloped 
virus, HPV-11 infectivity assays were performed followed by RT-PCR using nested 
primers targeted towards the viral mRNA transcript, E1^E4. This viral transcript is 
the most abundant transcript detected during the HPV-11 life cycle and infection.  
Therefore, its detection by RT-PCR would be indicative of active viral 
transcription.  As shown in Figure 14, treatment with 0.5% or 1% SDS Hydrogels 
resulted in at least a 10 fold decrease in the levels of viral transcript, E1^E4. The 
lowest concentration 0.1% (final concentration 0.05%) SDS Hydrogel did not 
decrease HPV-11 infectivity (data not shown).  The RT-PCR results show that 
formulated SDS Hyrdogel decreases HPV-11 infectivity by 90% in vitro.  This is 
evident by the loss of the E1^E4 band in the 10-5 columns in the 0.5% and 1% SDS 
Hydrogel experimental groups as compared to the 10-6 column in the Placebo and 
HPV experimental control group, which show viral infectivity. 
2.4.  Discussion: 
Globally, there is an urgent need to prevent the transmission of sexually transmitted 
diseases, such as HIV-1, HSV-2 and HPV. Previous studies have shown that 
infection with HSV-2 and/or HPV increases susceptibility to infection by HIV-1.  
Several strategies must be employed to stop the transmission of these incurable 
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diseases.  These include the accepted ABCs (A-abstinence, B-be faithful and C-
condom use), education, socioecomonic equality between genders and microbicide 
development and use.  A recent report presented at the National STD Conference in 
March 2008 by the CDC reported that one in four female adolescents (26%) in the 
United States has at least one of the most common sexually transmitted diseases 
(HPV, HSV-2, chlamydia and trichomoniasis). (Forhan 2008) Several studies 
(Balzarini and Van Damme 2007; van de Wijgert and Shattock 2007) have 
indicated that an ideal microbicide has to be non-toxic to the vaginal 
and cervical tissue to prevent host immune cells from being recruited into these 
tissues, thereby introducing more target cells for HIV-1 to infect.   
 Worldwide, a large portion of HIV-1 infections have been transmitted 
through exposure to the virus or virus infected cells in the female genital tract.  The 
exact mechanisms of viral spread remain unknown.  However, there are three 
proposed mechanisms of viral spread that have been described for HIV-1.  The first 
is the classical route of entry, which is characterized by the binding of cell-free 
virions to a permissive host cell via receptor-ligand interactions (binding of GP120 
and GP41 to CD4 and co-receptor, respectively), followed by entry into the 
cytoplasm via virion fusion and initiation of subsequent steps in the replicative 
process.(Kilby and Eron 2003; Pierson and Doms 2003; Piguet and Quentin 2004) 
Second, cells such as dendritic cells can capture virus via viral binding to the C-type 
lectins or other cell surface receptors, without necessarily becoming infected and re-
present infectious virions to a permissive target cell (a process known as infection in 
trans).(Jameson, Baridaud et al. 2002; Piguet and Quentin 2004)  Third, an HIV-1 
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infected cell can infect a second cell without the requirement for release of cell-free 
virions into the surrounding extracellular environment, which represents viral 
propagation through direct cell-to- cell transmission.(Piguet and Quentin 2004) 
 
 
Table 1:  Inactivation of HSV-2 Infectivity by SDS Hydrogel Formulations 
Prior to infection of CV-1 cells, HSV-2 was pre-treated with either 0.1%, 0.5% 
or 1% SDS Hydrogel, placebo or untreated medium control in equal volumes 
at 37° C for 10 minutes.  Final concentrations of SDS Hydrogels were 0.05%, 
0.25% and 0.5%, respectively.  Results are respresentative of 2 independent 
experiments with n=2/group with similar outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Treatment 
Average No. of   
plaques/plate at 48 hours  
post-infection 
  
  
Medium 99, 114 
Placebo 119, 121 
1% SDS Hydrogel 0, 0 
0.5% SDS Hydrogel 0, 0 
0.1% SDS Hydrogel 0, 0 
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 The first candidate microbicide for HIV-1 to reach phase III trials was the 
spermicidal detergent nonoxynol-9 (N-9), which inactivated HIV-1 in vitro by 
disrupting the outer membrane but failed to prevent sexual transmission in vivo.(Van 
Damme, Ramjee et al. 2002; Davis and Doms 2004)  Women using N-9 were shown 
to have higher rates of infection by HIV-1, most likely because the detergent 
disrupted the membranes of the epithelial cells in the genital tract which normally 
serve as a protective barrier against viral and bacterial infection.(Van Damme, 
Ramjee et al. 2002; Van De Wijgert and Coggins 2002; Davis and Doms 2004)   In 
murine studies that assessed the toxicity of N-9, as early as 2 hours post-application 
epithelial disruption of the cervix occurs accompanied by an intense infiltration of 
immune cells just below the basal layers, primarily in the regions without epithelial 
disruption.(Catalone, Kish et al. 2004) These findings indicate that N-9 greatly 
enhances inflammation and that the recruited lymphocytes may serve as targets for 
HIV-1.(Catalone, Kish et al. 2004) Another candidate microbicide to reach phase III 
trials was C31G, which is also a surfactant but is longer being developed as a 
vaginal microbicide.(van de Wijgert and Shattock 2007) The trial was underway for 
23 months and after a recommendation from an independent monitoring board the 
trial was halted because too few women were becoming infected with HIV-1 to 
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provide the statistical power needed to show a difference between C31G and the 
placebo. (Mascolini 2007; Peterson, Nanda et al. 2007)  The phase III trials of the 
Ushercell microbicide, a cellulose sulfate 
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Figure 13: SDS Hydrogels inactivate HIV-1 
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SDS Hydrogels inactivate cell-free and cell-associated HIV-1 in vitro.  Cell-
associated (A) or cell-free (B) HIV-1 were pre-treated with either 0.1%, 0.5% or 
1% SDS Hydrogel, placebo or left untreated, prior to infection of P4-R5 indicator 
cells which express β-gal if infected.  Viral inactivation with 1% SDS in media 
was included as an intra-assay control (Control).  Media only group show 
baseline expression of β-gal.  X-axis labeled with final concentrations of SDS in 
Hydrogel.  Results are representative of five independent experiments with 
n=3/group with similar outcomes. **=p<0.0001. 
 
 
 
compound that blocked viral entry into cells and that was developed by CONRAD, 
was also halted because interim analysis indicated that the rate of HIV-1 infection 
was higher in groups using the Ushercell as compared to the placebo group.(Honey 
2007)  The first candidate microbicide to complete phase III trials, Carraguard 
(developed by the Population Counsel) contains carrageenan and blocks viral entry 
into cells.  Carraguard failed the phase III trials again because the microbicide did 
not prevent HIV infections to a statistically significant level after comparing 
Carraguard to placebo.(2008) In stark contrast, our prototypic SDS Hydrogel 
differs because it inactivates and disrupts sexually transmitted viruses (HIV-1, 
HPV, HSV-1 and HSV-2) instead of  blocking infection by physically binding to 
virus surfaces as compared to other microbicides that have recently completed 
phase III clinical trials. 
It is known that SDS in an aqueous solution can cause skin irritation when 
introduced at high concentrations and for long exposure times.  This irritation has 
been proven to be dose and time dependent. (Aramaki, Loffler et al. 2001) Albeit 
brief, multiple daily exposure of the oral mucosa to toothpaste, which contains up 
to 8% of SDS, proves that SDS is innocuous to some mucosal tissues.  This result 
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is supported by billions of exposures. Previous studies from our laboratory have 
shown that at low concentrations, (1% or less) SDS in an aqueous solution has 
broad spectrum antiviral activity and is relatively non-toxic to vaginal 
keratinocytes and newborn foreskin in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: SDS Hydrogel decrease HPV11 Infectivity 
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RT-PCR shows treatment of HPV-11 with SDS Hydrogels decreased viral transcript, 
E1^E4, by at least a ten fold reduction relative to placebo.  Beta actin and the viral 
E1^E4 transcript is indicated by arrows.  The placebo hydrogel controls for viral 
infectivity.    
 
 
 
 
 
 
comparison to N-9 and C31G.(Howett, Neely et al. 1999; Krebs, Miller et al. 2000; 
Krebs, Miller et al. 2002)  To ensure that our SDS Hydrogels were not toxic, we 
treated human vaginal, cervical and newborn foreskin tissue with 0.1%, 0.5% and 1% 
SDS Hyrdogels and incubated the treated tissues continuously for up to 24 hours.  As 
seen in Figure 11 and 12, the Hematoxylin and Eosin staining shows that even the 
highest concentration of 1% SDS Hydrogel did not cause apparent disruption in the 
squamous epithelium of the vaginal tissue at the histologic level even after 24 hours 
of continued exposure.  Furthermore, there was no decrease in the thickness of the 
squamous epithelia in the SDS Hydrogel treated groups as compared to the no 
treatment groups.  A recent study by Ghosh and Blankschtein has shown that SDS in 
glyercol reduces pore number density and radius, decreasing SDS micelle penetration 
into the stratum cornuem and therefore decreasing the perturbation of the skin barrier 
as compared to SDS in an aqueous solution. (Ghosh and Blankschtein 2007)  Viscous 
gels containing SDS may also decrease micelle penetration into the stratrum 
corneum, thereby, further decreasing toxicity.  Testing is currently being conducted 
to evaluate the differences between aqueous and gelatinous SDS toxicities as well as 
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repeated exposure testing to determine the implications for efficacious microbicide 
development.     
  In 2006, a vaccine (Gardasil®, Merck Laboratories) containing the coat 
proteins of HPV (6, 11, 16 and 18) was approved by the FDA and made 
commercially available. Cervarix™ (Glaxo SmithKline) is another preventive 
vaccine and currently approved only in Europe. Both of these vaccines are currently 
for pre-sexually active females (ages 9-26), to prevent the initial HPV infection and 
the future possibility of the development of cervical cancer.  These vaccines do not 
cure existing infections. These two vaccines do not protect against other high-risk 
types they only offer prophylactic protection against the most prevalent types of HPV 
associated with cervical cancer.  This leaves a significant number of the women in the 
population unprotected and all women, vaccinated or not, vulnerable to infection by 
other types of human papillomaviruses. Thus, there is an urgent need for a broad 
spectrum microbicide that has been shown to have anti-HPV activity. Our in vitro 
results presented here support our previous findings of the microbicidal activity of 
SDS against non-enveloped virus.(Howett, Neely et al. 1999; Krebs, Miller et al. 
2000; Krebs, Miller et al. 2002; Kish, Ward et al. 2003; Urdaneta, Wigdahl et al. 
2005; Hartmann, Wigdahl et al. 2006)  Our studies show that <1% SDS disrupts HPV 
(Kish and Howett, unpublished results).  This is a unique feature of SDS that sets it 
apart from other candidate microbicides with a more limited scope of action.  
Currently, experiments are underway to determine if the formulated SDS Hydrogel 
has the same anti-HPV activity in vivo utilizing our laboratory’s mouse xenograft 
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model system.  This system emulates the full life cycle of HPV-11 and produces 
infectious virions.  Howett and Kreider pioneered this human tissue xenograft model 
to grow a fastidious organism, human papillomavirus, that could not be grown in cell 
culture (Kreider, Howett et al. 1985) and overcomes some of the problems that limit 
biological experimentation with HPV, for example, it is a human system with human 
tissue.(Kish, Budgeon et al. 2001) This model system has been adapted to grow many 
different organisms, such as, bovine papillomavirus, cottontail rabbit papillomavirus, 
poxviruses, HSV-2, varicella zoster virus and most recently HIV-1.(Howett, 
Christensen et al. 1997)  
  Many times it is overlooked that sexually transmitted diseases affect not only 
women, they also affect men, children, families and society as a whole.  These 
diseases cause some of the biggest problems in our society such as, infertility, 
cervical cancer and AIDS.  Several strategies must be employed simultaneously at 
both the population and individual levels to combat and overcome these diseases. 
Microbicides, vaccines, condom use, education and raising the socio-economic status 
of women and the poor all need to be addressed before we can defeat these diseases.   
 Based on the in vitro and ex vivo work set forth in this paper and our laboratory’s 
previous reports, our prototypic SDS Hydrogel meets the criteria for an ideal 
microbicide.  Experiments are currently under way to determine if the formulated 
SDS Hydrogels will have the same activity in vivo as in vitro.  Together the data 
presented in this article along with the ongoing in vivo work currently being 
conducted in our laboratory provide the basis for moving the SDS Hydrogels into 
Phase I Clinical Trials. The topical, non-toxic, broad activity of the formulated SDS 
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Hydrogels has the potential to prevent many of the health problems associated with 
sexually transmitted diseases, such as, AIDS, cervical cancer and genital ulcers.  The 
versatility of the SDS Hydrogels will have a significant impact on women’s health 
regardless of where they live and irrespective of their personal circumstances.   
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3.1 Introduction 
Chemokine receptors are G protein coupled receptors (GPCR) that have seven 
transmembrane domains with three extracellular loops and four intracellular 
loops.(Lederman 2006) Chemokine receptor 5 (CCR5) is a human receptor, which R5 
forms of HIV-1 utilize as a co-receptor for binding.  In 1996 a Hemophilia Growth 
and Multicenter AIDS Cohort study (Dean, Carrington et al. 1996) found that 
mutations in the CCR5 co-receptor, confers some resistance in humans to infection 
by R5 forms of HIV-1.  This mutation was found to be present in the Caucasian 
population worldwide at a frequency of approximately 10% while the frequency in 
the United States was 1%.    
 The rate of HIV-1 disease progression varies considerably among infected 
individuals.  A small but rare subset of chronically infected, therapy naïve individuals 
appear to maintain high and stable CD4+ and CD8+ T cell counts with low to 
undetectable plasma viral loads for an prolonged number of years.(Dean, Carrington 
et al. 1996; Mikhail, Wang et al. 2005) The CCR5Δ32 mutation is a 32 base pair 
deletion in the portion of the human CCR5 open reading frame that encodes the 
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second extracellular protein loop between transmembrane domains four and five of 
the seven transmembrane architecture.(Dean, Carrington et al. 1996; Agarwal, Zainab 
Van Horn et al. 2004; Oppermann 2004)  CCR5Δ32 encodes a truncated protein that 
is retained in the endoplasmic reticulum, which is not detectable on the cell 
surface.(Benkirane, Jin et al. 1997; Agrawal, VanHorn-Ali et al. 2004) People who 
are homozygous for the CCR5Δ32 mutation are resistant to HIV-1 infection from R5 
strains, which is the form most commonly sexually transmitted, and heterozygous 
individuals expressing CCR5Δ32 progress more slowly to AIDS.(Dean, Carrington et 
al. 1996) People that are homozygous for the CCR5Δ32 mutation appear to be 
phenotypically normal except for an increased susceptibility to contracting a fatal 
form of West Nile Virus infection.  For these reasons CCR5 has become a very 
attractive target of investigation to many researchers.   
 Many scientists have tried to develop microbicides with anti-HIV activity but 
microbicides are multi-faceted because the exact mechanisms by which HIV-1 gains 
entry is still largely unknown. Several neutralizing monoclonal antibodies targeted 
towards gp120 have been developed that conferred immunity to rhesus macaques that 
were vaginally challenged with virus, as long as the antibodies were present within a 
few hours of the virus challenge.(Shibata, Igarashi et al. 1999; Nishimura, Igarashi et 
al. 2003; Veazey, Shattock et al. 2003) However, even though monoclonal antibodies 
seem to be effective they are also very expensive.  When an individual is infected 
there is a genetic diversity of HIV-1 within that individual, which is a collection of 
closely related but genetically distinct viral variants.(Sullivan, Mandava et al. 2005) 
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Taken together it has not been definitely proven that these monoclonal antibodies will 
be effective at conferring immunity in humans.   
One encouraging method scientists have taken in developing microbicides is 
creating synthetic chemokines molecules that compete with HIV-1 for the CCR5 co-
receptor.  CCR5 is a human chemokine that normally binds MIP-1ą, MIP-1β and 
RANTES chemokines.  The most successful of the synthetic chemokines to inhibit 
binding of HIV-1 is PSC-RANTES, which is a RANTES analog chemically identical 
to native RANTES except for the substitution of a nonanoyl group, thioproline and 
cyclohexylglycine for the first three N-terminal amino acids of the native 
protein.(Lederman, Veazey et al. 2004) This synthetic PSC-RANTES was vaginally 
applied to rhesus macaques and upon challenging with SHIV, a Simian 
Immunodeficiency Virus and Human Immunodeficiency Virus chimera, it was shown 
that 12 out of the 15 monkeys treated were protected by 100 ųM 
treatment.(Lederman, Veazey et al. 2004)   
 Much of the human genome consists of remnants of previous transposon/virus 
invasions and elements that are still active, therefore one would expect that organisms 
need to fight off such invasions to prevent the genome from being completely 
overrun by molecular invaders.(Plasterk 2002) A novel approach in developing a 
microbicide is to use RNA interference (RNAi) targeted towards the CCR5 
chemokine receptor.  This RNA-based silencing mechanism has emerged as an 
ancient mechanism that is conserved among species from different kingdoms (fungi, 
animals and plants) and very likely acts as the immune system of the 
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genome.(Plasterk 2002) RNAi is a sequence specific posttrancriptional gene 
silencing, which is triggered by double stranded RNA. It has been shown that siRNA 
has been successful in down-regulating CCR5.  In U87-CCR5 cells, which are 
engineered to express CCR5, CCR5 was down-regulated by 48% decreasing viral 
entry by 55% resulting in inhibition of HIV-1 replication.(Martinez, Gutierrez et al. 
2002) siRNA targeted against CCR5 and HIV-1 p24 antigen together in infected 
macrophages also down-regulated CCR5 and inhibited viral entry for fifteen 
days.(Song, Lee et al. 2003) Another study showed down-regulation of CCR5 in 
MAGI-CCR5 cells that decreased CCR5 expression by ten fold, which in turn 
decreased viral replication by three to seven fold.(Qin, An et al. 2003) 
 It has recently been shown that siRNA based microbicides can protect mice from a 
lethal form of Herpes Simplex Virus 2 (HSV2) infection when treated with siRNA 
liposomal treatment two to four hours prior to viral challenge.(Palliser, Chowdhury et 
al. 2005) Previous studies have shown that siRNA can decrease CCR5 expression in 
cells but it needs to be further validated in human vaginal epithelial tissue.  We used 
human vaginal epithelial xenograft model to determine if CCR5 could be down 
regulated in human vaginal tissue using a cationic liposome delivery system, 
Lipofectamine 2000 (Invitrogen). Worldwide, a large portion of HIV-1 infections 
have been transmitted through exposure of the virus in the female genital tract.  The 
exact mechanisms of viral spread are still unknown. The human epithelial xenograft 
model was first developed to grow a fastidious organism, human papillomavirus, that 
could not be grown in cell culture.(Kreider, Howett et al. 1985)  This model system 
has been adapted to grow many different organisms, such as, bovine papillomavirus 
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(BPV), cottontail rabbit papillomavirusCRPV), poxviruses, herpes simplex virus type 
2 (HSV-2), varicella zoster virus and HIV-1.(Howett, Christensen et al. 1997) This 
model system uses the natural human tissue which HIV-1 normally infects.(Kish, 
Budgeon et al. 2001)  We used NOD/SCID mice, which do not have any humoral or 
cell mediated immunity, they lack natural killer cells and a complement 
system.(Janeway, Travers et al. 2001; Kish, Budgeon et al. 2001) Previous studies 
have shown that this in vivo model system can sustain active HIV-1 transmission and 
replication in human vaginal tissue, vagina or cervix, its normal environment during 
transmission.(Kish, Budgeon et al. 2001)  
3.2 Materials and Methods:  
3.2.1 Validation of Pooled CCR5-siRNA in P4-R5 MAGI HeLa Cell Lines and 
Testing of Different Transfection Reagents:  
The pooled CCR5-siRNA needed to be validated to prove that it could down-regulate 
CCR5 in vitro before attempting treatment in vivo.  The pooled siRNA (Dharmacon) 
was resuspended per the manufacturers’ instructions.  On the day prior to the 
experiment P4-R5 cells were seeded in twelve well plates at a density of 8x104 cells 
per well and incubated overnight at 37° with 5% CO2.  On the day of the assay when 
the P4-R5 cells were approximately 50% confluent, cells were washed serum free 
antibiotic free (SFAF) DMEM. The appropriate concentration of Lipofectamine 2000 
at a 1:5 ratio or pooled CCR5-siRNA (2nmol, 4nmol or 10nmol) was added to SFAF 
DMEM bringing the total volume to 525 µl, mixed and incubated at room 
temperature for 5 minutes.  Following the incubation equal volumes of the CCR5-
siRNA and Lipofectamine 2000 was mixed and incubated for 20 minutes at room 
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temperature.  The subsequent mixture was added dropwise (300 µl per well) to 
triplicate samples of P4-R5 cell monolayers and incubated at 37° with 5% CO2 for 
four hours with gentle rocking every thirty minutes.  At the end of the four hour 
incubation 650 µl of P4-R5 cell culture media was added to each well and incubated 
for 48, 72 or 96 hours at 37° with 5% CO2.  At the end of the incubation, the cells 
were washed with ice cold PBS, and cell lysate was collected by adding 120 µl of 
RIPA buffer (150mM Sodium Chloride,1% NP40, 0.5% DOC, 1% Sodium Dodecyl 
Sulfate, 50mM Tris, 1mM PMSF, 5µg/ml Aprotinin, 1µg/ml Pepstatin-A, 2 µg/ml 
Leupeptin and 200 µM Sodium Orthovandate) to each well and to ensure all of the 
cells were collected the bottom of the cell culture plate was scraped with a cell 
scraper.  The resulting cell lysate underwent three freeze/thaw cycles, was sonicated 
three times for 10 seconds each with cooling on ice in between each sonication and 
centrifuged.   A modified Lowry Protein assay was performed to determine total 
protein in each cell lysate and OD was read on a Beckman Coulter DU800 
spectrophotometer.  Also, following the protocol described above we tested other 
transfection reagents to determine if other reagents would increase transfection 
efficiency and decrease cell toxicity, as shown in the summary in Table 3.   
3.2.2 Absorption of fluorescent siRNA by vaginal tissue:   
The organ tissue culture model system (Collins, 2000) using human vaginal tissue 
was utilized to see absorption of fluorescently tagged siRNA targeted against CCR5. 
Briefly, vaginal tissue obtained from women undergoing reconstructive surgeries for 
non-cancerous reasons were collected immediately prior to performing the 
experiment, and transported in serum free Minimum Essential Media (Fisher 
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Scientific) containing 0.05% sodium bicarbonate (Mediatech, Herndon, VA) and 10 
mmol/L HEPES (Mediatech, Herndon, VA) as well as the following antibiotics:  
penicillin (100 U/ml; Mediatech, Herndon, VA); streptomycin (0.08 mg/ml; 
Mediatech, Herndon, VA); gentamicin (0.4 mg/ml; Mediatech, Herndon, VA); and 
fungizone (2.5 ųl/ml; Life Technologies). Only grossly normal samples released by 
surgeon were used.  All samples were from tissues that would normally be discarded.  
Tissue from a single donor was divided into 6 contiguous 6.0 mm circular pieces by 
an Acu-punch® biopsy scalpel. The cut tissue sections were soaked in an antibiotic 
wash containing fungizone (250 ug/ml: Life Technologies) and nystatin (12ul/ml; 
Sigma), penicillin and streptomyocin (20,000 U each; Mediatech), for 5-8 minutes 
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Figure 15: FITC-siRNA treated vaginal xenografts 
Human vaginal epithelial xenografts treated for 2, 4, 12, 24  or 48 hours with non-
specific fluorescein-tagged (FITC) siRNA nanoparticles to determine the tissue 
absorption of liposomoal delivered siRNA into the xenografts.  By 2 hours (B) post-
treatment a green positive FITC signal is clearly observed in the cytoplasm of the 
epithelial cells and at 4 hours (C ), 12 hours (D) the signal continues to brighten.  The 
signal is the brightest at 24 hours (E) and starts to fade by 48 hours (F) in the 
xenografts.  The untreated control (A) xenografts do not show a positive signal.   Red 
arrows indicate autofluorescence of connective tissue in the stroma, presumably type I 
collagen.  White arrows indicate green positive signal from the FITC-siRNA. DAPI 
staining was performed coloring the cell nuclei blue and to characterize the 
architecture of tissue.  All pictures shown are 60X magnification. 
 
 
 
 
and washed three times in serum-free and antibiotic-free DMEM (Mediatech, 
Herndon, VA).  The circular pieces of tissue with the epithelial layer oriented on top, 
were placed into the top chamber of 12-well Transwell dish.  A sterile 5% solution of 
agarose in Hank’s medium was added to the area surrounding the tissue and allowed 
to solidify creating a tight seal around the tissue.  Serum free and antibiotic free 
DMEM (1 ml) is added to the bottom chamber to keep the Transwell membrane in 
contact with the medium.  Also, 300 µl of serum-free and antibiotic-free DMEM 
containing different concentrations of FITC-tagged siRNA (Block-It™ Invitrogen) 
(either 10pM, 100pM, 2nM or 4nM siRNA) was added to the top chamber and 
incubated at 37º for 24 or 48 hours.  At each time point the tissue was removed from 
the agarose, snap frozen and cryosectioned.  Following the cryosectioning, the tissues 
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were fixed with 4% paraformaldehye and stained with DAPI (Santa Cruz 
Biotechnology), as per the manufacturer’s instructions.  The tissue sections were 
examined by immunofluorescent microscopy using an Olympus IX-81 
Immunofluorescent microscope at a magnification of 10X.  All of the resulting 
images were subjected to deconvolution to eliminate light emissions from other tissue 
planes.  To test for fluorescent siRNA leakage from the top chamber of the organ 
tissue culture system, at 24 or 48 hours the Raft media from the bottom chamber was 
examined by immunofluorescent microscopy.  During the initial validation 
experiments after surrounding vaginal tissue with agarose, 10% blue dextran in sterile 
phosphate buffer saline (PBS) was added to the top chamber and allowed to incbuate 
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Figure 16: FITC-nanoparticle treated Xenografts 
Human vaginal epithelial xenografts treated for 6 or 24 hours with fluorescein-tagged 
(FITC) polyethyleneglycol nanoparticles to assess the effectiveness of an alternate 
delivery method for the CCR5-siRNA.  A green positive FITC signal is clearly 
observed in the cytoplasm of the epithelial cells in 6 hour (C) and 24 hour (E) FITC-
nanoparticle treated xenografts.  The untreated control (A), 6 hour (B) and 24 hour (D) 
sodium fluorescein nanoparticle treated xenografts do not show a positive signal.   Red 
arrows indicate autofluorescence of connective tissue in the stroma, presumably type I 
collagen.  White arrows indicate green positive signal from the FITC-nanoparticles. 
DAPI staining was performed coloring the cell nuclei blue and to characterize the 
architecture of tissue.  All pictures shown are 60X magnification.  
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Figure 17:  Human vaginal tissue treated with a lentiviral vector system 
expressing green fluorescent protein (GFP). 
To assess the effectiveness of an alternate delivery method for an alternate molecule, 
CCR5-shRNA, human vaginal tissue was treated with a lentiviral vector expressing 
GFP for 24 hours.  There is no difference between the untreated (A) and the lentiviral 
vector treated (B) tissue that does not show any positive signal.   Red arrows indicate 
autofluorescence of connective tissue in the stroma, presumably type I collagen. DAPI 
staining was performed coloring the cell nuclei blue and to characterize the 
architecture of tissue.  All pictures shown are 60X magnification.  
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for 48 hours.  Following the incubation 500 ul of media was removed from the 
bottom chamber and subjected to spectrophotometry (Beckman Coulter, DU800) at 
595 nm.  The instrument was able to detect dilutions of blue dextran as high as 1x104  
in media.   
3.2.3 Validation of Pooled CCR5-siRNA in Human Vaginal Tissue Using the 
Organ Tissue Culture System:   
The OTC was set up as described in previous section.  The vaginal tissue was treated 
with 300 µl of serum-free and antibiotic-free DMEM containing liposomal complex 
containing10nmol of CCR5-siRNA (Dharmacon) was added to the top chamber and  
incubated at 37º for 72 or 96 hours.  At each time point the tissue was removed from 
the agarose, snap frozen and homogenized using FastPrep Machine and Bio101 
RNApro kit, per the manufacturers’ instructions.   
3.2.4 Human vaginal xenograft model treatment with either different siRNAs or 
infection HIV-1:  
Six to fourteen week old female NOD/LtSz-scid/scid mice (Jackson Laboratory, Bar 
Harbor, ME) were maintained under specific pathogen-free environmental conditions, 
in accordance with all Drexel University’s Institutional Review Board and 
Institutional Animal Care and Use Committee’s rules and bylaws.  Vaginal tissue was 
obtained from patients undergoing reconstructive surgeries for non-cancerous reasons.  
The vaginal tissue samples were cut into split-thickness grafts, ~ 2cm x 2cm x 0.5 mm 
in size, consisting of the vaginal epithelial layer with minimal stroma.  The tissues 
were rolled into a tubular conformation with the epithelial layer directed inward and 
placed within the subcutaneous space on the backs of the NOD/SCID mice.  Estrogen 
pellets were also implanted so that the circulating peripheral blood estrogen levels 
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were 200 pg/ml, the average normal level in pre-menopausal women. This allowed 
sustained growth of the human vaginal xenografts. Grafts were allowed to heal for ~21 
days after implantation, at which time they were infected with HIV-1 BaL or treated 
with liposomal complex (Lipofectamine 2000, Invitrogen) according to the 
manufacturer’s instructions, containing 2nmol or 4nmol FITC-siRNA (Block-It™ 
Invitrogen), 4nmol or 10nmol CCR5-siRNA, FITC-nanoparticles or untreated 
controls. At specified time points the mice were euthanized, the xenografts were 
removed and processed.  For the xenografts treated with fluorescein molecules (FITC-
siRNA and nanoparticles), immediately after removal the xenografts were snap frozen 
and cryosectioned.  Following the cryosectioning, the tissues were fixed with 4% 
paraformaldehye and stained with DAPI (Santa Cruz Biotechnology), as per the 
manufacturer’s instructions.  The tissue sections were examined by 
immunofluorescent microscopy using an Olympus IX-81 Immunofluorescent 
microscope at a magnification of 10X and 60X.  All of the resulting images were 
subjected to deconvolution to eliminate light emissions from other tissue planes.  For 
xenografts treated with CCR5-siRNA (Dharmacon), immediately after harvesting the 
xenografts were cut in half with one half being snap frozen for Western Blot analyzes 
and the other half being fixed in 5% formalin, paraffin embedded and subjected to 
immunohistochemical analyzes.  For xenografts infected with HIV-1 (BaL) upon 
harvesting the xenografts homogenized, total tissue RNA was extracted and RT-PCR 
was performed for viral Gag/Pol or Tat/Rev transcripts, as previously described.  To  
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Figure 18:  Successful HIV-1 infection in human vaginal epithelial xenografts. 
RT-PCR was performed on 200 ng of total cellular RNA from HIV-1 BaL infected 
vaginal xenografts.  Vaginal xenografts were infected and on days 0, 3 and 7 
xenografts were harvested, homogenized and total RNA was extracted.  Following 
RNA extraction RT-PCR was performed using primers specific for viral Gag/Pol 
transcripts to detect successful HIV-1 infection.  On day 0 the positive signal observed 
in both xenograft 1 and 2 is a residual signal from the inoculum; the signal almost 
completely disappears in xenograft 3 on day 3; the positive signal in xenograft 4 and 5 
on day 7 is indicative of active HIV-1 replication; and Kish xenograft day 7 is a 
positive control from our laboratories previous work for the RT-PCR.   
 
 
 
 
 
 
 
 
 
 
 
X
en
o 
1 
D
ay
 0
 
X
en
o 
2 
D
ay
 0
 
X
en
o 
3 
D
ay
 3
 
X
en
o 
4 
D
ay
 7
 
X
en
o 
5 
D
ay
 7
 
K
is
h 
X
en
o 
D
ay
 
7 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Western Blot of CCR5-siRNA treated cell lysates 
Western Blot showing down-regulation of CCR5 in P4-R5 cell lysates.  Cells were 
treated with CCR5-siRNA and incubated for either 48 or 72 hours after which lysates 
were collected as described in Materials and Methods.  Unglycosolated (immature) 
forms of CCR5 are ~49 kD and glycosolated (mature) forms are ~62kD in size. 
Scrambled non-specific control siRNA was included to show any effect that treatment 
or introduction of siRNA would have on the RNAi pathway.  Treatment with 4nmol at 
both 48 and 72 hour treatments partially down-regulated the glycosolated forms of 
CCR5, but do not appear to have any effect on the unglycosolated forms.  However, 
treatment with 10nmol siRNA at 48 hours almost completely eliminates the 
glycosolated form of CCR5 with little of no effect on the unglycosolated CCR5.  
Importantly, treatment with 10nmol siRNA for 72 hour completely eliminates 
glycosolated CCR5 and significantly down-regulates unglycosolated forms.  Results 
representative of two different experiments with duplicate samples.   
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Figure 20:  Detection of  CCR5 expression in vaginal xenografts by 
immunohistochemistry.   
Vaginal xenografts were treated with varying concentrations of CCR5-siRNA for 
either 24 hr or 48 hr prior to immunohistochemical staining.  Untreated human tonsil 
(A) was used as a postive control and pre-grafted vaginal tissue (B) was used to verify 
the person was not homozygous for the CCR5∆32 mutation.  Vaginal grafts were 
either left untreated (C) or treated with either 1pM (D), 10pM (E) or 100 pM(F) for 24 
hr; or 1 pM (G) 10pM (H), or 100pM (I) for 48 h prior with CCR5-specific siRNA.  
Arrows indicate characteristic pockets of CCR5 positive cells.  All magnifications 
shown are 10X with some sections (D, F and I) having been subjected to the wide 
angle mode of the camera. 
 
 
 C) Vaginal graft, untreated B) Vagina, pre-grafting A) Positive control (tonsil) 
 
 F) 100 pM CCR5 siRNA,  
24h 
E) 10 pM CCR5 siRNA, 24h D) 1 pM CCR5 siRNA, 24 h 
 
 
 I) 100 pM siRNA,  
48 h 
H) 10 pM CCR5 siRNA, 48h G) 1pM CCR5 siRNA, 48h 
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control for donor-to-donor variations, grafted tissue is distributed as evenly as possible 
across all treatment groups. 
3.2.5 Immunohistochemistry for detection of CCR5 in vaginal grafts:  
Paraffin embedded samples of harvested vaginal grafts were cut into 4 µm thickness 
tissue sections and stained with hematoxylin and eosin staining to examine 
morphology.  The tissue sections were stained for cell surface protein CCR5 using 
mouse monoclonal antibody (Santa Cruz Biotechnology) using the VectorStain Elite 
kit (Vector Laboratories, Burlingame, CA) as per the manufacturer’s instructions.  
Briefly, all tissue sections were baked at 55º C for one hour to evaporate the paraffin.  
The samples were then dehydrated and rehydrated by incubation with xylene and a 
graded alcohol series to prevent non-specific binding.  Endogenous peroxidases were 
destroyed by immersion with 3% hydrogen peroxide in deionized water for 10 
minutes.  After the appropriate antigen retrieval (recommended by the antibody 
manufacturer) samples were blocked with 10% horse serum (Vector Labs) in PBS for 
one hour at room temperature in a humidified chamber.  All antibodies were diluted in 
1% horse serum in PBS per the manufacturer’s instructions with a total volume of 150 
ųl was added to experimental samples and incubated overnight. Samples were washed 
twice for five minutes each with incubations were performed for 30 minutes at room 
temperature.  Color visualization of the complex was achieved by incubating the tissue 
sections with diaminobenzidine tetrahydrochloride PBS, incubated with a biotinylated 
anti-mouse secondary antibody (Vector Labs) for 60 minutes. After two more washes 
in PBS, the streptavidin-peroxidase conjugate containing Ni2+ for 5 minutes.  Lastly, 
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tissue samples were briefly rinsed in water and counterstained with hematoxylin for 10 
minutes.  Stained tissue was examined using a Olympus microscope at the 
magnifications indicated. 
3.2.6 Preparation of Tissue Lysates:  
Tissue lysates were collected from human tissue/xenografts using the FastPrep® 
Homogenizer (Bio101 Systems), according to the manufacturer’s instructions.  
Briefly, each frozen tissue section was diced, 500 µl of ice cold RIPA buffer (150mM 
Sodium Chloride,1% NP40, 0.5% DOC, 1% SDS, 50mM Tris, 1mM PMSF, 5µg/ml 
Aprotinin, 1µg/ml Pepstatin-A, 2 µg/ml Leupeptin and 200 µM Sodium Orthovandate) 
was added to each matrix tube and homogenized at a setting of 6.0 m/s2 for 30 
seconds. Tissue lysates were then subjected to sonication followed by an incubation on 
ice for 45 minutes and centrifuged at 16,000 g for 10 minutes at 4ºC.  Total cellular 
protein concentration was determined by performing a Modified Lowry Protein Assay 
(Pierce, Rockford, IL.) according to the manufacturer’s instructions and the samples 
were read using a Beckman Coulter DU800 spectrophotometer.  
3.2.7 Western Blot for detection of CCR5:   
50 µg of total cellular proteins from each tissue lysate were run on a 4/12% stacking 
SDS polyacrylamide gel using the BioRad Mini Protean II (BioRad) and transferred to 
nitrocellulose (Protran BA 83, Whatman Schleicher & Schuell, Dassel, Germany).  
Each membrane was than incubated for an hour at room temperature in 5% milk in 
TBS, washed three times at room temperature in TBS-T for ten minutes each then 
incubated in primary monoclonal mouse antibody (Santa Cruz Biotechnology, Santa 
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Figure 21:Western Blot of OTC CCR5-siRNA treated vaginal tissue 
Western Blot showing no down-regulation of CCR5 as compared to control siRNA in 
human vaginal tissue lysates. Using the organ tissue culture system vagina tissues 
were treated with 10nmol CCR5-siRNA and incubated for either 72 or 96 hours after 
which lysates were collected as described in Materials and Methods.  Unglycosolated 
(immature) forms of CCR5 are ~49 kD and glycosolated (mature) forms are ~62kD in 
size. Scrambled non-specific control siRNA was included to show any effect that 
treatment or introduction of siRNA would have on the RNAi pathway.  Normalization 
graph shows no down-regulation in CCR5-siRNA treated tissue as compared to 
control. Results are representative of two different experiments with duplicate 
samples.   
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Cruz, CA) specific for human CCR5.  Following incubation with primary antibody 
each blot was washed three times as previously described and incubated with 
secondary mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA) labeled with 
horseradish peroxidase tag.  After incubation with secondary antibody each blot was 
washed three times as previously described and developed using SuperSignal West 
Dura Chemiluminescent Detection Kit (Pierce, Rockford, IL.) per the manufacturer’s 
instruction on a Alpha Imaging system following the manufacturer’s instructions.  
Subsequent to the chemiluminescent detection of CCR5, each membrane was stripped 
and incubated with a goat polyclonal primary antibody specific for cyclophilin A for 
normalization with all subsequent steps being performed as described above.   
3.3 Results: 
3.3.1 Immunohistochemistry shows CCR5 expression in vaginal xenografts: 
To verify conservation of the normal morphology of grafted vaginal tissue, 
hematoxylin and eosin (H&E) staining was performed prior to grafting the tissue and 
after the healing process of the graft.  For every graft performed, all tissue sections 
showed maintenance of the normal architecture with the squamous epithelial and basal 
layers clearly visible (data not shown). To visualize CCR5 expression in the 
xenografts and to analyze down-regulation of CCR5 in response to siRNA treatment, 
we performed immunohistochemical staining of untreated and treated grafted vaginal 
tissue.  As shown in Figure 20, a positive signal for CCR5 in the avidin-biotin 
complex system used was indicated by a color change to brown, which was visible in 
the no treatment, 1 pM CCR5-siRNA, 10 pM or 100 pM CCR5-siRNA treated tissue 
sections that were treated for 24 and 48 hours. All observations were made at 10X 
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magnification.  Since we do not have the proper microscope with software to analyze 
and quantify immunohistochemistry we decided not to utilize this method of detection 
for future experiments.  However, these results confirmed the variation observed from 
xenograft to xenograft and helped the guide our troubleshooting process.  From the 
imunohistochemical staining we decided to decrease the time duration from tissue pick 
up to surgery (from eight to three hours) to ensure the immune cell population was 
retained in tissue before implantation as well as to increase the CCR5-siRNA 
concentrations.   
3.3.2 FITC-tagged siRNA penetrates human vaginal tissue in vivo:  
To determine the kinetics of absorption and to verify that the liposome-delivered 
siRNA would be absorbed through the squamous epithelia of the vaginal xenografts 
and have the potential to reach the target macrophages and Langerhan cells, we treated 
vaginal xenografts with non-specifc FITC-siRNA. Vaginal tissue was treated with 
4nM non-specific FITC-siRNA for 2, 4, 12, 24 or 48 hours and cryosections were 
examined by fluorescent microscopy. By 2 hours post-treatment a positive green FITC 
signal was observed in the FITC-siRNA treated xenografts, as indicated by the white 
arrows in Figure 15.  Some of these cells in the 2 hour treatment xenografts show 
positive FITC signal in the cytoplasm of the cells as is evident by the green signal 
directly adjacent to the blue DAPI stained nucleus.  As indicated by the white arrows 
in Figure 15, all of the xenografts treated for 4, 12 and 24 hour visibly show a positive 
green signal, which is clearly observed in the cytoplasm of the cells.  In these 
xenografts there is also an increased intensity in brightness of the FITC signal, with  
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the brightest signal being observed at 24 hours and at 48 hours the signal starts to fade.  
There was no positive signal in the untreated group. However, the red arrows indicate 
autofluorescence emanating from the connective tissue in the stroma, presumably type 
I collagen, which studies have shown that many connective tissues, specifically 
collagen, will autofluoresce when excitated in all wavelengths. 
3.3.3 FITC-nanoparticles penetrate human vaginal tissue in vivo but not lentiviral 
vector system:  
 To establish an alternate and a potentially more efficient siRNA delivery method we 
treated vaginal xenografts with FITC-nanoparticles or sodium fluorescein control for 
either 6 or 24 hours and examined the cryosections by fluorescent microscopy.  The 
nanoparticles were made of polyethyleneglycol and have had a FITC molecule 
conjugated the nanoparticles.  As shown in Figure 16, by 6 hours post-treatment the 
FITC-nanoparticle group we observed the FITC-nanoparticles (green) had penetrated 
the tissue but did not appear to have entered the cells.  However, in the 24 hour FITC-
nanoparticle treated tissue there was clear penetration into the tissue as well as entry 
into the cytoplasm as indicated by the white arrows.  There was no positive signal 
from the sodium fluorescein negative controls and untreated groups.  Red arrows 
indicate tissue autofluorescence originating from the connective tissue, presumably 
type I collagen.  We also treated vaginal tissue with a non-specific lentiviral vector 
system, which upon successful entry into cells and if active transcription is occurring a 
green fluorescent protein (GFP) is expressed.  As shown in Figure 17, there is no 
positive GFP signal observed in the vaginal tissue. 
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Figure 22: Western Blot of CCR5 siRNA treated Xenografts 
Western Blot with normalization showing no down-regulation of CCR5 in human 
vaginal xenograft tissue lysates. Using our laboratories human vaginal xenograft 
system, xenograft tissues were treated with 10nmol CCR5-siRNA and incubated for 
either 72 or 96 hours after which tissue lysates were collected as described in 
Materials and Methods.  Unglycosolated (immature) forms of CCR5 are ~49 kD and 
glycosolated (mature) forms are ~62kD in size. Untreated was included as a control to 
verify the person was not homozygous for the ∆32 mutation.  Scrambled non -specific 
control siRNA was included to show any effect that treatment or introduction of 
siRNA would have on the RNAi pathway.  
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Table 2:  Human Vaginal Xenograft Summary. 
Number 
of Mice 
Donor/ # 
Xenografts 
siRNA Treatment 
Groups  
(n=number of mice per 
group) 
Harvest 
Time 
(hrs) 
Observations 
and 
Conclusions 
3 Ungrafted 
mice 
Mouse blood & spleen 
harvested  
N/A No antibody cross 
reactivity 
10 Donor A/10  No Treatment, Liposome Only, 
1pM, 10pM or 100pM  
(For all groups n=1) 
24 and 48   
 
No down-
regulation 
7 Donor B & C/7 No Treatment (n=1), Liposome 
Only (n=1), 1pM (n=1), 10pM 
(n=2) or 100pM (n=2) 
48 No down-
regulation 
5 Donor D/5 No Treatment (n=1), 1pM (n=1), 
10pM (n=1) or 100pM (n=2) 
48 No down-
regulation 
8 Donor E & F/8 No Treatment, 1pM, 10pM or 
100pM CCR5 siRNA 
For all groups n=1 
24 and 48 No down-
regulation 
3 Donor G/3 No Treatment (n=1) and 4nM 
(n=2) 
48 No down-
regulation 
10 Donor H/10 No Treatment (n=2) and 4nM 
(n=8) 
24 and 48 No down-
regulation 
2 Donor I/2 No Treatment (n=2) N/A CCR5 WB 
detection 
6 Donor J/6 No Treat (n=2), 4 nmol FITC-
siRNA (n=4) or FITC-siRNA 
only (n=2) 
24 and 48 FITC in tissue & 
visible in 
cytoplasm  
12 Donor K/ 12 No Treat (n=2) or 4nmol FITC-
siRNA (n=10) 
0, 2, 4  & 
12 
FITC in tissue & 
visible in 
cytoplasm at 4 & 
12 hr 
10  Donor L/10 No Treat (n=2), 2nmol (n=4) or 
4 nmol CCR5 siRNA (n=4) 
24 and 48 No down-
regulation 
5 Donor M/5 No Treat (n=1), 4 nmol CCR5 
(n=2) or 4nmol Control siRNA 
(n=2) 
24 and 48 No down-
regulation 
10 Donor N/10 No Treat (n=3), 4 nmol CCR5 
(n=4) or Control siRNA (n=3) 
48 No down-
regulation 
6 Donor O/6 No Treat (n=1), FITC-
Nanoparticles (n=3) or Sodium 
Fluorescien (n=2) 
 
6 and 12 FITC in tissue not 
in cytoplasm 
9 Donors O, P/9  No Treat (n=1); FITC-
nanoparticles (n=1) or Sodium 
Fluorescin (n=1);  
6 xenografts did not form  
 
24 
 
FITC in tissue & 
visible in 
cytoplasm  
 
9 Donor Q/9 No treat (n=2); 10nmol CCR5 
(n=5) or Irrelevant siRNA (n=2) 
 
72 & 96  Partial down-
regulation  
6 Donor R/6 No treat (n=1); HIV-1 day 
0(n=2); day 3(n=1) or day 
7(n=2) 
0, 72 & 
168 
Detection of 
Gag/Pol transcript 
3 Donor R/3 L. plantarum CVN+ (n=3) 72  Detection of CVN 
10 Donor R/10 No treatment (n=2),  L. 
plantarum CVN+ (n=4);  L. 
plantarum WT (n=4) 
168 Not analyzed 
 
Total of 
134 mice 
 
Total of 131 
xenografts 
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3.3.4.Successful validation of pooled CCR5-siRNA in P4-R5 cells. 
To determine the effectiveness and ability of the liposomal delivered pooled CCR5-
siRNA we treated P4-R5 cells with either 4 nmol or 10 nmol pooled CCR5-siRNA or 
non-specific scrambled siRNA for 48 or 72 hours after which cell lysates were 
collected and analyzed by Western Blot.  Non-specific scrambled control siRNA was 
included to show any effect that treatment or introduction of siRNA would have on the 
RNAi pathway. In Figure 18, the top band corresponding to ~62kD is the glycosolated 
(mature) form of CCR5 and the bottom band corresponding to ~49 kD is the 
unglycosolated (immature) forms of CCR5.  As shown in Figure 18, treatment with 
4nmol pooled CCR5-siRNA for 48 and 72 hour treatments partially down-regulated 
the glycosolated forms of CCR5, but do not appear to have any effect on the 
unglycosolated forms.  However, treatment with 10nmol CCR5-siRNA for 48 hours 
almost completely abolishs the glycosolated form but has little effect on the 
unglycosolated CCR5.  Importantly, treatment with 10nmol CCR5-siRNA for 72 
hours completely eliminates the glycosolated CCR5 and partially down-regulates 
unglycosolated forms.   
3.3.5.  No down regulation of CCR5 observed in human vaginal tissue using the 
ex vivo OTC system 
To determine if CCR5 could be down regulated in human vaginal tissue 
lysates, we used the OTC system.  The vagina tissues were treated with 10nmol 
CCR5-siRNA and incubated for either 72 or 96 hours after which lysates were 
collected as described in Materials and Methods.  Unglycosolated (immature) forms of  
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CCR5 are ~49 kD and glycosolated (mature) forms are ~62kD in size. 
Scrambled non-specific control siRNA was included to show any effect that treatment 
or introduction of siRNA would have on the RNAi pathway. The epithelia and stroma 
were separated to help ascertain if down regulation was occurring in the entire tissue 
or just in one portion of the tissue.  This could be biologically relevant to the 
tranmission of HIV-1.  However, upon normaliztion of the Western Blot with 
cyclophilin A, both the 72 and 96 hour treatments with CCR5-siRNA showed no 
down-regulation in the epithelia, stroma or whole tissue.    
3.3.6. Treatment of human vaginal xenografts with CCR5-siRNA 
To detemine if we could successfully down regulated CCR5 in xenograft tissue, we 
treated xenograft with 10nmol CCR5-siRNA, incubated 72 or 96 hours followed by 
collection of tissue lysates.  Western blot did not show down-regulation of CCR5 in 
human vaginal xenograft tissue lysates as compared to scrambled controls.  
Unglycosolated (immature) forms of CCR5 are ~49 kD and glycosolated (mature) 
forms are ~62kD in size. Scrambled non-specific control siRNA was included to show 
any effect that treatment or introduction of siRNA would have on the RNAi pathway. 
Untreated controls were included to confirm that individual donor was not 
homozygous for CCR5∆32 mutation and that the individual did express CCR5.   
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Transfection 
Reagent 
 
 
Concentrations 
Tested 
 
Observed 
Lipofectamine 
2000 
 
2, 3, 4 or 5 ug/10 
nmol siRNA  
2 and 3 ug low transfection 
efficiency; 4 and 5 ug toxic < 80% 
cell death 
Fugene 6 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
2, 3 and 4 ug low transfection 
efficiency; 5 ug toxic < 65% cell 
death 
Arrestin 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
 All non-toxic 
 >15% transfection efficiency 
DharmaFect 1 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
2 and 3 ug low transfection 
efficiency; 4 and 5 ug toxic < 60% 
cell death 
DharmaFect 2 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
2, 3 and 4 ug low transfection 
efficiency; 5 ug toxic < 60% cell 
death 
DharmaFect 3 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
2 and 3 ug low transfection 
efficiency; 4 and 5 ug toxic < 60% 
cell death 
Dharmafect 4 
 
2, 3, 4 or 5 ug/10 
nmol siRNA 
2 and 3 ug low transfection 
efficiency; 4 and 5 ug toxic < 60% 
cell death 
 
 
Table 3:  Summary of different transfection reagents and concentrations tested. 
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3.3.7 Succesful infection of HIV-1 (BaL) in vaginal xenografts without 
reconstituting with PBMCs. 
 To confirm that we could successfully infect human vaginal xenografts without 
reconstituting the xenograft with peripheral blood mononuclear cells we inoculated 
five xenografts with 10 ul of undiluted HIV-1 (BaL), harvested the xenografts on day 
0, 3 and 7 and performed RT-PCR for the viral gag/pol transcripts.  It was necessary to 
harvest xenografts at these time points to verify de novo viral transciption.  This is 
based on our laboratories previous published work, which showed a positive signal 
was observed on day 0 (which was residual HIV-1 inoculum), disappears on day 3 and 
returns on day 7, indicating de novo viral transcriptional activity.  As shown in Figure 
18, the gag/pol is detected on day 0, almost completely disappears on day 3 and 
increases in intensity on day 7, indicating viral replication and active viral 
transcription is occurring.   
Discussion:   
We used human cell lines, vaginal tissue and human vaginal xenografts to 
determine if CCR5 could be down regulated using a cationic liposome delivery 
system. We started with Lipofectamine 2000 (Invitrogen) as our liposomal complex 
delivery system for our CCR5-siRNA and tested several different transfection reagents 
and concentrations, as shown in Table 3, to determine the best ratio of siRNA to 
transfection reagent to achieve maximum delivery of our siRNA molecules to the cells 
and tissues.   
After testing several different siRNAs targeting CCR5 we decided to use the 
validated SMARTpool siRNA from Dharmacon. To determine the effectiveness and 
ability of the liposomal delivered pooled CCR5-siRNA to down regulate CCR5, we 
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treated P4-R5 cells with either 4 nmol or 10 nmol pooled CCR5-siRNA or non-
specific scrambled siRNA for 48 or 72 hours.  Then cell lysates were collected and 
analyzed by Western Blot.  Non-specific scrambled control siRNA was included to 
show any effect that treatment or introduction of siRNA would have on the RNAi 
pathway.  The Western Blot data establishes that both the glycosolated (mature, 
~62kD) and unglycosolated (immature, ~49 kD) forms of CCR5 can be detected with 
our antibody.  The 4nmol pooled CCR5-siRNA treatment incubated for 48 and 72 
hours resulted in partially down-regulating the glycosolated forms of CCR5, but does 
not appear to have any effect on the unglycosolated forms when compared to the 
control siRNA.  However, a 48 hour treatment with 10nmol CCR5-siRNA almost 
completely eliminates the glycosolated form but has little effect on the unglycosolated 
form of CCR5.  Notably, a 72 hour treatment with 10nmol CCR5-siRNA completely 
eliminates the glycosolated CCR5 and partially down-regulates unglycosolated forms 
as determined by Western Blot analysis. This data indicates that CCR5 can be 
successfully down regulated in P4-R5 cells using the pooled CCR5-siRNA from 
Dharmacon using a single application. The validation of an efficient siRNA targeting 
CCR5 was necessary before proceeding to the ex vivo organ tissue culture system and 
the in vivo human vaginal xenograft system.  
Since we were able to down-regulate CCR5 in P4-R5 cells, which are adherent 
HeLa cells that do not normally express CCR5, we needed to determine if we could 
down regulate CCR5 in human vaginal tissue containing human lymphocytes.  To this 
end, an ex vivo organ tissue culture (OTC) system was utilized. Using the OTC, fresh 
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vaginal tissues were treated with 10nmol liposomal CCR5-siRNA or scrambled 
control siRNA, incubated for either 72 or 96 hours and then tissue lysates were 
collected.   At the time of harvesting, the stroma and epithelia were separated in one of 
the CCR5-siRNA treated tissues from both 72 and 96 hour time points.  This was 
necessary because it was not known if the siRNA would penetrate through all of the 
layers of the squamous epithelia.  By separating the epithelia from the stroma it could 
be deduced if CCR5 was being down-regulated in either or both of the tissue layers. 
Scrambled non-specific control siRNA was included to show any effect that treatment 
or introduction of siRNA would have on the RNAi pathway.  As seen in Figure 21, at 
72 and 96 hour post-treatment CCR5 was not down-regulated in either the epithelia, 
stroma or whole tissue as compared to the scrambled control siRNA.  Prior to 
normalization we thought that there was down reulgation of CCR5, but after 
normalization we believe that the high concentrations of Lipofectamine combined 
with the high concentrations of CCR5-siRNA was toxic to the tissue. 
The human vaginal xenograft model system was used to determine kinetics and 
absorption of liposome delivered siRNA or nanopartilces into human vaginal tissue for 
a potential use as a microbicide. To determine if the siRNA would be absorbed 
through the squamous epithelia of the vaginal xenografts and have the potential to 
reach the target macrophages and Langerhan cells, we treated vaginal xenografts with 
non-specifc FITC-siRNA. Vaginal tissue was treated with 4nM non-specific FITC-
siRNA for 2, 4, 12, 24 or 48 hours and cryosections were examined by 
immunofluorescent microscopy. By 2 hours post-treatment a positive green FITC 
signal was observed in the FITC-siRNA treated xenografts.  Some of these cells in the 
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2 hour treatment xenografts show positive FITC signal in the cytoplasm of the cells as 
is evident by the green signal directly adjacent to the blue DAPI stained nucleus.  All 
of the xenografts treated for 4, 12 and 24 hour visibly show a positive green signal, 
which is clearly observed in the cytoplasm of the cells.  In these xenografts there is 
also an increased intensity in brightness of the FITC signal, with the brightest signal 
being observed at 24 hours and at 48 hours the signal starts to fade.  There was no 
positive signal in the untreated group. However, there was autofluorescence emanating 
from the connective tissue in the stroma, presumably type I collagen, which studies 
have shown that many connective tissues, specifically collagen, will autofluorescence 
when excitated in all wavelengths.  
To establish an alternate and a potentially more efficient siRNA delivery 
method we treated vaginal xenografts with FITC-nanoparticles or sodium fluorescein 
control for either 6 or 24 hours and examined the cryosections by immunofluorescent 
microscopy.  The nanoparticles were made of polyethyleneglycol and have had a FITC 
molecule conjugated the nanoparticles.  By 6 hours post-treatment the FITC-
nanoparticle group we observed the FITC-nanoparticles (green) had penetrated the 
tissue but did not appear to have entered the cells.  However, in the 24 hour FITC-
nanoparticle treated tissue there was clear penetration into the tissue as well as entry 
into the cytoplasm as indicated by the white arrows.  There was no positive signal 
from the sodium fluorescein negative controls and untreated groups.  
Autofluorescence was again observed originating from the connective tissue, 
presumably type I collagen.   
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We were able to show that after 4 hours liposomal-siRNA and after 24 hours 
nanoparticles can adequately traverse the multiple layers of the squamous epithelia in 
human vaginal xenograft tissue.   Where a portion of the HIV CCR5-positive target 
cells are localized.  Surprisingly, originally when the xenografts were treated with 
4nM CCR5-siRNA there was no decrease in expression of CCR5 by 
immunohistological staining and Western Blot analyzes. Since we currently do not 
have a method for quantifying immunohistochemcial stained tissue sections we 
decided to perform Western Blot analysis to detect CCR5 protein levels.  To this end it 
was also necessary to determine the adequate dose of CCR5-specific siRNA required 
for treatment of vaginal tissue to abolish expression of CCR5.  
Based on the FITC-siRNA absorption data we decided to start with our 
laboratories human vaginal xenograft system prior to normalization of the CCR5-
siRNA OTC experiments.  Xenograft tissues were treated with 10nmol CCR5-siRNA 
and incubated for either 72 or 96 hours after which tissue lysates were collected as 
described in Materials and Methods.  Unglycosolated (immature) forms of CCR5 are 
~49 kD and glycosolated (mature) forms are ~62kD in size. Scrambled non-specific 
control siRNA was included to show any effect that treatment or introduction of 
siRNA would have on the RNAi pathway.  The xenograft CCR5-siRNA treatments 
were only performed once and need to be repeated but based on the Western Blot 
analysis and normalization data in Figure 22 there was no down-regulation of CCR5 in 
the xenografts.  Interestingly, three of the five xenografts treated with CCR5-siRNA 
and the scramble controls appear to have some upregulation of CCR5, indicating the 
siRNA itself may be affecting the pathway.  A microarray needs to be performed to 
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help assess changes in other genes in the RNAi pathway are being affected or possibly 
if regulatory genes for CCR5 recycling is being affected.  Based on these results that 
there was no down regulation of CCR5 in the xenograft tissue it may be necessary to 
increase the concentration of CCR5-siRNA and change the delivery vehicle to 
nanoparticles.  The xengrafts are metabolically active and contain the same proteins 
and enzymes found in normal vaginal tissue.  Even though the siRNA is encapsulated 
inside liposomes it may be possible for the CCR5-siRNA to be degraded after 
liposomal fusion with the outer most layer of the squamous epithelia.  The 
nanoparticles may provide more protection from siRNA degradation and may be less 
toxic, however, more testing is required to confirm this hypothesis.  Utilizing 
nanoparticle has its advantages such as they are can be stored at room temperature and 
based on our results the nanopartles also penetrate human vaginal epithelia.  The 
disadvantage to utilizing nanoparticles is the cost.   It may also be more appropriate 
target other surface molecules on the vaginal epithelia that are known to bind to HIV-
1, such as gp340 and syndecan-1. Targeting other molecules and testing different 
combinations of surface molecules could be performed at lower concentrations both 
siRNA and delivery vehicle whether it be liposomes, nanoparticles or other vehicle.   
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4. Lactobacilli secreting Cyanovirin: Probiotics can they work? 
 
Veronica Holmes, Yana Thaker, Li Ming, Bharat Ramratnam and Mary K. Howett 
 
 
 
The following chapter is written as an independent manuscript to allow for an easy 
transition from thesis format to submission format after combined with data from non-
human primates, which occurred in parallel at Brown Univeristy. 
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4.1 Introduction:   
The primary route of transmission for human immunodeficiency virus type 1 
(HIV-1) is vaginal and rectal sexual intercourse.  Some scientists believe that a 
prophylactic vaccine could potentially prevent sexual transmission of HIV-1, however, 
no clinically effective anti-HIV-1 vaccine has been successful in providing protective 
immunity. While consistent and reliable condom use is effective in preventing sexual 
transmission of HIV-1, this largely male-controlled method is not widely accepted 
among many at risk groups. (Tsai, 2004)   In the absence of an effective preventative-
vaccine, topical microbicides can provide a useful and cost-effective means of 
preventing new infections.(Pusch, 2005)   
In 1997 a novel protein, Cyanovirin-N (CVN), was discovered to have potent 
anti-HIV-1, anti-HIV-2 and anti-SIV activity.(Boyd, 1997)  CVN is an 11-kD protein, 
which is produced by the cyanobacterium, Nostoc ellipsosporum.  This protein has 
been shown to be resistant to physico-chemical degradation, multiple freeze-thaw 
cycles, heat and can withstand treatment with denaturants, detergents and some 
organic solvents. (Bewly, 1998; Boyd, 1997) Ex vivo experiments utilizing human 
cervical tissue and in vivo experiments utilizing adult female cynomolgus macaques 
(Macaca fasciularis) showed treatment with low doses of CVN in a gel formulation 
prevented infection from HIV-1 and SIV, respectively, when treatments occurred up to 
an hour before inoculation. (Tsai, 2004) Another recent study has shown that 
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combining CVN with the peptide 12p1, which was isolated from a phage display 
library, has a synergistic effect increasing the anti-HIV-1 activity of both compounds 
allowing lower dosages to be used without decreasing efficacy.(McFadden, 2007) The 
antiviral activity of CVN is due to the irreversible multivalent interactions between 
CVN and high mannose residues on the HIV-1 envelope glycoprotein, gp120.(Tsai, 
2004; Botos, 2002; Shenoy, 2002) It is these molecular interactions that prevent fusion 
of the virus particle with the target cells and make CVN an ideal candidate for 
investigation as a potential microbicide.   
One approach for delivering microbicides is to use probiotics, specifically 
recombinant normal flora in the vaginal environment.  According to the WHO 
probiotics are defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host”.(FAO/WHO, 2002)  In 1907 the Russian 
scientist, Elie Metchnikoff, hypothesized that replacing or diminishing the number of 
putrefactive bacteria in the gut with lactic acid bacteria could normalize bowel health 
and prolong life.(Anukam, 2007) Recently, a new probiotic product, Activa®, has 
been introduced into the marketplace by Dannon yogurt.  Activa® is a lowfat yogurt 
containing large quantities of a living unique bifidobacterium culture, Bifidus 
regularia™. Dannon proclaims that it is this unique bifidobacterium which slows 
intestinal transit of food thereby optimizing the function of the gastrointestinal tract. 
(Dannon, 2008)  For many years gynecologists have advised women to eat yogurt for 
its beneficial nutritional and probiotic properties.  Daily ingestion of yogurt containing 
live lactobacilli has been shown to decrease vulvovaginal Candida infections by three 
fold.(Hilton, 1992) 
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The predominate normal flora found in the vagina is lactobacilli.  These 
bacteria are gram-positive rods, primarily facultative anaerobes that generally have a 
fastidious growth environment.  They prefer an acidic environment and help create 
one by producing lactic and other acids.(Reid 2001)  Byproducts produced from 
lactobacilli metabolism have antagonistic effects against urinary and vaginal 
pathogens.  These byproducts consist of biosurfactants that inhibit adhesion; the acids, 
bacteriocins and hydrogen peroxide inhibit growth; the coaggregation molecules block 
the spread of pathogens. (Reid,  2001) 
Recent studies have shown that exogenously applied lactobacilli or indigenous 
lactobacilli can reduce the risk of urinary tract infections, where lactobacilli depletion 
is associated with bacterial vaginosis and yeast vaginosis.(Reid, 2001; Reid, 1995; 
Raz, 1993; Gupta, 1998)  Ingested lactobacilli, specifically L. rhamnosus GR-1 and L. 
reuteri RC-14, have been shown to influence the vaginal environment by being 
delivered to the vagina following oral ingestion via the natural passage through the 
intestine and along the perineal and vulval skin.(Reid and Bruce 2001; Anukam 2007) 
An imbalance in or a depletion of normal flora in the vaginal environment has been 
associated with an increased risk of acquiring opportunistic infections, including HIV-
1. (Chang 2003; Taha 1998)  Recently, recombinant lactobacilli as a delivery method 
for microbicidal molecules and compounds has attracted a lot of attention and may 
provide a unique opportunity to prevent the transmission of HIV-1.  The first 
recombinant lactobacilli tested was a recombinant L. jensenii Xna, which secreted 
CVN and a two domain soluble CD4 (2D CD4) molecule.(Chang, 2003) In vitro 
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testing of this lactobacilli showed a small decrease in HIV-1 binding.(Chang, 2003) 
As seen in Figure 23, our collaborator has combined two different expression 
cassettes, one for intracellular expression and a second for maximum secretion of 
CVN by lactobacilli.(Pusch, 2006)  Subsequent to the design of the CVN construct our  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23:  Cyanovirin (CVN) construct transformed into L. plantarum. 
Expression cassettes for intracellular expression (pTSV11-CVN) and secretion into the 
medium (pTSV2-CVN) were combined to create the above CVN construct.  
Restriction sites used for cloning are in bold.  ATGA Usp45 leader indicates gene 
fusions from the leader sequence of the lactococcal secreted protein Usp45, followed 
by its original signal peptidase cleage site DTNSD (D) for enhanced scretion (pTSV2-
D-CVN).  Vertical black arrows indicate the signal peptidase cleavage site (SPCS), 
followed by the propeptide sequence DTNSD (pTSV2-D-CVN/pTSV2-D-CVNco).  
CVNco indicates codon optimization of CVN for expression in different recombinant 
lactobacilli.  TT1 and TT2 represent the transcription terminators; LPS2 P is the 
bacteriophage promotor; SD, Shine-Dalgarno motif; ATG and ATGA (start/stop) are 
the translation initiation start codons; P11 TIR, translation initiation region from L. 
lactis promotor 11.  (Pusch, 2005) 
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Figure 24:  Western Blot detection of CVN secretion from different strains of 
lactobacilli. 
One gastrointestinal (GI) strain, L. plantarum, and two vaginal strains, L. jensenii and 
L. gasseri were transformed with the CVN construct from Figure 1.  Western Blot 
analysis shows that both L. plantarum (A) and L. gasseri (C) secreted more CVN as 
compared to L. jenseii (B). However, since L. gasseri does not produce hydrogen 
peroxide we chose L. plantarum as the first lactobacilli delivery system to test.  
Attempts were made to transform another strain, L. crispatus, but this strain could not 
be transformed with our CVN construct.(Unpublished results by Dr. Bharat 
Ramratnam, Brown University)   
 
 
A B C 
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collaborator transformed L. plantarum, L. jensenii and L. gasseri that all secrete CVN 
as detected by Western Blot analysis, as shown in Figure 24.(Ming and Ramratnam, 
unpublished data) In this report we describe a system for utilizing one of the 
recombinant lactobacilli, L. plantarum, to synthesize and secrete an anti-HIV-1 
compound reconstituted on human vaginal tissue and human vaginal xenografts.   
4.2 Material & Methods: 
4.2.1 Determination of generation time and growth rates of recombinant and wild 
type lactobacilli.    
The recombinant lactobacilli that secretes cyanovirin, L. plantarum CVN+, utilized 
was designed and supplied by Dr. Bharat Ramratnam at Brown University 
(Providence, Rhode Island) and was always grown in Man, Rogosa and Sharpe (MRS) 
media or agar (Difco) with erythromycin (10 ug/ml) added for selection of 
recombinant bacteria. The wild type lactobacilli, L. plantarum, was purchased from 
American Type Culture Collection (Manassas, VA) and was always grown in MRS 
media.  To determine the growth rate of each strain of lactobacilli MRS was 
inoculated from glycerol stocks and the optical density was measured on a DU 800 
spectrophotometer (Beckman Coulter Fullerton, CA) at specified time points.     To 
determine generation times either wild type or recombinant L. plantarum was grown 
overnight in MRS media and then diluted to 1x10-4, 1x10-5 or 1x10-6 in MRS media.  
After which each dilution was plated on MRS agar for WT L. plantarum or MRS agar 
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with erythromycin (10 ug/ml) added for selection of recombinant L. plantarum and 
incubated at 37º C until colonies appeared (approximately 7.5 hours).    Following 
incubation the colonies on each plate were counted and the total number of bacteria 
was counted utilizing a hemocytometer, to obtain generation times and colony forming 
units (CFU).  Calculation of generation time was determined using the following 
formula:  
 n= log(N) – log(N0)  and to get hours   t/n 
           log 2 
 
Where N is the number of cells after growth and N0 is the initial number of cells.  
Once n is determined then divide t, which is the time in between N0 and N by n to get 
the hours.   
4.2.2 Reconstitution of lactobacilli on human vaginal tissue in OTC:   
The organ tissue culture model system (Gupta, 2002) using human vaginal tissue was 
utilized to determine if the lactobacilli would grow and adhere to normal vaginal 
tissue. Briefly, vaginal tissue obtained from women undergoing reconstructive 
surgeries for non-cancerous reasons were collected immediately prior to performing 
the experiment.  Only grossly normal samples released by surgeon were used.  All 
samples were from tissues that would normally be discarded.  Tissue from a single 
donor was divided into 6 contiguous 6.0 mm circular pieces by an Acu-punch® biopsy 
scalpel. The cut tissue sections were washed three times in serum-free and antibiotic-
free DMEM (Mediatech, Herndon, VA).  The circular pieces of tissue with the 
epithelial layer oriented on top, were placed into the top chamber of 12-well Transwell 
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dish.  A sterile 5% solution of agarose in Hank’s medium was added to the area 
surrounding the tissue and allowed to solidify creating a tight seal around the tissue.  
Antibiotic free DMEM supplemented with 10% fetal bovine serum (1 ml) was added 
to the bottom chamber to keep the Transwell membrane in contact with the medium 
and feed the tissue from underneath.  Also, 500 µl of MRS media containing either 
recombinant L. plantarum CVN+, wild type L. plantarum or L. lactis grown to an 
O.D. of 1.8 was added to the top chamber and incubated in a humidified chamber at 
37º for 24, 48 or 72 hours.  At each time point 300 µl of MRS media was removed 
from the top chamber and 300 µl of fresh media was added, tested for a decrease in pH 
and cyanovirin secretion as well as Gram stained.  
4.2.3 Detection of lactobacilli from bacteria cultures and on human vaginal tissue 
by Gram stain.   
Lactobacilli were grown on normal human vaginal tissue using the organ tissue culture 
system described above or as bacterial cultures.  At the specified time points (24, 48 or 
72 hours) lactobacilli was collected from each inoculated tissue and Gram stains were 
performed to detect the bacteria.  Each bacterial smear was heat fixed, incubated for 
20 seconds with crystal violet and washed with distilled water.  After which Gram’s 
iodine solution was applied to each smear, incubated for 1 minute and rinsed with 95% 
ethanol to decolorize.  To stop the reaction of the alcohol each smear was washed with 
distilled water for 5 seconds and incubated with safranin for 20 seconds followed by 
washing with distilled water.  All smears were examined using an Olympus IX-81 
microscope and all magnifications are shown are 60X. 
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4.2.4. Detection of cyanvirin by indirect antibody ELISA.  
The indirect ELISA was performed using the Protein Detector ELISA HRP Microwell 
Kit (Kirkegaard & Perry Laboratories, Gaithersburg, MD) according to the 
manufacturer’s instructions.  Briefly, a 96 well plate was coated with 100 µl of either 
supernatant from inoculated cultures or vaginal xenografts and incubated for one hour 
at room temperature.  Following incubation the plate was emptied and 300 µl of the 
bovine serum albumin/blocking solution was added to each well, incubated at room 
temperature for 15 minutes after which the plate was emptied and washed four times 
with wash solution supplied in the kit.  Subsequently, 100 µl of secondary antibody 
was applied to each well, incubated for one hour at room temperature, emptied and 
wash five times.  Followed by 100 µl of substrate solution being added to each well, 
after development of color 100 µl of stop solution was added to each well and the 
plate was read on a plate reader at 405 nm.   
4.2.4 Western Blot Analysis of CVN secretion from bacteria cultures. 
Experiments were performed as previously described.(Pusch, 2005)  Briefly, bacterial 
cultures were grown to an optical density of 1.8, centrifuged at 1000 RPMs for 10 
minutes at 4ºC.  Culture supernatant was removed, filtered through a 0.45 µm syringe 
filter and subjected to a Lowry protein assay to determine total protein levels.  Proteins 
(50 ug) were then resolved on a 15% sodium dodecyl sulfate (SDS) polyacrylamide 
gel and transferred onto a Hybond polyvinylidene fluoride (PVDF) membrane 
(BioRad, Hercules, CA).  The membrane was probed with a rabbit polyclonal antibody 
(provided by Barry O’Keefe, NCI) and immunodetection was performed using the 
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peroxidase-based ECL Plus detection system (Amersham Biosciences, Piscataway, 
NJ) according to the manufacturer’s instructions.   
4.2.5 HIV-1 Cell-free Inactivation Assay.   
Experiments were performed as previously described.(Urdaneta, Wigdahl et al. 2005) 
Briefly, one day prior to the assay, P4-R5 HeLa cells (Charneau, Mirambeau et al. 
1994) were seeded into 12-well culture dishes at a concentration of 8x104 cells per 
well and incubated overnight at 37°C with 5% CO2.  The cells used in this assay, P4-
R5, are HeLa cells that have been engineered to express HIV-1 receptors (CD4, CCR5 
and CXCR4) and have an integrated HIV-1 promoter fused to a B-Galactosidase (β-
gal) reporter gene.(Charneau, Mirambeau et al. 1994) This allows β-gal expression to 
be measured when the HIV-1 promoter has been activated.  On the day of the assay 5 
µl of a high titer stock (107.17 tissue culture infective dose 50/ml) (TCID50) of HIV-1 
(strain IIIB; Advanced Biotechnologies, Inc., Columbia, MD) was treated with an 
equal volume (5 µl) of the MRS culture media and incubated for ten minutes at 37°C. 
This MRS media incubated with HIV-1 was collected from recombinant L. plantarum 
or wild type L. plantarum cultures grown to an O.D. of 3.0, after which 1M sodium 
hydroxide was added dropwise to increase the pH of the media to 7.0.  To stop the 
reaction, 990 µl of RPMI media (supplemented with 10% FBS) was added to the 
virus/media mixture and 300 µl of this dilution was applied to the P4-R5 cells in 
triplicate.  Following a two-hour incubation at 37°C with 5% CO2, 2 ml of fresh 
DMEM media (supplemented with 10% FBS and with half the concentration of 
puromycin 250 ug/ml) was added to each well.   After incubation for 46 hours at 37°C 
with 5% CO2, cells were washed twice with phosphate buffered saline, lysed and 
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incubated for one hour at room temperature with reaction buffer supplied in Galacto-
Star™ β-Galactosidse Reporter Gene Assay System (Applied Biosystems, Foster City, 
CA), per the manufacturer’s instructions.  Following the incubation β-gal expression 
was quantified utilizing Fluoroskan Ascent FL Luminometer (Thermo Scientific, 
Waltham, MA). β-gal expression was measured in relative luminescence units per 
second (RLU/s).  A one-way ANOVA followed by Dunnett’s (compare all versus 
control) post-test was performed using GraphPad Software to determine statistical 
significance.   
4.2.6 Reconstitution of human vaginal xenograft model system with recombinant 
lactobacilli:  
Six to fourteen week old female NOD/LtSz-scid/scid mice (Jackson Laboratory, Bar 
Harbor, ME) were maintained under specific pathogen-free environmental conditions, 
in accordance with all Drexel University’s Institutional Review Board and 
Institutional Animal Care and Use Committee’s rules and bylaws.  Vaginal tissue was 
obtained from patients undergoing reconstructive surgeries for non-cancerous reasons.  
The vaginal tissue samples were cut into split-thickness grafts, ~ 2cm x 2cm x 0.5 mm 
in size, consisting of the vaginal epithelial layer with minimal stroma.  The tissues 
were rolled into a tubular conformation with the epithelial layer directed inward and 
placed within the subcutaneous space on the backs of the NOD/SCID mice.  Estrogen 
pellets were also implanted so that the circulating peripheral blood estrogen levels 
were 200 pg/ml, the average normal level in pre-menopausal women.  This allowed 
sustained growth of the human vaginal xenografts. Grafts were allowed to heal for ~21 
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days after implantation, at which time the xenografts were inoculated with 10 ul of 
either wild type L. plantarum or recombinant L. plantarum CVN+ and incubated for 
72 hours.  At the 72 hour time point the xenografts were either harvested (as decribed 
below) or challenged with 10 ul of HIV-1 BaL (Advanced Biotechnologies, Columbia, 
MD) and incubated for 7 days. Following the incubation the mice were euthanized, the 
xenografts were removed, washed with sterile phosphate buffered saline (PBS).  The 
resulting wash PBS was centrifuged with the supernatant to undergo indirect ELISA to 
detect CVN secretion and the pellet was to be used for Gram stain, as described above. 
The HIV-1 challenged xenografts were to undergo homogenization, total tissue RNA 
extraction and RT-PCR for HIV-1 Gag/Pol and Tat/Rev transcripts.  However, this 
analysis will occur at our collaborator’s laboratory at Brown University, Rhode Island 
due to the unfortunate passing of our laboratory’s Principle Investigator.  To control 
for donor-to-donor variations, grafted tissue was distributed as evenly as possible 
across all inoculation groups. 
4.3 Results: 
4.3.1 Wild Type and recombinant L. plantarum grow at different rates.   
To determine the growth rate of both recombinant and WT L. plantarum bacterial 
cultures were grown in MRS media with optical density measurements of the 
inoculated cultures being performed every thirty minutes.   As shown in the growth 
curves in Figure 25 the WT L. plantarum doubled approximately every hour as 
compared to the recombinant L. plantarum, which doubled approximately every three 
hours.  This doubling time was also confirmed by estimating the generation times 
utilizing the formula described in the Materials and Methods section.  It was 
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determined that the estimated generation time for recombinant L. plantarum was 2.51 
hours as compared to the WT which had a generation time of 1.06 hours.    
4.3.2 Detection of Lactobacilli by Gram stain, subsequent pH changes and CVN 
secretion.   
To verify the growth of the lactobacilli along with the resultant pH change and CVN 
secretion, WT or recombinant L. plantarum was grown in the MRS media for 24, 48 
or 72 hours.  At the specified time points 2 ml was removed from each culture 
subjected to Gram stain and the remaining volume was filtered.  The subsequent 
filtered product was subjected to pH measurement, Western Blot and indirect ELISA 
for the detection of CVN.  As shown in Figure 26A and 26B both WT and 
recombinant L. plantarum are detectable by Gram stain and Figure 26E shows that the 
pH of the cultures changed from 6.5 to 4.5 indicating growth and lactic acid secretion.  
The Western Blot analysis in Figure 27 shows that CVN was detected in all of the 
time points collected (24, 48 and 72 hours) for the recombinant L. plantarum but not 
the negative control L. lactis.  To determine the minimum detection limits for CVN 
from bacterial cultures we utilized an indirect ELISA.  Figure 28A shows the 
minimum detection limits was in the nanogram range for CVN concentration using the 
indirect ELISA method and the resulting standard curve.  From the standard curve in 
Figure 28A we were able to determine the minimum volume required from filtered 
supernatant that allowed for detection of our secreted CVN, which corresponded to 0.1 
to 1 µl from recombinant L. plantarum culture supernatant, as shown in Figure 28B.    
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4.3.3 Re-coloniozation of human vaginal tissue in OTC with lactobacilli. 
No previous studies have been published which have grown or reconstituted 
recombinant L. plantarum on human vaginal tissue ex vivo.  To determine that WT 
and recombinant L. plantarum could be grown on human vaginal tissue we utilized an 
ex vivo organ tissue culture system (OTC) as previously described. (Gupta 2002) The 
vaginal tissue was placed epithelia side up in a transwell dish, surrounded by agarose, 
treated with either WT or recombinant L. plantarum cultures and incubated  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25:  Recombinant and WT L. plantarum grow at different rates. 
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Figure 26:  Gram stain and pH change in vitro and ex vivo. 
Detection of both recombinant (A) and WT (B) L. plantarum from bacteria cultures as 
well as recombinant (C) and WT (D) L. plantarum from inoculated organ tissue 
cultures by Gram stain at 24, 48 and 72 hours after inoculation.  In all samples a pH 
change from 6.5 to 4.5 was detected after 48 hours post-inoculation.  Results of all 
Gram stains were similar and pictures are representative all experiments. Pictures 
shown are 48 hour post-inoculation and in 60X magnification.   
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for either 24, 48 or 72 hours.  The OTC system allows the tissue to be oriented in a 
manor that allows for treatment/inoculation with the bacteria.  In this system the only 
exposed portions of the tissue are the squamous epithelia cells, which are the cells that 
the lactobacilli naturally adhere to in the vaginal environment.   As shown in Figure 
26C and 26D both the WT and recombinant L. plantarum was detected by Gram stain 
by 48 hours post-inoculation with a subsequent change in pH from 6.5 to 4.5 as seen 
in Figure 26E.   Results were similar after 72 hours post-inoculation (data not shown).  
There was no change in pH detected in the recombinant L. plantarum OTC cultures 
after 24 hours but low quantities of bacterial were detected by Gram stain (data not 
shown).   
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4.3.4 Recombinant L. plantarum secreted cyanovirin decrease cell-free HIV-1 
infectivity in vitro.  
To verify the cyanovirin secreted from the recombinant L. plantarum retained its anti-
HIV-1 activity we tested filtered bacterial culture supernatant against cell-free HIV-1.  
Recombinant or WT L. plantarum was grown in MRS media until the optical density 
reached approximately 3.0, after which the cultures were centrifuged and the 
supernatants were collected, filtered and the pH adjusted to 7.0 to ensure the pH would 
not be a contributing factor in decreasing HIV-1 infectivity.  Three separate 
experiments with triplicate samples were performed and in each experiment a 
statistically significant (p<0.01) decrease in anti-HIV-1 activity was observed in the 
recombinant L. plantarum grown for 48 hours (O.D. 3.0) relative to uninfected 
control, as shown in Figure 29.   
 
 
 
 
 
 
 
 
 
 
 
 
24hr  48hr  72hr  24hr  48hr     72hr 
 1  2  3  4  5     6 
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Figure 27:  Cyanovirin secreted from recombinant L. plantarum as detected by 
Western Blot. 
WT L. lactis (lanes 1, 2, 3) and recombinant L. plantarum (4, 5, 6) were grown in 
Man, Rogosa and Sharpe media at 37º for 24, 48 and 72 hours.  At each time point 3 
ml of media was removed from inoculated cultures, centrifuged, filtered and subject to 
Western Blot.  Cyanovirin was detected in all of the CVN positive L. plantarum  lanes  
while the L. lactis are negative for cyanovirin.  Results shown are for the 48 hour 
collection time point.   
 
 
 
 
 
 
 
4.3.5 Expected re-colonization of recombinant L. plantarum in vivo and the effect 
on HIV-1 infectivity. 
Our previous ex vivo experiments have shown that both recombinant and WT 
L.plantarum can be grown on human vaginal tissue and subsequently detected, but we 
did not know if both bacteria could be grown and re-colonize in the lumen of our 
human vaginal xenograft model system.  To determine this we inoculated the lumens 
of vaginal xenografts with 10 ul of either recombinant or WT L.plantarum from 
bacterial cultures that were grown for 48 hours (O.D. 3.0) and incubated for 72 hours.  
Following the incubation the xenografts were either harvested or challenged with 
HIV-1, with the HIV- 1 challenged vaginal xenografts being allowed to incubate for 
an additional 7 days for viral replication.  These xenografts have not been analyzed 
due to the unfortunate passing of our laboratory’s Principle Investigator, therefore this 
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analysis will occur at our collaborator’s laboratory at Brown University.    However, 
based on our ex vivo results we are expecting that both the recombinant and WT 
L.plantarum to have reconstituted the xenografts and secreted CVN.   
4.4 Discussion 
The bacterial species that colonize the human body are both numerous and diverse.  
These bacteria or normal flora inhabit the skin, the entire digestive system and 
urogenital tract in women. Many of these normal flora contribute to the healthy 
development of the immune system, prevent infection from pathogenic and 
opportunistic microbes as well as maintain the intestinal barrier function.  Illness, 
HIV-1 infection, poor nutrition, use of antibiotics and other factors can affect this 
delicate balance and cause emergence of harmful bacterial. An imbalance in or a  
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Figure 28:  Minimum detection limits of CVN from recombinant L. plantarum 
by indirect ELISA. 
WT or recombinant L. plantarum was grown in MRS media until the O.D. reached 
1.8.  At which time cultures were collected, centrifuged, filtered and subject to indirect   
ELISA. A standard curve was used to determine the concentration of CVN produced 
by the inoculated recombinant L. plantarum cultures. As shown in the standard curve 
(A) the sensitivity of the lower detection limits for the CVN concentration by indirect 
ELISA is in the nanogram range, which corresponds to volume of recombinant L. 
plantarum supernatant (B) of 0.1 to 1 µl.   
 
 
 
 
 
 
 
Figure 29:  Secreted cyanovirin decreases cell-free HIV-1 activity in vitro. 
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HIV-1 was pre-treated with supernatant from either MRS media, WT or recombinant 
L. plantarum after the pH was adjusted to 7.0, prior to infection of P4-R5 indicator 
cells which express β-gal if infected. Media only and uninfected MRS groups show 
baseline expression of β-gal; infected control and infected MRS act as viral infectivity 
controls; CVN+ 24 hr and 48 hr represent the recombinant L. plantarum supernatant 
grown for 24 or 48 hours, respectively; and WT 24 hr and 48 hr represent the wild 
type L. plantarum supernatant grown for 24 or 48 hours respectively.  Results are 
representative of 3 different experiments with n=3/group with similar outcomes. 
*=p<0.01  
 
 
 
 
 
 
 
 
 
depletion of normal flora in the vaginal environment has been associated with an 
increased risk of acquiring opportunistic infections, including HIV-1. (Chang, 2003; 
Taha, 1998)  It has been shown that the daily ingestion of yogurt containing live 
lactobacilli has been shown to decrease vulvovaginal Candida infections by three 
fold.(Hilton, 1992)  The normal flora found in the vagina environment is lactobacilli. 
These bacteria prefer an acidic environment and help create one by producing lactic 
and other acids.(Reid 2001)  Byproducts produced from lactobacilli metabolism have 
antagonistic effects against urinary and vaginal pathogens.   
There are many challenges that confront the development of an effective HIV-
1 microbicide.  The microbicide must be able to target and neutralize a genetically 
diverse population of viruses. Mucosal administration of the microbicide must not 
cause adverse effects such as immune cell infilitration in the host or sexual partner and 
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must be able to maintain sufficient muscosal concentrations of active compound over 
extended periods of time.  Some microbicides that require application immediately 
prior to coital acts may lower the frequency of compliance and complicate evaluations 
of efficiacy.  Unfortunately, in many societies cultural norms prevent women from 
taking the necessary steps to apply a vaginal microbicide immediately before 
intercourse.  There must be alternatives to topical microbicides because even the most 
efficacious topical microbicide may be of limited value if it can not easily be used.  
Thus, a vital need exists to develop efficient systems that allow for the delivery of 
microbicides to mucosal surfaces over extended periods of time.   
 One approach for delivering microbicides with the capability of synthesizing 
an antiviral compound is to use probiotics, specifically recombinant normal flora in 
the vaginal environment. A recent study tested a recombinant lactobacilli, L. jensenii 
Xna, which secreted CVN and a two domain soluble CD4 (2D CD4) molecule.(Chang, 
2003) In vitro testing of this lactobacilli showed a small decrease in HIV-1 
binding.(Chang, 2003)  We have also decided to test a recombinant lactobacilli, L. 
plantarum, that secretes CVN, which was developed by our collaborator, Dr. Bharat 
Ramratnam at Brown University.   CVN has been shown to have effective antiviral 
(HIV-1, HIV-2 and SIV) activity.(Boyd, 1997)  
To determine the feasibility of using recombinant lactobacilli, L. plantarum, as 
a microbicide we measured the growth rates of both WT and recombinant L. 
plantarum and measured CVN secretion.  This was necessary to evaluate if the 
recombinant L. plantarum would grow and compete for resources with the normal 
flora in the vaginal environment.  As shown in the growth curves in Figure 25 the WT 
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L. plantarum grew at a much quicker rate doubling approximately every hour as 
compared to the recombinant L. plantarum, which grew at a much slower rate 
doubling approximately every three hours.  The recombinant L. plantarum would not 
be able to compete for food and resources with the WT lactobacilli already colonizing 
the vagina. Growth curves need to be performed on the other recombinant lactobacilli, 
L. jensenii or L. gasseri, which may grow at quicker rates that are closer to their 
comparable WT strains and therefore would be more likely to be able to compete for 
resources.  
To verify the recombinant L. plantarum was secreting CVN, WT or 
recombinant L. plantarum was grown in the MRS media for 24, 48 or 72 hours.  The 
supernatant was then subjected to Western Blot and indirect ELISA for the detection 
of CVN. The Western Blot analysis in Figure 27 shows that CVN was detected in all 
of the time points collected (24, 48 and 72 hours) for the recombinant L. plantarum 
but not the negative control. The detection of CVN from very small volume of 
supernatant was very important because when utilizing the human vaginal xenograft 
model system the largest instilling volume is 10 ul maximum.   To determine the 
minimum detection limits for CVN from bacterial cultures we utilized an indirect 
ELISA.  Figure 28A shows the minimum detection limits was in the nanogram range 
for CVN concentration using the indirect ELISA method and the resulting standard 
curve.  From the standard curve in Figure 28A we were able to determine the 
minimum volume required from filtered supernatant that allowed for detection of our 
secreted CVN, which corresponded to 0.1 to 1 µl from recombinant L. plantarum 
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culture supernatant, as shown in Figure 28B.  These results indicated that once the 
vaginal xenografts were recolonized with the recombinant L. plantarum, we could 
detect CVN secretion and determine its effect on HIV-1 infectivity. 
The recombinant L. plantarum CVN microbicide would protentially provide 
benefits to a women that is infected with HIV-1 and is being treated with highly active 
antiretroviral therapy (HAART).  It is known that HAART causes imbalances in the 
normal flora of people who are required to take it for survival and specifically many 
times women have recurrent vaginal yeast infections.  A recombinant L. plantarum 
microbicide, which secretes CVN, given regularly to a HIV-1 infected women to 
recolonize the vaginal environment could decrease vaginal yeast infections but also 
decrease cell-free HIV-1 in vaginal secretions.   
Before beginning the in vivo testing, the anti-HIV-1 activity of the CVN 
secreted from the recombinant L. plantarum was assessed.  Filtered recombinant or 
WT L. plantarum culture supernatant with the pH adjusted to 7.0 was tested against 
cell-free HIV-1. The pH had to be adjusted to ensure the pH would not be a 
contributing factor in decreasing HIV-1 infectivity.  Three separate experiments with 
triplicate samples were performed and in each experiment a statistically significant 
(p<0.01) decrease in anti-HIV-1 activity was observed in the recombinant L. 
plantarum grown for 48 hours (O.D. 3.0) relative to uninfected control, as shown in 
Figure 29.  These results show the CVN secreted from the recombinant L. plantarum 
retained its anti-HIV-1 activity in vitro.   
To date there are no published reports of recolonizing human vaginal tissue ex 
vivo or in vivo with recombinant lactobacilli.  To determine if the WT and 
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recombinant L. plantarum could be grown on human vaginal tissue we utilized an ex 
vivo organ tissue culture system (OTC) as previously described. (Gupta 2002)  
Vaginal tissue treated with either WT or recombinant L. plantarum cultures and 
incubated for either 24, 48 or 72 hours. This system allows the lactobacilli to only be 
exposed to the squamous epithelial cells, which the lactobacilli naturally adhere to in 
the vaginal environment.   As seen in Figure 26C and 26D both the WT and 
recombinant L. plantarum was detected by Gram stain by 48 hours post-inoculation 
with a subsequent change in pH from 6.5 to 4.5 as seen in Figure 26E.   Results were 
similar after 72 post-inoculation (data not shown).  There was no change in pH 
detected in the recombinant L. plantarum OTC cultures after 24 hours but low 
quantities of bacterial were detected by Gram stain (data not shown). The change in 
pH detected indicates the bacteria were growing on the human tissue and secreting 
lactic acid into the surrounding environment similar to the vaginal environment.   
Our data have shown that we were able to grow and detect the recombinant 
lactobacilli, the secreted CVN retatined its anti-HIV-1 activity in vitro and recolonize 
human vaginal tissue ex vivo.  Also, we have shown in Figure 18 (chapter 3), that we 
were able to successfully infect human vaginal xenografts without the need of 
reconstituting the xenografts with human peripheral blood mononuclear cells, as was 
required previously for this HIV-1 xenograft model system.    Subsequently, to 
determine if the lactobacilli would colonize the lumen of the vaginal xenografts the 
xenografts were inoculated with recombinant lactobacilli and upon harvesting were 
washed with PBS and subjected to Gram stain. Afterward the wash was sent to Brown 
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University for detection of CVN by indirect ELISA, a Gram stain was also performed 
but only a small population of lactobacilli was detected (data not shown) but more 
xenografts need to inoculated to ensure the lactobacilli detected was not residual 
bacteria from the initial inoculum.   To determine if the recombinant lactobacilli 
would decrease HIV-1 infectivity we inoculated the lumen of vaginal xenografts and 
challenged with HIV-1.  Upon harvesting, the vaginal xenografts were sent to Brown 
University for analysis due to the closing of Dr. Mary K. Howett’s laboratory at 
Drexel University.  
A study determining the kinetics of vaginal and oral delivery of the drug 
misoprostol, which is used to prevent stomach ulcers and for inducing labor, 
demonstrated that vaginal delivery provided a superior delivery method as compared 
to the oral administration for the induction of labor.(Zieman 1997) Another study 
demonstrated that vaginally administered indomethacin, which is used to treat many 
different types of arthritis and to stop preterm births, was more effect than oral 
indomethacin for halting preterm labor.(Abramov 2000) Vaginal drug delivery has 
been routinely used by clinicans to deliver bromocriptine to treat high prolactin levels 
in women suffering from nausea and vomiting making treatment with an oral 
medication difficult.  These studies combined with the FITC-siRNA absorption data 
from chapter 2 (Figures 15 and 16) in this thesis demonstrate that vaginal tissue can 
absorb medications and small molecules.    Therefore it is possible for the secreted 
CVN from the recombinant lactobacilli to be absorbed by the tissue in the vaginal 
environment and may travel to the lymph nodes providing another avenue to 
irrevesibly bind HIV-1.   
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Vaginal normal flora have been shown to effect HIV-1 viral load within 
vaginal secretions of HIV-1 positive women.(Hitti 2008) In an observation cohert 
study that collected cervico-vaginal lavages from  HIV-1 positive women showed that 
lactobacilli, which secreted hydrogen peroxide, had an effect on HIV-1 viral load in 
vaginal secretions.(Hitti 2008) The women whose vaginal normal flora changed from 
bacterial species that cause bacterial vaginosis(BV) to lactobacilli experienced a five 
fold decrease in HIV-1 viral load; and the women whose normal flora changed from 
lactobacilli to the bacterial species that cause BV experienced a three fold increase in 
HIV-1 viral load.(Hitti 2008)  A change in vaginal normal flora women has also been 
associated with bacterial vaginosis and an increased risk of HIV-1 infection.(Chang 
2003; Taha 1998) 
Previous work that has been performed in our laboratory has shown that the 
human vaginal xenografts do not retain the normal flora from the patient (Welsh and 
Howett, unpublished results), thus, making the xenograft system an ideal model 
system to evalute the recombinant L. plantarum as an anti-HIV-1 microbicide.  These 
experiments provide (and will provide) proof-of-principle in determining if the 
amount of cyanovirin produced and secreted can sufficiently decrease HIV-1 activity 
in vivo to reduce its transmission.  Consequently, this will also help in determining if 
recombinant probiotics can be utilized as a microbicide.  Future experiments to be 
performed using the vaginal xenograft model system will include testing of other 
recombinant lactobacilli, which secrete CVN; combining these recombinant and WT 
bacteria in the initial inoculum to detemine if the recombin ant lactobacilli can 
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compete with the WT in an environment completely devoid of bacteria; creating 
different recombinant lactobacilli that can secrete other microbicidal compounds or 
peptides (e.g. 5P12-RANTES, fucans or 12p1 peptide); and combining recombinant 
lactobacilli that secrete different anti-HIV-1 compounds as a way of delivering and 
testing combination microbicides with different modes of action.   Live microbial 
microbicide delivery strategies, as outlined in this thesis, potentially have many 
advantages over gel delivered topical microbicides, such as, deliverying long lasting 
protection due to bacterial colonization decreasing the need for immediate precoital 
application and low cost to manufacturer once normal flora bacteria has been 
transformed.   
 
  
 
 
 
 
 
5. Overall Discussion and future directions 
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 The sexually transmitted disease epidemic has been compared to an iceberg, 
what is seen is just a minuscule portion of a much larger problem, most of which is 
unseen. (CA policy Review 2007) At the end of December 2007, worldwide 34 
million people were infected with human immunodeficiency virus type 1 (HIV-1) 
(UNAIDS 2007), approximately 20 million people were infected with human 
papillomavirus (HPV) (CDC 2007) and at least 45 million people, in the United States 
alone, are infected with herpes simplex virus type 2 (HSV-2).(CDC 2006)  There are 
no cures for these persistent and recurrent infections just pharmacological 
maintenance regimes or surgical treatments.  If diagnosis occurs early in infection, 
management of the subsequent chronic disease can be the only option.  These diseases 
can potentially cause major physical and psychological limitations in the daily lives of 
people who are infected.  In our society, chronic diseases are prevalent and among the 
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most costly health problems. Many chronic diseases are considered preventable.(insert 
ref) The cost of preventing these diseases is significantly less than post-infection 
treatment.  The Center for Disease Control (CDC) has estimated that the cost of 
prevention (Safer Choice Program, school based STI and pregnancy program) is 37% 
of the cost of treatment.(CDC, 2008) A recent government report estimated the 
numbers of newly acquired STIs in teenagers in California for 2005 was 1.12 million 
with a resulting combined cost of treatment of $1.11 billion. (CA Policy Rev,2007) 
The cost estimate included lifetime medical costs based on incidence rates, 
undiagnosed and untreated disease and treatment costs.  This estimate does not include 
indirect costs, such as lost wages due to time off of work or productivity. (CA Policy 
Rev, 2007)  In the United States direct medical costs for treating STIs totals $15.3 
billion annually.  Sixty congressman co-sponsored a resolution to Congress requesting 
all levels of government to provide additional funding for screening and increased 
programming for education focused on the risks and the prevention of sexually 
transmitted diseases.(Congresswomen Jones, Ohio) 
 Although the impact to families has been highly publicized, the impact of 
sexually transmitted diseases to our society and the world population is often 
overlooked.  These diseases are the root of several of our society’s biggest problems, 
infertility, cervical cancer and AIDS. Several strategies must be employed 
simultaneously at both the population and individual levels to combat and overcome 
these diseases. Microbicides, vaccines, condom use, education and raising the socio-
economic status of women and the poor all need to be addressed before we can defeat 
these diseases.  
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 The development of an effective anti-HIV-1 vaccine has proven to be a 
difficult task.  The traditional methods for producing vaccines, using attenuated virus, 
is too dangerous with HIV-1 because some virions may retain or regain adequate 
replication potential to produce new infectious virions.(Robinson 2007; Whitney 004)  
Another setback encountered in the anti-HIV-1 vaccine program was antibodies that 
were produced which targeted viral envelope protein gp120, a protein known to have 
highly variable sequences and high levels of glycosylation.(Robinson, 2007; 
Richmann 2003; Wei, 1995)  Once antibodies bound to the specific gp120 molecules 
rapid selection would occur on these variable sequences causing escape mutants, plus 
these antibodies were ineffective on other HIV-1 quasispecies found in the HIV-1 
population.  An alternate approach taken by vaccine researchers is to elicit a effector 
T-cell response utilizing several different methods, such as:  using recombinant viral 
vectors to delivery viral proteins; using DNA vaccines to delivery viral proteins; 
delivering adjuvanted proteins and peptides; or combining two or more modalities for 
antigen delivery in heterologous prime/boost regimens.(Robinson 2007)  The problem 
with many of the above approaches is effective delivery of DNA, protein or peptide to 
the appropriate antigen presenting cells without activating a memory immune response 
that could be due to a  previous exposure to the delivery method.   The proliferation of 
HIV-1 infections combined with the lack of an anti-HIV-1 vaccine further highlights 
the dire need for new preventative measures to stop transmission, like topical 
microbicides (for review see (Balzarini and Van Damme 2007; van de Wijgert and 
Shattock 2007). 
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Summary of Conclusions by Chapter: 
Chapter 2: Formulated Sodium Dodecyl Sulfate (SDS) Hydrogel.  We 
hypothesized that our formulated SDS Hydrogel would have potent anti-viral activity 
against enveloped and non-enveloped sexually transmitted viruses.   
• Histological examination indicates SDS Hydrogel is non-toxic to human 
vaginal, cervical and foreskin tissues ex vivo.   
• SDS Hydrogel inactivates cell-free and cell-associated HIV-1 in vitro at low 
concentrations and with rapid kinetics. 
• SDS Hydrogel inactivates HSV-2 in vitro at low concentrations and with rapid 
kinetics. 
• SDS Hydrogel decreases de novo HPV-11 transriptional activity in vitro by 
90%. 
• Formulations of SDS Aquadapt hydrogel appear safe for epithelia application 
and effective for virus inactivation. 
Chapter 3: Liposomal delievered CCR5-siRNA microbicide.  We hypothesized 
that down-regulating human chemokine receptor 5 on HIV-1 target cells (CD4+ T-
cells, Langerhan cells and tissue macrophages) normally found in the vaginal 
environment would decrease and prevent HIV-1 binding and the subsequent infection 
both in vitro and in vivo.   
• Liposomal delivered pooled CCR5-siRNA down regulates CCR5 in vitro on 
human P4-R5 HeLa cells. 
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• Fluorescent, non-specific siRNA enters the cytoplasm of human vagainl 
xenograft epithelium.  Efficiency of liposomal delivery is greater than siRNA 
nanoparticle delivery. 
Chapter 4: Lactobacilli the secreting anti-HIV-1 compound, cyanovirin (chapter 
to be inserted in revision).  We hypothesized that HIV-1 transmission would be 
decreased by using a recombinant probiotic lactobacilli with the ability to secrets 
cyanovirin (CVN), an anti-HIV-1 compound, known to decrease HIV-1 binding and 
transmission in vitro and in vivo.   
• Recombinant lactobacilli secreting CVN grow at a slower rate than wild type 
lactobacilli in vitro and ex vivo.   
• Recombinant lactobacilli secrete cyanovirin into surrounding media in vitro. 
• Cyanovirin secreted from recombinant lactobacilli decreased HIV-1 activity in 
vitro. 
• Recombinant lactobacilli can be reconstituted on human vaginal epithelial 
tissue in ex vivo organ tissue culture system. 
 
During the sexual revolution in the 1960’s and 1970’s over the counter 
spermicides gained enormous popularity and gave rise to the novel idea of a 
microbicide. These popular topical spermicides are alternatives to oral birth control 
systems and are available in foams, creams, films and as condom coatings.(Howett 
Kuhl 2005)  A microbicide is defined as any compound that can be applied inside the 
vagina to prevent the transmission of sexually transmitted diseases. In microbicidal 
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research and development there is the dream of “the ideal microbicide” which must 
encompass all of the following characteristics:  non-toxic, non-inflammatory, 
undetectable, broad spectrum activity against bacterial and viral sexually transmitted 
infections, efficacy against cell-free and cell-associated HIV-1, no effect on the 
structural integrity of vaginal and cervical mucosal epithelium, stability at tropical 
temperatures, resistant to acidic pH and allow for the retention or reconstitution of 
lactobacilli. (Balzarini 2007; Howett & Kuhl 2005) To make it attractive for use, it 
must be odorless, colorless, tasteless, low cost and readily accessible.(Balzarini and 
Van Damme 2007) In addition to the difficult standards set by the legend of the “ideal 
microbicide”, as explained above, there are also the practical requirements set by the 
buying public that must also be taken into consideration when developing a new 
microbicide.  It ultimately depends on the willingness of women to use a specific 
microbicide.  In practical use, if women find the formulation unacceptable and avoid 
using the microbicide, then the best microbicide will be no more effective than a 
placebo.  This scenario leaves no chance to prevent the transmission of these incurable 
viruses that are continually plaguing our society.  For a microbicide to be successful it 
must also be made accessible to the people who need it the most, the poorest in our 
society and in the developing world.  Once a compound has successfully completed 
clinical trials and enters the marketplace, it must first be given to community liaisons, 
such as, doctors and tribal leaders, to ensure the microbicide is properly presented in a 
culturally acceptable manner in the societies where it is introduced.  It is very probable 
that there will not be a microbicide “silver bullet”, in other words one microbicide 
may not be universally acceptable for all individuals in all situations.  Hopefully, 
151 
 
 
microbicidal research will produce several different microbicides with different modes 
of action that can be used under different circumstances. For a microbicide to 
empower women, scientists must take into account diverse cultural sensibilities around 
the world when developing a microbicide.  Once a successful microbicide is approved 
by the FDA for public use it is the end of the beginning, companies and universities 
must continue to develop new applications (e.g. vaginal films or rings) for entry into 
clinical trials.   
A clinical trial is a research study on human volunteers to answer specific 
health questions with the results being submitted to the FDA in a new drug 
application.(FDA 2008) The experimental compound is administered to human 
subjects where safety and efficacy is determined.  The different classifications of 
clinical trials are treatment, prevention, screening and quality of life trials. 
Microbicide clinical trials are classified as prevention clinical trials because they 
examine ways to prevent diseases using medicines, vitamins, vaccines, prophylaxis or 
lifestyle changes.(FDA 2008) Traditionally, there are three phases to clinical trials but 
the FDA has fast tracked HIV-1 microbicides because of the urgent need and the 
clinical development challenges that a candidate microbicide must endure.  The two 
main challenges a candidate microbicide must deal with in clinical trials are the low 
seroconversion rate and condom counseling. (FDA Memoramdum 2003) Ethical 
conduct necessitates safe sex and condom counseling combined with low 
seroconversion rates (the measurable endpoint of efficacy) both contribute to the very 
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large sample size (several thousand) required to provide adequate power when 
determining if the effect of the microbicide is statistically significant.   
 The first candidate microbicide to reach Phase III clinical trials was the 
spermicidal non-ionic surfactant nonoxynol-9 (N-9), which inactivated HIV-1 in vitro 
by disrupting the outer membrane but failed to prevent sexual transmission in 
vivo.(Van Damme, Ramjee et al. 2002; Davis and Doms 2004)  In murine studies 
designed to evaluate the toxicity of N-9, cervical epithelial disruption and immune cell 
infiltration was observed by two hours post-treatment.(Catalone, Kish et al. 2004) 
Indicating that N-9 drastically increases inflammation providing additional 
lymphocyte targets for HIV-1.(Catalone, Kish et al. 2004) Women using N-9 were 
shown to have higher HIV-1 infection rates, almost certainly because N-9 disrupted 
the epithelial cell membranes in the genital tract that serve as a protective barrier 
against viral and bacterial infection and increased inflammation.(Van Damme, Ramjee 
et al. 2002; Van De Wijgert and Coggins 2002; Davis and Doms 2004)  Exploratory 
analysis showed that the treatment group had an increase in genital tract lesions with 
an epithelial breach, which was linked to a higher incidence of HIV-1 
seroconversion.(Balzarini 2007) 
 Another candidate microbicide to reach Phase III clinical trials was C31G.  
This compound is also a surfactant that is comprised of an equimolar mixture of two 
surface-active amphoteric agents, buffered with citric acid.(Balzini) Twenty three 
months into phase III clinical trials an independent monitoring board recommended 
halting the trial because too few women were becoming infected with HIV to provide 
the statistical power needed to show a difference between C31G and the placebo. 
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(Mascolini 2007; Peterson, Nanda et al. 2007) A separate clinical study has since 
shown that many patients were hesitant to use C31G because of the associated burning 
sensations.(Balzini and Wyrick, 2002) C31G is no longer being developed as a vaginal 
microbicide (van de Wijgert and Shattock 2007) but continues to be tested as a 
spermicide.   
 The development of the Ushercell microbicide, a cellulose sulfate polyanionic 
compound which blocked viral entry into cells, has also been halted in phase III 
clinical trials.  CONRAD and Polydex Pharmaceuticals were developing this 
compound.  Interim analysis of 1300 women in Benin, South Africa, Uganda and 
India indicated higher HIV-1 infection rates in women using the cellulose sulfate 
compound as compared to placebo.(Honey 2007) Based on these results, an 
independent data monitoring committee decided to stop the study.  There were more 
seroconversions in the Ushercell group.  Of the 1,425 women enrolled in the trial, 41 
seroconverted 25 of which were using Ushercell and 16 using placebo. (IAS Conf 
Sydney 2007; Microbicide Quarterly March 2007)  An additional exploratory analysis, 
that excluded women because they stopped using Ushercell, revealed that there were 
more infections among women using Ushercell as compared to the placebo and the 
difference was statistically significant.(IAS Conf Sydney 2007) 
 The first candidate microbicide to complete phase III clinical trials, 
Carraguard, contains galactose-linked polysaccharides (carrageenan) from red 
seaweek Gigartina skottsbergii.(Balzini 2002) Carraguard blocks viral entry into cells 
and blocks the trafficking of HIV-1 infected macrophages from the vagina to the 
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lymph nodes.(Balzini 2002, Perotti 2003; Schaeffer 2000) The Population Counsel 
was developing Carraguard.  Unfortunately, Carraguard failed in phase III trials 
because the microbicide did not prevent a statistically significant level of HIV-1 
infections when compared to placebo.(2008) There were over 4,200 women who 
completed this study in South Africa, of which there were 134 seroconversions in the 
microbicide group as compared to 151 seroconversion in the placebo group.  In 
contrast to Carraguard, our prototypic SDS Hydrogel differs because it kills sexually 
transmitted viruses (HIV-1, HPV and HSV-2) instead of blocking infection by 
physically binding to virus surfaces. 
 There are two schools of thought in microbicidal research and development.  
The first group asserts that the viruses must be killed to prevent infection and 
transmission. A disadvantage with this school of thought is that many of the 
compounds examined and tested have been strong compounds that also caused 
damage to the human epithelia at the concentrations required for anti-viral activity. 
The second group asserts that blocking the virus from binding to receptors allows the 
virus to be expelled from the vaginal environment before the infection and 
transmission occurs.  A disavantage with this school of thought is that binding the 
virus can be reversible overtime and if the virus is not expelled from the vaginal 
environment the infectious virions may still have the capacity for infection.  Much of 
microbicide research has been focused on preventing HIV-1 infection and one of the 
problems in the HIV-1 microbicide field is more times than not the two schools of 
thought are not combined.  Recently, the groups are moving closer together realizing 
that it is more advantageous to utilize both schools of thought with many different 
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modes of action for developing a non-toxic and efficiacous microbicides.  Combining 
microbicides with different modes of action to prevent HIV-1 infectivity is where the 
field of HIV-1 microbicide research headed.   
 Microbicide research is a very challenging field because of the species 
specificity of sexually transmitted viruses, the private nature of how they are 
transmitted and the social and cultural norms that surround such private acts.  One of 
the many obstacles in this challenging field is no one knows which tissues and cells 
are infected first.  It is not known if it is vaginal, cervical, endometrial or uterian tissue 
or all of the tissues.  Also, it is not known which are the first cells that become 
infected no one knows if it is T cells, dendritic cells that bind and capture HIV-1 using 
mannose receptors (DC-SIGN) and transport the infectious virions to the lymph nodes 
where they are presented to the target cells.  In addition, new receptors (gp340, 
syndecans, α4β7 integrins, galactosyl ceramide) are constantly being discovered that 
bind HIV-1 and allow HIV-1 to remain in the vaginal environment instead of being 
expelled and the virion can remain infectious for an extended period of time.  Another 
challenge in microbicide research is the vaginal environment and how HIV-1 gains 
access to its target cells.  During coital acts tears and rips can occur in the vaginal 
wall, which allow sexually transmitted viruses (specifically HIV-1 and HPV) to gain 
access to their target cells.  Also, in the vaginal enviroment there are vaginal rugae that 
increase the surface area of the vagina by expanding to accommodate intercourse and 
there are no tight junctions in vaginal and cervical tissues allowing the immune cells 
to move in and out of the mucosa. Based on these challenges I propose the following 
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model. During coital acts infected seminal fluid enters the vaginal environment 
(vaginal, cervical and uterian tissue all being exposed) and the infected virions can do 
one or more following simulanteously: bind T-cells (resulting in infection); bind DC-
Sign being captured by dendritic cells are then transported back to the lymph node and 
presented to target cells; are trancytosed through the epithelia to target cells in stroma; 
bind gp340, syndecans or other glycoproteins remaining infectious until an immune 
target cell moves into the vaginal environment and encounters the infectious virion 
while trying to clear any foreign pathogens left behind following intercourse. After 
coital acts the vaginal rugae contract possibly trapping infected seminal fluid, which 
has been shown to increase HIV-1 infectivity, thereby preventing some of the 
infectious virions from being expelled. 
 The work set forth in this thesis examined three vastly different microbicides 
each with very different modes of action. The SDS Hydrogel has broad spectrum 
activity and inactivates HIV-1, HSV-2 and disrupts HPV-11 infectivity.  The 
liposomal delivered short interfering RNA (siRNA) targeting human chemokine 
receptor 5 (CCR5) may potentially inhibit binding of M-tropic HIV-1 forms from 
binding to the co-receptor, thus, preventing subsequent infection.  Lastly, the pro-
biotic cyanovirin secreting lactobacilli microbicide works specifically to block 
infection by binding the HIV-1 glycoprotein 120 (gp120). The first of these 
microbicides has broad-spectrum activity against bacteria and viruses while other two 
microbicides are specific only for HIV-1, for example, attacking specific stages of the 
HIV-1 lifecycle.  Although these microbicides work very differently from each other 
the final objective of this work always remained the same, to use current technologies 
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to prevent the transmission of sexually transmitted viruses.    
SDS Hydrogels 
Anonic surfactants, such as sodium dodecyl sulfate (SDS) and other alkyl 
sulfates, possess chaotropic properties in addition to their surfactancy.  Detergents are 
amphipathic in nature, containing a polar head group at one end and long hydrophobic 
carbon chain at the other end.  The polar group forms hydrogen bonds with water 
molecules, while the hydrocarbon chains aggregate via hydrophobic 
interactions.(Leninger 2003) SDS has previously been shown to disrupt enveloped 
viruses and in cell culture will dissociate membranes into their lipid and protein 
components.(Becker, Helenius et al. 1975; Howett, Neely et al. 1999)  Importantly, 
the surfactant and chaotropic properties of alkyl sulfates give SDS very effective anti-
microbial and anti-viral activity.  As far back as 1952, SDS was combined with 
sodium perborate for use as a douche to treat vaginal infections. (Karnaky 1952; 
O'Brien and Thoms 1955) In intact mucosal tissues, surface keratinization, vaginal 
exudate and cervical mucus form a barrier layer not easily disrupted by SDS.  Sodium 
dodecyl sulfate and other alkyl sulfates are Generally Recognized As Safe (GRAS) by 
the FDA (FDA 2006), are regularly used as a common component in topically applied 
consumer products for skin and mucosa (e.g. body lotions, baby wipes, toothpaste and 
shampoo) and as food additives (e.g. marshmallows and gelatin).  Our laboratory has 
previously shown that at concentrations ranging from 0.01% to 1% SDS kills HIV-1, 
HPV, herpes simplex virus (HSV) types 1 and 2 (Howett, Neely et al. 1999; Krebs, 
Miller et al. 1999; Krebs, Miller et al. 2000; Krebs, Miller et al. 2002; Howett and 
  
158 
Kuhl 2005; Urdaneta, Wigdahl et al. 2005; Hartmann, Wigdahl et al. 2006), 
Chlamydia trachomatis (Achilles, Shete et al. 2002) Neisseria gonorrhea as well as 
Gram positive and Gram negative bacteria (Hartmann and Howett, unpublished 
results). As a result of our laboratories previously published reports we decided to test 
three different concentrations of SDS in the Hydrogel vehicle.  The three different 
concentrations tested for anti-viral activity were 0.1%, 0.5% and 1% SDS in the 
Hydrogel vehicle. 
To determine toxicity to issues that would be exposed to an SDS-based 
microbicide, human vaginal, cervical and newborn foreskin tissues were exposed ex 
vivo to either placebo, 0.1%, 0.5% or 1% SDS Hydrogel formulations and incubated 
for 3, 5, 16 or 24 hours. The hematoxylin and eosin staining shows that even the 
highest concentration of 1% SDS Hydrogel did not cause apparent disruption in the 
squamous epithelium of the vaginal tissue at the histologic level even after 24 hours of 
continued exposure.  Furthermore, there was no decrease in the thickness of the 
squamous epithelia in the SDS Hydrogel treated groups as compared to the no 
treatment groups. A recent study by Ghosh and Blankschtein has shown that SDS in 
glyercol reduces pore number density and radius, decreasing SDS micelle penetration 
into the stratum cornuem and therefore decreasing the perturbation of the skin barrier 
as compared to SDS in an aqueous solution. (Ghosh and Blankschtein 2007)  Viscous 
gels containing SDS may also decrease micelle penetration into the stratrum corneum, 
thereby, further decreasing toxicity. Another factor contributing to the formulated 
SDS’s low toxicity is that SDS is bound to the patented Hydrogel, SA Aquadapt, 
which allows the SDS to retain its potent anti-viral activity while decreasing the 
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exposure points of intact epithelia. A very important property of the Hydrogel is its 
design.  These gels are designed to remain adhered to mucosal surfaces, specifically 
vaginal epithelia in our instance, for three hours and then expelled or “sloughed off” 
from the vagina. Between the closing of vaginal space, extrusion of cervical mucus 
and vaginal cell exudates the vagina is a “self emptying” orifice.  Since SDS is bound 
to the Hydrogel the SDS will also be expelled after the three hours further decreasing 
the chances for irritation and immune cell infiltration.  Previous studies in our 
laboratory have shown that SDS in aqueous cell culture media inactivated HIV-1 in 
one minute.  This inactivation data and adding additional lag time for application of 
the SDS Hyrdogels before coital acts occur, were the main contributing factors in 
determining the “sloughing off” time point.   Our ex vivo histological data using 
human tissues show that 1% SDS Hydrogel is non-irritating at the macroscopic levels.  
However, further testing will be required to prove to the FDA that our prototypic 1% 
SDS Hydrogel is non-toxic to the potential sites of exposure, mainly cervical, vaginal 
and penile tissues. To support the safety of a potential microbicide and to evaluate 
acute, subchronic and chronic toxicity the FDA requires studies be performed in at 
least two animal species, with one species being a non-rodent.  Several different 
models can easily be utilized to test for tissue toxicity.  The first model that should be 
employed is the rabbit vaginal irritation model system (RVI). This model system is 
ideally suited for histological analysis that will examine tissue morphology and 
architecture to determine any subsequent changes in the epithelia due to treatment 
with the SDS Hydrogels.  However, the exposed targets in RVI is columnar epithelum 
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not squamous epithelium.  RVI studies conducted via an NIH contracted study have 
shown that 1% aqueous SDS scores equal to placebo buffer alone in a 10 day RVI.  
The work to be preformed in this RVI system would need to include at least three 
different doses of the SDS Hydrogels to indicate the upper, middle and lower limits 
for toxicity.  Preferably the doses would include a higher SDS concentration (2% - 
4%) that will serve to indicate the upper range were toxicity is known to occur; the 
prototypic 1% SDS Hydrogel active dose, per the data in this thesis; and a much lower 
dose (0.05% - 0.1%) SDS concentration that has been shown to have limited anti-viral 
activity and will serve to show the lower range. The rabbit vaginal irritation system 
will allow the toxicity and absorption or toxicokinetic studies to be performed 
simultaneously to evaluate SDS Hydrogel ADME (absorption, disposition, 
metabolism and excretion) profile using the same animals.  At the appropriate time 
points, blood shall be taken and after euthanization of the rabbits additional rabbit 
organs (at a minimum the blood, liver, kidneys and spleen) should be harvested to 
determine if the SDS Hydrogels are systemically absorbed.  The FDA recommends the 
use of the rabbit vaginal irritation model to study toxicity and irritation after 
application of the compound.  This model system can also be used for intravaginal 
repeated exposure testing using the prototypic 1% SDS Hydrogel.  Several studies in 
mouse have shown an inflammatory response after single (Catalone 2004) and 
repeated exposures to N-9.(Fichorova, 2004; Nirthuthisard 1991) and benzalkonium 
chloride (BZK) (Fichorova, 2004), a cationic detergent and component of the 
Protectaid™ contraceptive sponge.  To ensure there is no irritation or toxicity due to 
repeated exposures, which will occur during Phase I clinical trials, of the SDS 
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Hydrogels one intravaginal application per day should be applied over the course of 10 
days or longer.  The SDS Hydrogels are designed to be expelled from the vagina after 
three hours, therefore, at the four hour time point (prior to the next application) a 
vaginal lavage should be performed and the resulting fluid should analyzed for an 
increase in cytokine activity.  It is important to restate that the cellular architecture of 
rabbit vaginal tissue differs from human vaginal tissue.  The majority of the rabbit 
vaginal tissue is comprised of columnar epithelia, which is more sensitive and similar 
to human rectal epithelia. Due to the increased sensitivity of columnar epithelia, if no 
disruption is detected after application of a compound it is assumed that no disruption 
will occur in the hardier squamous epithelia of the human vaginal tissue.  A second 
model system that can be used is the non-human primate models that are housed and 
cared for by the National Center for Research Resources.  There are several different 
non-primate model systems that are used for toxicity and efficacy testing.  The three 
most common models are the pigtail macaque, Rhesus macaque and the cynomolgus 
macaque, which all require challenging with either simian immunodeficiency virus 
(SIV) or an SIV/HIV-1 chimera.(Kim 2006; D’Cruz, 2007; Subbarao 2007; Kish-
Catalone 2007)  There are several inherent problems with using non-human primates, 
they are very expensive to purchase and/or maintain, difficult to handle and there is 
chance of the infection being transmitted to the animal technician.  Another problem is 
that in some of the colonies, specifically the pigtailed macaques, are used repeatedly 
for many different compounds. They therefore may have over-sensitized or damaged 
the cervical or vaginal epithelia.  An alternative model system for testing toxicity and 
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absorption is the porcine model system.  Several studies have shown that pigs have 
similar vaginal tissue architecture and permability.(Squier 2008; D-Cruz 2007) 
Our laboratory has previously shown effective HSV-2 inactivation by 0.1% 
SDS diluted in cell culture media.(Howett, Neely et al. 1999) We performed HSV-2 
plaque assays with SDS Hydrogels to determine the effectiveness of the formulated 
SDS Hydrogels against this enveloped virus.  In two separate experiments with 
duplicate samples all of the SDS Hydrogel treatment concentrations showed strong 
anti-HSV-2 activity. Treatment concentrations as low as 0.05% to 0.5% were effective 
at inactivating HSV-2 in vitro, as was indicated by abolishing the virus’ ability to 
generate plaques in African Green monkey kidney cell monolayers. This data is 
consistent with our laboratories previously published reports that establish that an 
aqueous SDS solution completely inactivated HSV-2 by dissolving the lipid envelope 
and denaturing viral proteins.(Howett, Neely et al. 1999)    
An ideal microbicide must be active against both cell-free and cell-associated 
HIV-1, which is found in semen and vaginal secretions.  We tested our formulated SDS 
Hydrogels against both forms.  Our laboratory has previously shown that SDS diluted 
in cell culture media inactivates cell free HIV-1 within 1 minute.(Howett, Neely et al. 
1999; Urdaneta, Wigdahl et al. 2005) To verify that our formulated SDS Hydrogels 
have the same efficacy against HIV-1 as SDS in cell culture media, five separate 
experiments with triplicate samples were performed to determine anti-viral activity.  
Experiments were conducted using both cell-free and cell-associated forms of HIV-1.  
In each experiment highly statistically significant anti-HIV-1 activity (p<0.0001) was 
observed in all concentrations of SDS Hydrogel against both infectious forms relative 
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to untreated HIV-1 control. HIV-1 infectivity experiments were performed using P4-R5 
MAGI HeLa cells to test if the formulated SDS Hydrogels had anti-HIV-1 activity 
against both cell-free and cell-associated virus the 0.5% and 1% SDS Hydrogels 
completely inactivated cell-associated HIV-1. Furthermore, our data shows that all 
concentrations of the formulated SDS gels were highly active against cell free HIV 
with a highly statistically significant p value of 0.0001.  In the cell free HIV-1 
infectivity assays it was observed in all experiments that the placebo slightly increased 
HIV-1 infectivity.  However, this pro-infectivity effect was completely ablated in the 
presence of even the lowest concentrations of SDS in the Hydrogel formulations.  SDS 
has such potent anti-viral activity that at 1% and 0.5% SDS Hydrogel completely 
inactivated HIV-1 and at the lowest concentration (0.1%) of the SDS formulation viral 
infectivity decreased >95%.  The modest proinfectivity of the placebo that was 
observed in vitro may not be seen in vivo.  It may be due to the bioadhesiveness of the 
Hydrogel placebo or to the ability of the gel to exclude the virus therefore slightly 
increasing the effective concentration. Viral infectivity may be artificially increased 
due to pre-treating the virus with the formulated Hydrogel placebo and then applying 
infectious mixture to the cells.  In normal vaginal tissue there is a protective coating of 
mucus that is not found on the cells in culture.  This problem may be overcome by 
treating the cells with cervical mucus, thereby providing the protective layer, after 
which the cells could be pre-treated with a coating layer of Hydrogel placebo and 
subsequently adding infectious virus.  The proinfectivity of the Hydrogel placebo is 
negliable relative to the large decrease in virus infectivity seen in the presence of SDS.  
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The data from both cell-free and cell-associated HIV-1 experiments combined 
with the data from the HSV-2 experiments prove that the SDS Hydrogels have anti-
viral activity against sexually transmitted enveloped viruses.  Recent studies show that 
semen increases HIV-1 infectivity by as much as 50 fold (Munch 2007) and aids in 
epithelial tissue penetration.(Maher 2005)  In light of these reports, continued studies 
should be performed to determine if our prototypic SDS Hydrogel is as efficacious 
when either HIV-1 or HSV-2 is diluted in semen, vaginal secretions or a combination 
of both.  After which in vivo experiments using our laboratory’s human epithelial 
vaginal xenograft model system need to be performed to determine the effectiveness of 
our formulated prototypic SDS Hydrogel against HIV-1 and HSV-2.  The experiments 
to be performed in vivo should also include testing using HIV-1 and HSV-2 diluted in 
cell culture media, semen, vaginal secretions or a combination of both.  
To determine if the SDS Hydrogel formulations had activity against non-
enveloped virus, HPV-11 infectivity assays were performed followed by RT- PCR 
using nested primers targeted towards the de novo viral mRNA transcript, E1^E4. This 
viral transcript is the most abundant transcript detected during the HPV-11 life cycle 
and infection.  Therefore, its detection by RT-PCR would be indicative of active  de 
novo viral transcription.  Our results show that treatment with 0.5% or 1% SDS 
Hydrogels resulted in a 10 fold decrease in the levels of viral transcript, E1^E4. The 
initial concentration 0.1% (final concentration 0.05%) SDS Hydrogel did not decrease 
HPV-11 activity (data not shown).  The RT-PCR results show that formulated SDS 
Hyrdogel decreases HPV-11 infectivity by 90% in vitro.  This is evident by the loss of 
the E1^E4 band in the 10-5 columns in the 0.5% and 1% SDS Hydrogel experimental 
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groups as compared to the 10-6 column in the Placebo and HPV experimental control 
group, which show viral infectivity.  Our laboratory’s previous studies show that <1% 
SDS disrupts HPV and releases DNA (Kish and Howett, unpublished results).  This is a 
unique feature of SDS that sets it apart from other candidate microbicides with a more 
limited scope of action.  The next steps should include experiments being performed 
utilizing our laboratory’s human vaginal xenograft model system, to determine the 
effectiveness of our formulated prototypic SDS Hydrogel in decreasing the ability of 
experimentally generated HPV-11, HPV-16 or both to form experimental papillomas.  
Our laboratory has recently and successfully infected human foreskin and cervical 
tissue ex vivo with an experimentally generated HPV-16.(Alquist, 2006; Lao and 
Howett, unpublished results)  It is important to show and further strengthens our case 
for the phase I clinical trials, to be able to successfully show that our prototype SDS 
Hydrogel had the same activity in vivo against HPV-16, one of the high risk 
papillomaviruses associated with cervical cancer, as HPV-11.    
The prototypic SDS Hydrogel works by killing the viruses thereby preventing 
the problem of infectious virus or infected seminal fluid remaining in the vaginal 
environment even if captured by dentritic cells or trapped in contacted vaginal rugae. 
Liposomal delievered CCR5-siRNA microbicide 
Chemokines or chemotactic cytokines, are small proteins that are involved in 
activation and trafficking of leukocytes to sites of inflammation as well as 
dysregulation of these processes.(Kuhmann 2008; Opperman 2004; Yoshie, 2001)  
These proteins are divided in two subfamilies, CC- and CXC-chemokines, depending 
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on the location of the first two conversed cysteines.  Chemokine receptors are G 
protein coupled receptors (GPCR) that have seven transmembrane domains with three 
extracellular loops and four intracellular loops.(Lederman 2006) Chemokine receptor 
5 (CCR5) is a human receptor with an extracellular amine terminal tail and an 
cytoplasmic carboxy terminal tail.(Opperman 2004; Lederman 2006; Kuhmann 2008)  
CCR5 normally binds MIP-1ą, MIP-1β and RANTES chemokines. By competing for 
binding with HIV-1, MIP-1α, MIP-1β and RANTES have been shown to be major 
suppressive factors produced by CD8+ T-cells [bind pat #9].  There is a proposed two-
step model for CCR5 binding and recycling.   After a ligand binding, CCR5 undergoes 
a conformational change that activates the bound intracellular G protein.  When the G 
protein is activated it disassociates and activates phospholipase C producing two 
second messengers, inositol 1,4,5 triphosphate and diacylglycerol.(Lederman 2006)  
Both C and G protein-coupled receptor kinases phosphorylate the serine residues 
found in the carboxy terminus tail of CCR5, which in turn recruits β-arrestins.  These 
β-arrestins have clathrin binding sites, which connect CCR5 to the clathrin network.  
Once this complex binds the clathrin network receptor endocytosis is initiated.  In the 
subsequent endosome, CCR5 and bound ligand are separated, dephosphorylation of 
CCR5 occurs and the CCR5 receptor is recycled to the cells surface.  (Lederman 2006, 
12-16)   
A 1996 Hemophilia Growth and Multicenter AIDS Cohort study (Dean et al. 
1996) discovered that mutations in CCR5 conferred some resistance in humans to 
HIV-1 (R5) infection.  This mutation was found to be present at a frequency of 
approximately 10% in the Caucasian population in the United States and Europe but is 
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not found in Asian, African, Middle East or American Indian populations.(Galvani 
2003; Dean 1996; Samsone 1996) It was originally believed that this mutation in 
CCR5 arose from the Bubonic Plaque, which struck and ravaged Europe in the mid 
1300’s.  The mutation was traced back through descendents of survivors of the “Black 
Death”. Nonetheless, this is controversial, some researchers attribute the mutation to 
selective pressurers from smallpox infections.(Galvani et al. 2003)  An alternate 
hypothesis on the origins of this mutation is that the “Black Death” was not really the 
bubonic plaque but rather a viral hemorrhagic fever that was undetectable by the 
methods of that time.(Duncan et al. 2005)  It is further hypothesized that this viral 
hemorrhagic fever would have caused the same bulbous swelling in the lymph nodes, 
which was one of the main indicators for diagnoses of the bubonic plaque.  Also, 
people infected with viral hemorrhagic fevers develop visible black blotches due to the 
formation of subcutaneous hemorrhages directly under the skin, for which the “Black 
Death” is named.  The most notable discrepancy in the original hypothesis is that the 
responsible bacterium of the plague, Yersinia pestis, does not use CCR5 as a receptor.   
Other scientists believe that the selective pressure that caused the CCR5Δ32 mutation 
occurred long before the “Black Death” devastated Europe, due to its detection in a 
Bronze Age skeleton.(Duncan, 2004; Hummel 2004) 
This mutation was named CCR5Δ32 due to a 32 base pair deletion that 
encodes the second extracellular protein loop between transmembrane domains four 
and five of the seven transmembrane architecture.(Dean, Carrington et al. 1996; 
Agarwal, Zainab Van Horn et al. 2004; Oppermann 2004) CCR5Δ32 encodes a 
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truncated protein that is retained in the endoplasmic reticulum, which is not detectable 
and unstable on the cell surface.(Benkirane, Jin et al. 1997; Agrawal, VanHorn-Ali et 
al. 2004) Homozygous individuals expressing CCR5Δ32/CCR5Δ32 mutation are 
resistant to HIV-1 infection by M-Tropic strains and heterozygous individuals 
expressing CCR5Δ32/wt alleles progress at a much slower rate to AIDS.(Dean, 
Carrington et al. 1996) People who are homozygous with this mutation seem 
phenotypically normal except for an increased susceptibility to contracting a fatal form 
of West Nile Virus infection.  For these reasons CCR5 has become a very attractive 
target of investigation to many researchers.   
 A promising approach has been to create synthetic chemokines molecules that 
compete with HIV-1 for the CCR5 co-receptor. The most successful of the synthetic 
chemokines to inhibit binding of HIV-1 is PSC-RANTES and 2-RANTES, which is a 
RANTES analog chemically identical to native RANTES except for the substitution of 
a nonanoyl group, thioproline and cyclohexylglycine for the first three N-terminal 
amino acids of the native protein.(Lederman, Veazey et al. 2004) This synthetic PSC-
RANTES was vaginally applied to rhesus macaques and upon challenging with SHIV, 
a Simian Immunodeficiency Virus and Human Immunodeficiency Virus chimera, it 
was shown that 12 out of the 15 monkeys treated were protected by 100 ųM 
treatment.(Lederman, Veazey et al. 2004)   
 Several studies have shown that short interfering RNA (siRNA) has 
successfully down-regulated CCR5, which had an effect on HIV-1 entry and 
replication.(27,28,29) In siRNA treated U87-CCR5 cells, engineered to express 
CCR5, a 48% decrease in CCR5 expression was observed followed by a 55% decrease 
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in viral entry, which resulted in inhibition of HIV-1 replication.(Martinez, Gutierrez et 
al. 2002) Another study showed treating infected macrophages with siRNA targeting 
both CCR5 and HIV-1 p24 antigen subsequently down-regulated CCR5 and precluded 
viral entry for fifteen days.(Song, Lee et al. 2003) It has also been shown that down-
regulating CCR5 in MAGI-CCR5 cells decreased CCR5 expression by ten fold, which 
in turn decreased viral replication by three to seven fold.(Qin, An et al. 2003) A recent 
study has shown that liposomal delivered siRNA as a microbicide can protect mice 
from a lethal form of Herpes Simplex Virus 2 (HSV2) infection when treated two to 
four hours prior to viral challenge.(Palliser, Chowdhury et al. 2005)  
We used human cell lines, vaginal tissue and human vaginal xenografts to 
determine if CCR5 could be down regulated using a cationic liposome delivery 
system.  There are many cationic liposome mediated delivery systems but they all 
have a number of common features.(Sioud and Sorensen 2003) Typically, there is a 
positively charged head group that incorporates one or more positively charged 
nitrogen atoms allowing for the interaction between the transfection reagent and the 
negatively charged sugar-phosphate backbone of the nucleic acid molecule, which will 
be incorporated into the liposome.(Sioud and Sorensen 2003; Dalby, Cates et al. 2004) 
The charged head group is normally linked to one, two or three hydrocarbon chains by 
a spacer allowing for more potential for structural variations in these molecules. 
(Sioud and Sorensen 2003; Dalby, Cates et al. 2004) We choose Lipofectamine 2000 
(Invitrogen) as our liposomal complex delivery system for our CCR5-siRNA. 
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Optimization of the concentrations of Lipofectamine to siRNA was performed to 
ensure the maximum delivery of our siRNA molecules to the cells and tissues.   
After testing several different siRNAs targeting CCR5 we decided to use the 
validated SMARTpool siRNA from Dharmacon.  The SMARTpool plan makes use of 
Dharmacon’s SMARTselection program, which pinpoints siRNAs that have an 
excellent possibility of effective and specific silencing.  To increase the probability of 
silencing messenger RNA (mRNA) even more, the SMARTpool combines four of the 
SMARTselection designed siRNAs into a single pool. The SMARTpool platform has 
been validated in HeLa, HEK 293 and NIH3T3 cell lines.   
 To determine the effectiveness and ability of the liposomal delivered pooled 
CCR5-siRNA to down regulate CCR5, we treated P4-R5 cells with either 4nmol or 
10nmol pooled CCR5-siRNA or non-specific scrambled siRNA for 48 or 72 hours.  
Then cell lysates were collected and analyzed by Western Blot.  Non-specific 
scrambled control siRNA was included to show any effect that treatment or 
introduction of siRNA would have on the RNAi pathway.  The Western Blot data 
establishes that both the glycosolated (mature, ~62kD) and unglycosolated (immature, 
~49 kD) forms of CCR5 can be detected with our antibody.  The 4nmol pooled CCR5-
siRNA treatment incubated for 48 and 72 hours resulted in partially down-regulating 
the glycosolated forms of CCR5, but does not appear to have any effect on the 
unglycosolated forms when compared to the control siRNA.  However, a 48 hour 
treatment with 10nmol CCR5-siRNA almost completely eliminates the glycosolated 
form but has little effect on the unglycosolated form of CCR5.  Notably, a 72 hour 
treatment with 10nmol CCR5-siRNA completely eliminates the glycosolated CCR5 
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and partially down-regulates unglycosolated forms as determined by Western Blot 
analysis. This data indicates that CCR5 can be successfully down regulated in P4-R5 
cells using the pooled CCR5-siRNA from Dharmacon using a single application. The 
validation of an efficient siRNA targeting CCR5 was necessary before proceeding to 
the ex vivo organ tissue culture system and the in vivo human vaginal xenograft 
system.  This validation has to be performed every time a new shipment of pooled 
siRNA is ordered because there can be lot to lot or batch to batch variation in the 
efficiency of the siRNA.  Also, if we did not observe down-regulation of CCR5 we 
would have tested each siRNA in the pool to find out which one was the most 
effective and which siRNA was the least effective.  This may have been necessary 
because the strongest siRNA may overshadow the effectiveness of the other siRNA in 
the pool.  After testing each siRNA individually we would have eliminated the less 
effective siRNA ensure uniform distribution of the effective siRNA to all cells.      
Since we were able to down-regulate CCR5 in P4-R5 cells, which are adherent 
HeLa cells that do not normally express CCR5, we needed to determine if we could 
down regulate CCR5 in human vaginal tissue containing human lymphocytes.  To this 
end, an ex vivo organ tissue culture (OTC) system was utilized. Using the OTC, fresh 
vaginal tissues were treated with 10nmol liposomal CCR5-siRNA or scrambled 
control siRNA, incubated for either 72 or 96 hours and then tissue lysates were 
collected.   At the time of harvesting, the stroma and epithelia were separated in one of 
the CCR5-siRNA treated tissues from both 72 and 96 hour time points.  This was 
necessary because it was not known if the siRNA would penetrate through all of the 
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layers of the squamous epithelia.  By separating the epithelia from the stroma it could 
be deduced that CCR5 was being down-regulated in either or both of the tissue layers.  
Down-regulation of CCR5 in the epithelia but not in the stroma could have an effect 
on HIV-1 infectivity.  Scrambled non-specific control siRNA was included to show 
any effect that treatment or introduction of siRNA would have on the RNAi pathway.  
At 72 and 96 hours post-treatment CCR5 was not down-regulated in the epithelia, 
stroma or whole tissue as compared to the scrambled control siRNA.  
To confirm that the normal morphology and architecture of the xenograft 
vaginal tissue was preserved before performing experiments, hematoxylin and eosin 
(H&E) staining was performed on vaginal tissue prior to grafting and after the healing 
process.  For every xenograft performed, all tissue sections retained the normal 
architecture with the squamous epithelial and basal layers being clearly visible.   The 
histological results of the vaginal xenografts demonstrated that the xenograft system 
was operational at Drexel University, thus, allowing siRNA experiments to proceed.   
The human vaginal xenograft model system was used to determine kinetics and 
absorption of liposome delivered siRNA or nanopartilces into human vaginal tissue for 
the potential use as a microbicide. To determine the kinetics of absorption and to 
verify that the liposome-delivered siRNA would be absorbed through the squamous 
epithelia of the vaginal xenografts and have the potential to reach the target 
macrophages and Langerhan cells, we treated vaginal xenografts with non-specifc 
FITC-siRNA. Vaginal tissue was treated with 4nM non-specific FITC-siRNA for 2, 4, 
12, 24 or 48 hours and cryosections were examined by immunofluorescent 
microscopy. By 2 hours post-treatment a positive green FITC signal was observed in 
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the FITC-siRNA treated xenografts.  Some of these cells in the 2 hour treatment 
xenografts show positive FITC signal in the cytoplasm of the cells as is evident by the 
green signal directly adjacent to the blue DAPI stained nucleus.  All of the xenografts 
treated for 4, 12 and 24 hour visibly show a positive green signal, which is clearly 
observed in the cytoplasm of the cells.  In these xenografts there is also an increased 
intensity in brightness of the FITC signal, with the brightest signal being observed at 
24 hours and at 48 hours the signal starts to fade.  There was no positive signal in the 
untreated group. However, there was autofluorescence emanating from the connective 
tissue in the stroma, presumably type I collagen, which studies have shown that many 
connective tissues, specifically collagen, will autofluoresce when excitated in all 
wavelengths.  
To establish an alternate and a potentially more efficient siRNA delivery 
method we treated vaginal xenografts with FITC-nanoparticles or sodium fluorescein 
control for either 6 or 24 hours and examined the cryosections by immunofluorescent 
microscopy.  The nanoparticles were made of polyethyleneglycol and have had a FITC 
molecule conjugated the nanoparticles.  By 6 hours post-treatment the FITC-
nanoparticle group we observed the FITC-nanoparticles (green) had penetrated the 
tissue but did not appear to have entered the cells.  However, in the 24 hour FITC-
nanoparticle treated tissue there was clear penetration into the tissue as well as entry 
into the cytoplasm as indicated by the white arrows.  There was no positive signal 
from the sodium fluorescein negative controls and untreated groups.  
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Autofluorescence was again observed originating from the connective tissue, 
presumably type I collagen.   
We were able to show that after 4 hours liposomal-siRNA and after 24 hours 
nanoparticles can adequately traverse the multiple layers of the squamous epithelia in 
human vaginal xenograft tissue.   Where a portion of the HIV CCR5-positive target 
cells are localized.  Surprisingly, originally when the xenografts were treated with 
4nM CCR5-siRNA there was no decrease in expression of CCR5 by 
immunohistological staining and Western Blot analyzes. Immunohistochemical 
staining was performed on untreated and CCR5-siRNA treated grafted vaginal tissue, 
to detect and visualize CCR5 expression in the xenografts.  A positive signal for 
CCR5 in the avidin-biotin complex system used was indicated by a color change to 
brown, which was visible in the CCR5-siRNA treated and untreated tissue sections 
that were treated for 24 and 48 hours.  Since we currently do not have a method for 
quantifying immunohistochemcial stained tissue sections we decided to perform 
Western Blots to detect CCR5 protein levels. To this end it was also necessary to 
determine the adequate dose of CCR5-specific siRNA required for treatment of 
vaginal tissue to abolish expression of CCR5.  
Based on the FITC-siRNA absorption data we decided to start with our 
laboratories human vaginal xenograft system prior to normalization of the CCR5-
siRNA OTC experiments. Xenograft tissues were treated with 10nmol CCR5-siRNA 
and incubated for either 72 or 96 hours after which tissue lysates were collected as 
described in Materials and Methods.  Unglycosolated (immature) forms of CCR5 are 
~49 kD and glycosolated (mature) forms are ~62kD in size. Scrambled non-specific 
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control siRNA was included to show any effect that treatment or introduction of 
siRNA would have on the RNAi pathway. The xenograft CCR5-siRNA treatments 
were only performed once and need to be repeated but based on the Western Blot 
analysis and normalization data in Figure 22 there was no down-regulation of CCR5 in 
the xenografts.  Interestingly, three of the five xenografts treated with CCR5-siRNA 
and the scramble controls appear to have some upregulation of CCR5, indicating the 
siRNA itself may be affecting the RNAi pathway.  A microarray needs to be 
performed to help assess changes in other genes in the RNAi pathway are being 
affected or possibly if regulatory genes for CCR5 recycling is being affected.  Based 
on these results that there was no down regulation of CCR5 in the xenograft tissue it 
may be necessary to increase the concentration of CCR5-siRNA and change the 
delivery vehicle to nanoparticles.  The xengrafts are metabolically active and contain 
the same proteins and enzymes found in normal vaginal tissue.  Even though the 
siRNA is encapsulated inside liposomes it may be possible for the CCR5-siRNA to be 
degraded after liposomal fusion with the outer most layer of the squamous epithelia.  
The nanoparticles may provide more protection from siRNA degradation and may be 
less toxic, however, more testing is required to confirm this hypothesis.  Utilizing 
nanoparticle has its advantages such as they are can be stored at room temperature and 
based on our results the nanopartles also penetrate human vaginal epithelia.  The 
disadvantage to utilizing nanoparticles is the cost.   It may also be more appropriate 
target other surface molecules on the vaginal epithelia that are known to bind to HIV-
1, such as gp340 and syndecan-1. Targeting other molecules and testing different 
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combinations of surface molecules could be performed at lower concentrations both 
siRNA and delivery vehicle whether it be liposomes, nanoparticles or other vehicle.   
Using siRNA technology to prevent the transmission of STI, specifically HIV-
1, is something many researchers have tried.  Unfortunately, targeting HIV-1 only is 
effective for short periods of time and results in escape mutants. (Boden, 2006)  The 
HIV-1 population in an infected individual is a genetically diverse population of 
quasispecies, which has contributed to virus’ evolution and why targeting the HIV-1 is 
not the best strategy. That would be adding another selective pressure that the virus 
can easily overcome.  However, a much better strategy is to target a human gene that 
HIV-1 needs as a co-receptor, such as CCR5.  If our experiments are successful then 
this study could provide proof-of-principle for using siRNA targeting human genes as 
a microbicide but also for prevention of other infectious diseases.  Until the projected 
cost of producing an siRNA microbicide could be decreased this microbicide would be 
targeted towards developed nations and is not designed for immediate use before 
coital acts.  This microbicide would need to be administered several times a week to 
ensure CCR5 down regulation.   
Recombinant Normal Flora as a Microbicide 
The bacterial species that colonize the human body are both numerous and 
diverse.  These bacteria or normal flora inhabit the skin, the entire digestive system 
and urogenital tract in women. Many of these normal flora contribute to the healthy 
development of the immune system, prevent infection from pathogenic and 
opportunistic microbes as well as maintain the intestinal barrier function.  Illness, 
HIV-1 infection, poor nutrition, use of antibiotics and other factors can affect this 
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delicate balance and cause emergence of harmful bacterial. An imbalance in or a 
depletion of normal flora in the vaginal environment has been associated with an 
increased risk of acquiring opportunistic infections, including HIV-1. (Chang, 2003; 
Taha, 1998)  It has been shown that the daily ingestion of yogurt containing live 
lactobacilli has been shown to decrease vulvovaginal Candida infections by three 
fold.(Hilton, 1992)  The normal flora found in the vagina environment is lactobacilli. 
These bacteria prefer an acidic environment and help create one by producing lactic 
and other acids.(Reid 2001)  Byproducts produced from lactobacilli metabolism have 
antagonistic effects against urinary and vaginal pathogens.   
There are many challenges that confront the development of an effective HIV-
1 microbicide.  The microbicide must be able to target and neutralize a genetically 
diverse population of viruses. Mucosal administration of the microbicide must not 
cause adverse effects such as immune cell infilitration in the host or sexual partner and 
must be able to maintain sufficient muscosal concentrations of active compound over 
extended periods of time.  Some microbicides that require application immediately 
prior to coital acts may lower the frequency of compliance and complicate evaluations 
of efficiacy.  Unfortunately, in many societies cultural norms prevent women from 
taking the necessary steps to apply a vaginal microbicide immediately before 
intercourse.  There must be alternatives to topical microbicides because even the most 
efficacious topical microbicide may be of limited value if it can not easily be used.  
Thus, a vital need exists to develop efficient systems that allow for the delivery of 
microbicides to mucosal surfaces over extended periods of time.   
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 One approach for delivering microbicides with the capability of synthesizing 
an antiviral compound is to use probiotics, specifically recombinant normal flora in 
the vaginal environment. A recent study tested a recombinant lactobacilli, L. jensenii 
Xna, which secreted CVN and a two domain soluble CD4 (2D CD4) molecule.(Chang, 
2003) In vitro testing of this lactobacilli showed a small decrease in HIV-1 
binding.(Chang, 2003)  We have also decided to test a recombinant lactobacilli, L. 
plantarum, that secretes CVN, which was developed by our collaborator, Dr. Bharat 
Ramratnam at Brown University.   CVN has been shown to have effective antiviral 
(HIV-1, HIV-2 and SIV) activity.(Boyd, 1997)  
To determine the feasibility of using recombinant lactobacilli, L. plantarum, as 
a microbicide we measured the growth rates of both WT and recombinant L. 
plantarum and measured CVN secretion.  This was necessary to evaluate if the 
recombinant L. plantarum would grow and compete for resources with the normal 
flora in the vaginal environment.  As shown in the growth curves in Figure 25 the WT 
L. plantarum grew at a much quicker rate doubling approximately every hour as 
compared to the recombinant L. plantarum, which grew at a much slower rate 
doubling approximately every three hours.  The recombinant L. plantarum would not 
be able to compete for food and resources with the WT lactobacilli already colonizing 
the vagina. Growth curves need to be performed on the other recombinant lactobacilli, 
L. jensenii or L. gasseri, which may grow at quicker rates that are closer to their 
comparable WT strains and therefore would be more likely to be able to compete for 
resources.  
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To verify the recombinant L. plantarum was secreting CVN, WT or 
recombinant L. plantarum was grown in the MRS media for 24, 48 or 72 hours.  The 
supernatant was then subjected to Western Blot and indirect ELISA for the detection 
of CVN. The Western Blot analysis in Figure 27 shows that CVN was detected in all 
of the time points collected (24, 48 and 72 hours) for the recombinant L. plantarum 
but not the negative control. The detection of CVN from very small volume of 
supernatant was very important because when utilizing the human vaginal xenograft 
model system the largest instilling volume is 10 ul maximum.   To determine the 
minimum detection limits for CVN from bacterial cultures we utilized an indirect 
ELISA.  Figure 28A shows the minimum detection limits was in the nanogram range 
for CVN concentration using the indirect ELISA method and the resulting standard 
curve.  From the standard curve in Figure 28A we were able to determine the 
minimum volume required from filtered supernatant that allowed for detection of our 
secreted CVN, which corresponded to 0.1 to 1 µl from recombinant L. plantarum 
culture supernatant, as shown in Figure 28B.  These results indicated that once the 
vaginal xenografts were recolonized with the recombinant L. plantarum, we could 
detect CVN secretion and determine its effect on HIV-1 infectivity. 
The recombinant L. plantarum CVN microbicide would protentially provide 
benefits to a women that is infected with HIV-1 and is being treated with highly active 
antiretroviral therapy (HAART).  It is known that HAART causes imbalances in the 
normal flora of people who are required to take it for survival and specifically many 
times women have recurrent vaginal yeast infections.  A recombinant L. plantarum 
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microbicide, which secretes CVN, given regularly to a HIV-1 infected women to 
recolonize the vaginal environment could decrease vaginal yeast infections but also 
decrease cell-free HIV-1 in vaginal secretions.   
Before beginning the in vivo testing, the anti-HIV-1 activity of the CVN 
secreted from the recombinant L. plantarum was assessed.  Filtered recombinant or 
WT L. plantarum culture supernatant with the pH adjusted to 7.0 was tested against 
cell-free HIV-1. The pH had to be adjusted to ensure the pH would not be a 
contributing factor in decreasing HIV-1 infectivity.  Three separate experiments with 
triplicate samples were performed and in each experiment a statistically significant 
(p<0.01) decrease in anti-HIV-1 activity was observed in the recombinant L. 
plantarum grown for 48 hours (O.D. 3.0) relative to uninfected control, as shown in 
Figure 29.  These results show the CVN secreted from the recombinant L. plantarum 
retained its anti-HIV-1 activity in vitro.   
To date there are no published reports of recolonizing human vaginal tissue ex 
vivo or in vivo with recombinant lactobacilli.  To determine if the WT and 
recombinant L. plantarum could be grown on human vaginal tissue we utilized an ex 
vivo organ tissue culture system (OTC) as previously described. (Collens 20001)  
Vaginal tissue treated with either WT or recombinant L. plantarum cultures and 
incubated for either 24, 48 or 72 hours. This system allows the lactobacilli to only be 
exposed to the squamous epithelial cells, which the lactobacilli naturally adhere to in 
the vaginal environment.   As seen in Figure 26C and 26D both the WT and 
recombinant L. plantarum was detected by Gram stain by 48 hours post-inoculation 
with a subsequent change in pH from 6.5 to 4.5 as seen in Figure 26E.   Results were 
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similar after 72 post-inoculation (data not shown).  There was no change in pH 
detected in the recombinant L. plantarum OTC cultures after 24 hours but low 
quantities of bacterial were detected by Gram stain (data not shown). The change in 
pH detected indicates the bacteria were growing on the human tissue and secreting 
lactic acid into the surrounding environment similar to the vaginal environment.   
Our data has shown that we were able to grow and detect the recombinant 
lactobacilli, the secreted CVN retatined its anti-HIV-1 activity in vitro and recolonize 
human vaginal tissue ex vivo.  Also, we have shown in Figure 18 (chapter 3), that we 
were able to successfully infect human vaginal xenografts without the need of 
reconstituting the xenografts with human peripheral blood mononuclear cells, as was 
required previously for this HIV-1 xenograft model system.    Subsequently, to 
determine if the lactobacilli would colonize the lumen of the vaginal xenografts the 
xenografts were inoculated with recombinant lactobacilli and upon harvesting were 
washed with PBS and subjected to Gram stain. Afterward the wash was sent to Brown 
University for detection of CVN by indirect ELISA, a Gram stain was also performed 
but only a small population of lactobacilli was detected (data not shown) but more 
xenografts need to inoculated to ensure the lactobacilli detected was not residual 
bacteria from the initial inoculum.   To determine if the recombinant lactobacilli 
would decrease HIV-1 infectivity we inoculated the lumen of vaginal xenografts and 
challenged with HIV-1.  Upon harvesting, the vaginal xenografts were sent to Brown 
University for analysis due to the closing of Dr. Mary K. Howett’s laboratory at 
Drexel University.   
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Vaginal normal flora has been shown to effect HIV-1 viral load within vaginal 
secretions of HIV-1 positive women.(Hitti 2008) In an observation cohert study that 
collected cervico-vaginal lavages from  HIV-1 positive women showed that 
lactobacilli, which secreted hydrogen peroxide, had an effect on HIV-1 viral load in 
vaginal secretions.(Hitti 2008) The women whose vaginal normal flora changed from 
bacterial species that cause bacterial vaginosis (BV) to lactobacilli experienced a five 
fold decrease in HIV-1 viral load; and the women whose normal flora changed from 
lactobacilli to the bacterial species that cause BV experienced a three fold increase in 
HIV-1 viral load.(Hitti 2008)  A change in vaginal normal flora women has also been 
associated with bacterial vaginosis and an increased risk of HIV-1 infection.(Chang 
2003; Taha 1998) 
Previous work that has been performed in our laboratory has shown that the 
human vaginal xenografts do not retain the normal flora from the patient (Welsh and 
Howett, unpublished results), thus, making the xenograft system an ideal model 
system to evalute the recombinant L. plantarum as an anti-HIV-1 microbicide.  These 
experiments provide (and will provide) proof-of-principle in determining if the 
amount of cyanovirin produced and secreted can sufficiently decrease HIV-1 activity 
in vivo to reduce its transmission.  Consequently, this will also help in determining if 
recombinant probiotics can be utilized as a microbicide.  Future experiments to be 
performed using the vaginal xenograft model system will include testing of other 
recombinant lactobacilli, which secrete CVN; combining these recombinant and WT 
bacteria in the initial inoculum to detemine if the recombinant lactobacilli can compete 
with the WT in an environment completely devoid of bacteria; creating different 
183 
 
 
recombinant lactobacilli that can secrete other microbicidal compounds or peptides 
(e.g. 5P12-RANTES, fucans or 12p1 peptide); and combining recombinant lactobacilli 
that secrete different anti-HIV-1 compounds as a way of delivering and testing 
combination microbicides with different modes of action.   Live microbicide delivery 
strategies, as outlined in this thesis, potentially have many advantages over gel 
delivered topical microbicides, such as, deliverying long lasting protection due to 
bacterial colonization decreasing the need for immediate precoital application and low 
cost to manufacturer once normal flora bacteria has been transformed.   
My future interests in microbicidal research would focus on common surface 
receptors that multiple viruses may utilize for the initial infection of genital epithelia 
and if those receptors could be down regulated to prevent infection. Semen, vaginal 
secretions and cervical mucus all play roles in both the protection and contribute to the 
infectivity of viruses.  Researchers are now beginning to study the mechanisms and 
model systems need to be developed, standardized and validated using these biological 
fluids. Another area of interest is co-infection studies, for example, is co-infection by 
two or more different strains of high risk HPV a pre-requisite for progression to 
cervical cancer. Viral probiotics and recombinant probiotics are both very interesting 
and an avenue worth exploring.  Recombinant viruses and their effects on the human 
immune system in the vaginal environment need to be studied to determine if they can 
safely be utilized.   
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ABC     Abstinence, Be faithful, Condom use  
ADME  Absorption, disposition, metabolism and 
excretion  
AIDS     Acquired immunodeficiency syndrome 
ANOVA    Analysis of variance  
BZK     benzalkonium chloride  
CA     California 
CAS     Chemical Abstract Service 
CCR5     Chemokine Receptor 5 
CCR5Δ32 Chemokine Receptor 5 mutation with 32 base 
pair deletion 
CD4     Cluster of Differentiation-4  
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CDC     Center for Disease Control 
cDNA     Complementary Deoxyribonucleic Acid 
CIN     Cervical Intraepithelial neoplasia 
CMC     Critical micellar concentration 
CVN     Cyanovirin 
CXCR4    Chemokine (C-X-C motif) Receptor 4 
DMEM    Dulbecco's Modified Eagle Medium 
DNA     Deoxyribonucleic Acid 
ER     Endoplasmic reticulum 
FAO     UN Food and Agriculture Organization  
FBS     Fetal Bovine Serum  
FDA     US Food and Drug Administration 
gD     Glycoprotein D, HSV 
GP41     Glycoprotein 41 
GP120     Glycoprotein 120 
GPCR     G Protein-Coupled Receptor 
GRAS     Generally Recognized As Safe  
H&E Hematoxylin and Eosin  
HIV-1     Human immunodeficiency virus type 1 
HSV-2     Herpes simplex virus type 2 
HPV     Human papillomavirus 
L1     Late 1, HPV major capsid protein 
  
196 
L2      Late 2, HPV minor capsid protein 
LAT     Latency active transcript 
MAGI Multinuclear Activation of a Galactosidase 
Indicator Discussion  
MIP     Macrophage Inflammatory Protein (e.g., MIP-
1α) 
mRNA     Messenger RNA 
N-9     Nonoxynol 9 
NOD/SCID    Non-obese diabetic severely compromised  
     Immunodeficient mice 
O-T-C     Over the counter 
OTC     Organ tissue culture system 
P53     Tumor suppressor protein 53 
PCR     Polymerase chain reaction   
PIC     Pre-integration complex 
pRB     Retinoblastoma protein 
PSC-RANTES   Na-(n-nonanoyl)-des-Ser1-EL-thioproline2, 
L-α-cyclohexyl-glycine3 Regulated on 
Activation, Normal T Expressed and Secreted  
 
RISC     RNA induced silencing complex 
RLU     Relative Luminescence Units    
RNA     Ribonucleic Acid 
RNAi     RNA interference 
RPMI     Roswell Park Memorial Institute media 
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SIV Simian Immunodeficiency Virus 
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TCID     Tissue Culture Infective Dose 
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